


Appendix— Review of Organic Chemistry


Carol N. Angstadt



Functional Groups

Alcohols

The general formula of **alcohols** is R–OH, where R equals an alkyl or aryl group. They are classified as *primary*, *secondary*, or *tertiary*, according to whether the hydroxyl (OH)-bearing carbon is bonded to no carbon or one, two, or three other carbon atoms:



Aldehydes and Ketones

Aldehydes and **ketones** contain a carbonyl group:



Aldehydes are



and a **ketone** has two alkyl groups at the carbonyl group




Acids and Acid Anhydrides



Carboxylic acids contain the functional group



(–COOH). Dicarboxylic and tricarboxylic acids contain two or three carboxyl groups. A carboxylic acid ionizes in water to a negatively charged carboxylate ion:




Names of carboxylic acids usually end in *-ic* and the carboxylate ion in *-ate*. **Acid anhydrides** are formed when two molecules of acid react with loss of a molecule of water. An acid anhydride may form between two organic acids, two inorganic acids, or an organic and an inorganic acid:



Esters


Esters form in the reaction between a carboxylic acid and an alcohol:



Esters may form between an inorganic acid and an organic alcohol, for example, glucose 6-phosphate.

Hemiacetals, Acetals, and Lactones

A reaction between an aldehyde and an alcohol gives a **hemiacetal**, which may react with another molecule of alcohol to form an **acetal**:




Lactones are cyclic esters formed when an acid and an alcohol group on the same molecule react and usually require that a five- or six-membered ring be formed.

Unsaturated Compounds


Unsaturated compounds are those containing one or more carbon-carbon multiple bonds, for example, a double bond: $-C=C-$

Amines and Amides

Amines, $R-NH_2$, are organic derivatives of NH_3 and are classified as *primary*, *secondary*, or *tertiary*, depending on the number of alkyl groups (R) bonded to the nitrogen. When a fourth substituent is bonded to the nitrogen, the species is positively charged and called a *quaternary ammonium ion*:



Amides contain the functional group




where X can be H (simple) or R (*N* substituted). The carbonyl group is from an acid, and the *N* is from an amine. If both functional groups are from amino acids, the amide bond is referred to as a **peptide bond**.

Types of Reactions

Nucleophilic Substitutions at an Acyl Carbon

If the acyl carbon is on a carboxylic group, the leaving group is water. Nucleophilic substitution on carboxylic acids usually




requires a catalyst or conversion to a more reactive intermediate; biologically this occurs via enzyme catalysis. $X-H$ may be an alcohol ($R-OH$), ammonia, amine ($R-NH_2$), or another acyl compound. Types of nucleophilic substitutions include *esterification*, *peptide bond* formation, and *acid anhydride* formation.

Hydrolysis and Phosphorolysis Reactions

Hydrolysis is the cleavage of a bond by water:



Hydrolysis is often catalyzed by either acid or base. *Phosphorolysis* is the cleavage of a bond by inorganic phosphate:





Oxidation-Reduction Reactions

Oxidation is the loss of electrons; **reduction** is the gain of electrons. Examples of oxidation are as follows:

- $Fe^{2+} + \text{acceptor} \rightarrow Fe^{3+} + \text{acceptor} \cdot e^-$
- $S(\text{substrate}) + O_2 + DH_2 \rightarrow S-OH + H_2O + D$
- $S-H_2 + \text{acceptor} \rightarrow S + \text{acceptor} \cdot H_2$

Some of the group changes that occur on oxidation-reduction are:






Stereochemistry

Stereoisomers are compounds with the same molecular formulas and order of attachment of constituent atoms but with different arrangements of these atoms in space.

Enantiomers are stereoisomers in which one isomer is the mirror image of the other and requires the presence of a chiral atom. A chiral carbon (also called an asymmetric carbon) is one that is attached to four different groups:



Enantiomers will be distinguished from each other by the designations *R* and *S* or *D* and *L*. The maximum number of stereoisomers possible is 2^n , where n is the number of chiral carbon atoms. A molecule with more than one chiral center will be an achiral molecule if it has a point or plane of symmetry.


Diastereomers are stereoisomers that are not mirror images of each other and need not contain chiral atoms. **Epimers** are diastereomers that contain more than one chiral carbon and differ in configuration about *only one* asymmetric carbon.

Anomers are a special form of carbohydrate epimers in which the difference is specifically about the anomeric carbon (see p. 1140). Diastereomers can also occur with molecules in which there is restricted rotation about carbon–carbon bonds. Double bonds exhibit **cis–trans isomerism**. The double bond is in the *cis* configuration if the two end groups are on the same side and is *trans* if the two ends of the longest chain are on opposite sides. Fused ring systems, such as those found in steroids (see p. 1145), also exhibit *cis–trans* isomerism.



Types of Forces Involved in Macromolecular Structures

A **hydrogen bond** is a dipole–dipole attraction between a hydrogen atom attached to an electronegative atom and a nonbonding electron pair on another electronegative atom: Hydrogen bonds of importance in macromolecular structures occur between two nitrogen atoms, two oxygen atoms, or an oxygen and a nitrogen atom.



A **hydrophobic interaction** is the association of nonpolar groups in a polar medium. *Van der Waals* forces consist of dipole and induced-dipole interactions between two nonpolar groups. A nonpolar residue dissolved in water induces a highly ordered, thermodynamically unfavorable, solvation shell. Interaction of nonpolar residues with each other, with the exclusion of water, increases the entropy of the system and is thermodynamically favorable.


Ionic (electrostatic) interactions between charged groups can be attractive if the charges are of opposite signs or repulsive if they are of the same sign. The strength of an electrostatic interaction in the interior of a protein molecule may be high. Most charged groups on the surface of a protein molecule interact with water rather than with each other.

A **disulfide bond** (S–S) is a covalent bond formed by the oxidation of two sulfhydryl (SH) groups.


Carbohydrates

Carbohydrates are polyhydroxy aldehydes or ketones or their derivatives. **Monosaccharides** (simple sugars) are those carbohydrates that cannot be hydrolyzed into simpler compounds. The generic name of a monosaccharide includes the type of function, a Greek prefix indicating the number of carbon atoms, and the ending -ose; for example, *aldohexose* is a six-carbon aldehyde and *ketopentose* is a five-carbon ketone. Monosaccharides may react with each other to form larger molecules. With fewer than eight monosaccharides, either a Greek prefix indicating the number or the general term *oligosaccharide* may be used. **Polysaccharide** refers to a polymer with more than eight monosaccharides. Oligo- and polysaccharides may be either homologous or mixed.

Most *monosaccharides* are asymmetric, an important consideration since enzymes usually work on only one isomeric form. The simplest carbohydrates are glyceraldehyde and dihydroxyacetone, whose structures, shown as Fischer projections, are as follows:




D-Glyceraldehyde may also be written as follows:




In the Cahn–Ingold–Prelog system, the designations are (*R*) (rectus; right) and (*S*) (sinister, left).


The configuration of monosaccharides is determined by the stereochemistry at the asymmetric carbon furthest from the carbonyl carbon (number 1 for an aldehyde; lowest possible number for a ketone). Based on the *position* of the OH on the highest number asymmetric carbon, a monosaccharide is D if the OH projects to the *right* and L if it projects to the *left*. The D and L monosaccharides with the same name are *enantiomers*, and the substituents on all asymmetric carbon atoms are reversed as in




Epimers (e.g., glucose and mannose) are stereoisomers that differ in the configuration about *only one* asymmetric carbon. The relationship of OH groups to *each other* determines the specific monosaccharide. Three aldohexoses and three pentoses of importance are




Fructose, a ketohexose, differs from glucose only on carbon atoms 1 and 2:




Five- and six-carbon monosaccharides form **cyclic hemiacetals** or *hemiketals* in solution. A new asymmetric carbon is generated so two isomeric forms are possible:




Both five-membered (furanose) and six-membered (pyranose) ring structures are possible, although pyranose rings are more common. A furanose ring is written as follows:




The isomer is designated α if the OH group and the CH₂OH group on the two carbon atoms linked by the oxygen are trans to each other and β if they are cis. The hemiacetal or hemiketal forms may also be written as modified *Fischer projection formulas*: α if OH on the acetal or ketal carbon projects to the same side as the ring and β if on the opposite side:



Haworth formulas are used most commonly:






The ring is perpendicular to the plane of the paper with the oxygen written to the back (upper) right, C-1 to the right, and substituents above or below the plane of the ring. The OH at the acetal or ketal carbon is below in the α isomer and above in the β . Anything written to the right in the Fischer projection is written down in the Haworth formula.


The α and β forms of the same monosaccharide are special forms of epimers called *anomers*, differing only in the configuration about the anomeric (acetal or ketal) carbon. Monosaccharides exist in solution primarily as a mixture of the hemiacetals (or hemiketals) but react chemically as aldehydes or ketones. *Mutarotation* is the equilibration of α and β forms through the free aldehyde or ketone. Substitution of the H of the anomeric OH prevents mutarotation and fixes the configuration in either the α or β form.

Monosaccharide Derivatives


A **deoxymonosaccharide** is one in which an OH has been replaced by H. In biological systems, this occurs at C-2 unless otherwise indicated. An **amino monosaccharide** is one in which an OH has been replaced by NH_2 , again at C-2 unless otherwise specified. The amino group of an amino sugar may be *acetylated*:




An aldehyde is reduced to a primary and a ketone to a secondary **monosaccharide alcohol (alditol)**. Alcohols are named with the base name of the sugar plus the ending *-itol* or with a trivial name (glucitol = sorbitol). Monosaccharides that differ around only two of the first three carbon atoms yield the same alditol. D-Glyceraldehyde and dihydroxyacetone give glycerol:




D-Glucose and D-fructose give D-sorbitol; D-fructose and D-mannose give D-mannitol. Oxidation of the terminal CH_2OH , but not of the CHO, yields a **uronic acid**, a *monosaccharide acid*:




Oxidation of the CHO, but not the CH_2OH , gives an **-onic acid**:



Oxidation of both the CHO and CH_2OH gives an **-aric acid**:





Ketones do not form acids. Both -onic and -uronic acids can react with an OH in the same molecule to form a **lactone** (see p. 1138):




Reactions of Monosaccharides

The most common *esters* of monosaccharides are phosphate esters at carbon atoms 1 and/or 6:






To be a **reducing sugar**, mutarotation must be possible. In alkali, enediols form that may migrate to 2,3 and 3,4 positions:








Enediols may be oxidized by O_2 , Cu^{2+} , Ag^+ , and Hg^{2+} . Reducing ability is more important in the laboratory than physiologically. A hemiacetal or hemiketal may react with the OH of another monosaccharide to form a disaccharide (*acetal: glycoside*) (see below):



One monosaccharide still has a free anomeric carbon and can react further. Reaction of the anomeric OH may be with any OH on the other monosaccharide, including the anomeric one. The anomeric OH that has reacted is fixed as either α or β and cannot mutarotate or reduce. If the glycosidic bond is not between two anomeric carbon atoms, one of the units will still be free to mutarotate and reduce.

Oligo- and Polysaccharides

Disaccharides have two monosaccharides, either the same or different, in glycosidic linkage. If the glycosidic linkage is between the two anomeric carbon atoms, the disaccharide is nonreducing:



Maltose = 4-*O*-(α -D-glucopyranosyl)D-glucopyranose; reducing

Isomaltose = 6-*O*-(α -D-glucopyranosyl)D-glucopyranose; reducing

Cellobiose = 4-*O*-(β -D-glucopyranosyl)D-glucopyranose; reducing


Lactose = 4-*O*-(β -D-galactopyranosyl)D-glucopyranose; reducing

Sucrose = α -D-glucopyranosyl- β -D-fructofuranoside; non-reducing

As many as thousands of monosaccharides, either the same or different, may be joined by glycosidic bonds to form *polysaccharides*. The anomeric carbon of one unit is usually joined to C-4 or C-6 of the next unit. The ends of a polysaccharide are not identical (reducing end = free anomeric carbon; nonreducing = anomeric carbon linked to next unit; branched polysaccharide = more than one nonreducing end). The most common carbohydrates are homopolymers of glucose; for example, starch, glycogen, and cellulose. Plant starch is a mixture of **amylose**, a linear polymer of maltose units, and **amylopectin**, branches of repeating maltose units (glucose–glucose in α -1,4 linkages) joined via isomaltose linkages. **Glycogen**, the storage form of carbohydrate in animals, is similar to amylopectin, but the branches are shorter and occur more frequently. **Cellulose**, in plant cell walls, is a linear polymer of repeating cellobioses (glucose–glucose in β -1,4 linkages).

Mucopolysaccharides contain amino sugars, free and acetylated, uronic acids, sulfate esters, and sialic acids in addition to the simple monosaccharides. **N-Acetylneur-**

aminic acid, a sialic acid, is



Lipids

Lipids are a diverse group of chemicals related primarily because they are insoluble in water, soluble in nonpolar solvents, and found in animal and plant tissues.

Saponifiable lipids yield salts of fatty acids upon alkaline hydrolysis. *Acylglycerols* = glycerol + fatty acid(s); *phosphoacylglycerols* = glycerol + fatty acids + HPO_4^{2-} + alcohol; *sphingolipids* = sphingosine + fatty acid + polar group (phosphoryl alcohol or carbohydrate); *waxes* = long-chain alcohol + fatty acid. *Nonsaponifiable lipids* (*terpenes*, *steroids*, *prostaglandins*, and related compounds) are not usually subject to hydrolysis. *Ambipathic* lipids have both a polar "head" group and a nonpolar "tail." Ambipathic molecules can stabilize emulsions and are responsible for the lipid bilayer structure of membranes.


Fatty acids are monocarboxylic acids with a short (<6 carbon atoms), medium (8–14 carbon atoms), or long (>14 carbon atoms) aliphatic chain. Biologically important ones are usually linear molecules with an even number of carbon atoms (16–20). Fatty acids are numbered using either arabic numbers (COOH is 1) or the Greek alphabet (COOH is not given a symbol; adjacent carbon atoms are α , β , γ , etc.). **Saturated fatty acids** have the general formula $\text{CH}_3(\text{CH}_2)_n\text{COOH}$. (*Palmitic acid* = C_{16} ; *stearic acid* = C_{18} .) They tend to be extended chains and solid at room temperature unless the chain is short. Both trivial and systematic (prefix indicating number of carbon atoms + *anoic acid*) names are used. $\text{CH}_3(\text{CH}_2)_{14}\text{COOH}$ = palmitic acid or hexadecanoic acid.

Unsaturated fatty acids have one or more double bonds. Most naturally occurring fatty acids have *cis* double bonds and are usually liquid at room temperature. Fatty acids with *trans* double bonds tend to have higher melting points. A double bond is indicated by n , where n is the number of the first carbon of the bond. *Palmitoleic* = 9 -hexadecenoic acid; *oleic* = 9 -octadecenoic acid; *linoleic* = 9,12 -octadecadienoic acid; *linolenic* = 9,12,15 -octadecatrienoic acid; *arachidonic* = 5,8,11,14 -eicosatetraenoic acid. Since fatty acids are elongated *in vivo* from the carboxyl end, biochemists use alternate terminology to assign these fatty acids to families: omega (ω) minus x (or $n - x$), where x is the number of carbon atoms from the methyl end where a double bond is first encountered. *Palmitoleic* is an $\omega - 7$ and *oleic* is an $\omega - 9$ acid, *linoleic* and *arachidonic* are $\omega - 6$ acids, and *linolenic* is an $\omega - 3$ acid. Addition of carbon atoms does not change the family to which an unsaturated fatty acid belongs.


Since the pK values of fatty acids are about 4–5, in physiological solutions, they exist primarily in the ionized form, called salts or "soaps." Long-chain fatty acids are insoluble in water, but soaps form micelles. Fatty acids form esters with alcohols and thioesters with CoA.

The following are biochemically significant reactions of unsaturated fatty acids:


1. Reduction




2. Addition of water





3. Oxidation




Prostaglandins, *thromboxanes*, and *leukotrienes* are derivatives of C_{20} polyunsaturated fatty acids, especially arachidonic acid. Prostaglandins have the general structure:




The series differ from each other in the substituents on the ring and whether C-15 contains an OH or O · OH group. The subscript indicates the number of double bonds in the side chains. Substituents indicated by $-(\beta)$ are above the plane of the ring; (α) below:




Thromboxanes have an oxygen incorporated to form a six-membered ring:



Leukotrienes are substituted derivatives of arachidonic acid in which no internal ring has formed; R is variable:




Acylglycerols are compounds in which one or more of the three OH groups of glycerol are esterified. In **triacylglycerols** (triglycerides) all three OH groups are esterified to fatty acids. At least two of the three R groups are usually different. If R₁ is not equal to R₃, the molecule is asymmetric and of the L configuration:




The properties of the triacylglycerols are determined by those of the fatty acids they contain, with *oils* being liquid at room temperature (preponderance of short-chain and/or cis-unsaturated fatty acids) and *fats* being solid (preponderance of long-chain, saturated, and/or trans-unsaturated).


Triacylglycerols are hydrophobic and do not form stable micelles. They may be hydrolyzed to glycerol and three fatty acids by strong alkali or enzymes (lipases). *Mono-* [usually with the fatty acid in the β(2) position] and *diacylglycerols* also exist in small amounts as metabolic intermediates. Mono- and diacylglycerols are slightly more polar than triacylglycerols. *Phosphoacylglycerols* are derivatives of L-α-glycerolphosphate (L-glycerol 3-phosphate):




The parent compound, **phosphatidic acid** (two OH groups of L-α-glycerolphosphate esterified to fatty acids), has its phosphate esterified to an alcohol (XOH) to form several series of phosphoacylglycerols. These are amphipathic molecules, but the net charge at pH 7.4 depends on the nature of X-OH.




In **plasmalogens**, the OH on C-1 is in *ether*, rather than ester, linkage to an alkyl group. If *one* fatty acid (usually β) has been hydrolyzed from a phosphoacylglycerol, the compound is a *lyso*-compound; for example, lyso-phosphatidylcholine (lysolecithin):




Sphingolipids are complex lipids based on the C-18, unsaturated alcohol, sphingosine. In *ceramides*, a long-chain fatty acid is in amide linkage to sphingosine:



Sphingomyelins, the most common Sphingolipids, are a family of compounds in which the primary OH group of a ceramide is esterified to phosphorylcholine (phosphorylethanolamine):




They are amphipathic molecules, existing as zwitterions at pH 7.4 and the only sphingolipids that contain phosphorus. *Glycosphingolipids* do not contain phosphorus but contain carbohydrate in glycosidic linkage to the primary alcohol of a ceramide. They are amphipathic and either neutral or acidic if the carbohydrate moiety contains an acidic group. **Cerebrosides** have a single glucose or galactose linked to a ceramide. *Sulfatides* are galactosylceramides esterified with sulfate at C-3 of the galactose:




Globosides (ceramide oligosaccharides) are ceramides with two or more neutral monosaccharides, whereas **ganglio-sides** are an oligosaccharide containing one or more sialic acids.


Steroids are derivatives of cyclopentanoperhydrophenanthrene. The steroid nucleus is a rather rigid, essentially planar structure with substituents above or in the plane of the rings designated β (solid line) and those below called α (dotted line):




Most steroids in humans have methyl groups at positions 10 and 13 and frequently a side chain at position 17. *Sterols* contain one or more OH groups, free or esterified to a fatty acid. Most steroids are nonpolar. In a liposome or cell membrane, **cholesterol** orients with the OH toward any polar groups; cholesterol esters do not. **Bile acids** (e.g., cholic acid) have a polar side chain and so are amphipathic:






Steroid hormones are oxygenated steroids of 18–21 carbon atoms. *Estrogens* have 18 carbon atoms, an aromatic ring A, and no methyl at C-10. *Androgens* have 19 carbon atoms and no side chain at C-17. *Glucocorticoids* and *mineralocorticoids* have 21 carbon atoms, including a C_{21} of oxygenated side chain at C-17. *Vitamin D₃ (cholecalciferol)* is not a sterol but is derived from 7-dehydrocholesterol in humans:



Terpenes are polymers of two or more isoprene units. **Isoprene** is




Terpenes may be linear or cyclic, with the isoprenes usually linked head to tail and most double bonds trans (but may be cis as in vitamin A). *Squalene*, the precursor of cholesterol, is a linear terpene of six isoprene units. Fat-soluble *vitamins* (A, D, E, and K) contain isoprene units:



Amino Acids

Amino acids contain both an *amino* (NH_2) and a *carboxylic acid* (COOH) group. Biologically important amino acids are usually α -amino acids with the formula




The amino group, with an unshared pair of electrons, is basic, with a pK_a of about 9.5, and exists primarily as $-\text{NH}_3^+$ at pH values near neutrality. The carboxylic acid group ($pK_a \approx 2.3$) exists primarily as a carboxylate ion. If R is anything but H, the molecule is asymmetric with most naturally occurring ones of the L configuration (same relative configuration as L-glyceraldehyde: see p. 1139).

The *polarity* of amino acids is influenced by their side chains (R groups) (see p. XX for complete structures). *Nonpolar* amino acids include those with large, aliphatic, aromatic, or undissociated sulfur groups (aliphatic = Ala, Ile, Leu, Val; aromatic = Phe, Trp; sulfur = Cys, Met). *Intermediate* polarity amino acids include Gly, Pro, Ser, Thr, and Tyr (undissociated).

Amino acids with ionizable side chains are *polar*. The pK values of the side groups of arginine, lysine, glutamate, and aspartate are such that these are nearly always charged at physiological pH, whereas the side groups of histidine ($pK = 6.0$) and cysteine ($pK = 8.3$) exist as both charged and uncharged species at pH 7.4 (acidic = Glu, Asp, Cys; basic = Lys, Arg, His). Although undissociated cysteine is nonpolar, cysteine in dissociated form is polar.


All amino acids are at least *dibasic acids* because of the presence of both the α -amino and α -carboxyl groups, the ionic state being a function of pH. The presence of another ionizable group will give a tribasic acid as shown for cysteine.



The **zwitterionic form** is the form in which the *net* charge is zero. The *isoelectric point* is the average of the two pK values involved in the formation of the zwitterionic form. In the above example this would be the average of $pK_1 + pK_2$.

Purines and Pyrimidines


Purines and **pyrimidines**, often called *bases*, are nitrogen-containing heterocyclic compounds with the structures



Major bases found in nucleic acids and as cellular nucleotides are the following:


Purines	Pyrimidines
Adenine: 6-amino	Cytosine: 2-oxy, 4-amino
Guanine: 2-amino, 6-oxy	Uracil: 2,4-dioxy
	Thymine: 2,4-dioxy, 5-methyl
Other important bases found primarily as intermediates of synthesis and/or degradation are	
Hypoxanthine: 6-oxy	Orotic acid: 2,4-dioxy, 6-carboxy
Xanthine: 2,6-dioxy	

Oxygenated purines and pyrimidines exist as *tautomeric* structures with the keto form predominating and involved in hydrogen bonding between bases in nucleic acids:



Nucleosides have either β -D-ribose or β -D-2-deoxyribose in an *N*-glycosidic linkage between C-1 of the sugar and N-9 (purine) or N-1 (pyrimidine).

Nucleotides have one or more phosphate groups esterified to the sugar. Phosphates, if more than one are present, are usually attached to each other via phosphoanhydride bonds. Monophosphates may be designated as either the base monophosphate or as an *-ylic acid* (AMP: adenylic acid):



By conventional rules of *nomenclature*, the atoms of the base are numbered 1–9 in purines or 1–6 in pyrimidines and the carbon atoms of the sugar 1–5. A nucleoside with an unmodified name indicates that the sugar is ribose and the phosphate(s) is/are attached at C-5 of the sugar. Deoxy forms are indicated by the prefix d (dAMP = deoxyadenylic acid). If the phosphate is esterified at any position other than 5, it must be so designated [3 -AMP; 3 -5 -AMP; (cyclic AMP = cAMP)]. The nucleosides and nucleotides (ribose form) are named as follows:

Base	Nucleoside	Nucleotide
Adenine	Adenosine	AMP, ADP, ATP
Guanine	Guanosine	GMP, GDP, GTP
Hypoxanthine	Inosine	IMP
Xanthine	Xanthosine	XMP
Cytosine	Cytidine	CMP, CDP, CTP
Uracil	Uridine	UMP, UDP, UTP
Thymine	dThymidine	dTMP, dTTP
Orotic acid	Orotidine	OMP

Minor (modified) bases and nucleosides also exist in nucleic acids. *Methylated* bases have a methyl group on an amino group (*N*-methyl guanine), a ring atom (1-methyl adenine), or on an OH group of the sugar (2 -*O*-methyl adenine). *Dihydrouracil* has the 5–6 double bond saturated. In *pseudouridine*, the ribose is attached to C-5 rather than to N-1.

In **polynucleotides** (*nucleic acids*), the mononucleotides are joined by phosphodiester bonds between the 3 -OH of one sugar (ribose or deoxyribose) and the 5 -OH of the next (see p. 567 for the structure).

Index

HOW TO USE THIS INDEX. The letter "f" after a page number designates a figure; "t" designates tabular material; "cc" designates a Clinical Correlation **Boldface** page numbers show where terms are explained. "See" cross-references direct the reader to the synonymous term. "See also" cross-references direct the reader to (1) related topics or (2) the synonym under which a more detailed topic breakdown may be found.

A

A band, **948**

A face, **143**

A peptide, **832**, 833

A site, 727

A23187 (calcium ionophore), 212, 212f, 212t

Abetalipoproteinemia, 59cc, 195cc, 380cc, 1082cc

ABP. *See* Androgen binding protein

Absorption of nutrients, 1057, 1058f.

See also Digestion, *specific nutrients*

Abzyme, **164**, 164-165, 165f

ACAT (acyl-CoA:cholesterol acyltransferase), **416**

Acceptor atom, **66**

Acceptor molecule, **80**

Acetaldehyde, 139cc, **280**

Acetals, **1138**

Acetate, **559**

Acetate thiokinase, **227**, **411**

Acetoacetate, **227**, **379**, 379f, 379-380, 388f, 388-389, 389f.

See also Ketone bodies

Acetoacetic acid, 1044

Acetoacetyl CoA, in utilization of ketone bodies, 389

Acetokinase, **411**

Acetone, 380, 388-389.

See also Ketone bodies

Acetyl CoA, **224**, **226**, 226f, 226-231, 231f

in acetoacetate synthesis, 388

in cholesterol synthesis, 410-415

in ketone body formation, 387-390

as source of fatty acids, 366

sources, 227, 231f, 369-370

transfer from mitochondria to cytosol, 369-371

transport, 369-371, 371f

N-Acetyl-5-methoxytryptamine, 476

Acetylcholine, **202**, 904, **1061**, 1061f

in muscle contraction, 954

reactions at synapse, 928, 928f

release, 928

as secretagogue, 1061, 1061t

and stress response, 853, 855f

structure, 202f

synthesis, **928-929**

Acetylcholine receptor(s), **202**, **923**, 954.

See also Nicotinic-acetylcholine channel

Acetylcholinesterase, 928, **928**, 929f

Acetyl-CoA carboxylase, **366**, 366f, 1122

N-Acetylgalactosamine, blood type determined by, 347

N-Acetylglucosamine, 345-346, 353-354, 1141

N-Acetylglucosamine sulfatase deficiency, 352cc

N-Acetylglucosaminidase deficiency, 352cc

N-Acetylglutamate, **454**, 454f, 455

N-Acetylglutamate synthetase, **455**

deficiency, 456cc

Acetylneuraminic acid, **345**, 346, 347f, **426**, 426f, **1142-1143**

N-Acetylserotonin, **866**

N-Acetyltransferase, **866**

Acid(s), 7, 7-12, 1137.

See also Acid-base balance; *specific acid*

acid-base pairs, 8t

-aric, **1141**

biological importance, 7-9

buffering, 10-12

dibasic, 1146

general, **160**

-onic, **1141**

-uronic, **1141**

-ylic, **1147**

Acid anhydrides, **1137**, 1138

Acid-base balance, 32f, 32-33, 1041-1046.

See also Acidosis; Alkalosis, pH

bone in, 1042cc

buffer systems and, 1036-1038

clinical data, evaluation, 1051cc

disorders, 1042, 1043t, 1046-1050

kidneys in, 1043

regulation, 556-559

Acid-base catalysis, 160, 161f

Acid-base pairs, conjugate, 7-10, 8t, **1038**

Acid-base state

compensated, 1046, **1046**, 1047-1049

partially compensated, **1046**

uncompensated, **1046**

Acidosis, 12cc, 380, **556**, **1041**

2,3-bisphosphoglycerate in, 1036, 1036f

metabolic, 390cc, 479cc, **1042**, 1046, 1048, 1048f

blood bicarbonate concentration in, 12cc

renal tubular, 1042

respiratory, **1042**, 1046, 1047, 1047f

chronic, 1048cc

Acid-stable lipase, **1078**

Aciduria, hereditary orotic, 505, 505cc

Aconitase, **233**, **1006**, 1007

cis-Aconitate, 233

Acquired immunodeficiency syndrome. *See* AIDS

ACTH. *See* Adrenocorticotrophic hormone (corticotropin)

Actin, **948**, 948t, **951**

fibrous. *See* F-actin

globular. *See* G-actin

types, 951, 951t

Actin binding site, myosin, 950

Actinin, 948t, 952

Actin-myosin cross-bridges, **953**, 954f

Actin-myosin interaction, 957-959, 958f, 959

Activated glucose, **319**

Activated intermediates, transport, 491

Activation energy (E_a), **159**

Activator site, 152

Active oxygen species, neutralization, **933**

Active site, **129**, 155-158

Active-site direction, **101**

Acute intermittent porphyrin, 1012t, 1013cc

Acute phase reactants, **553**

Acyclovir, **520**, 520f

for herpesvirus infection, **517**

Acyl carrier protein (ACP), **368**

Acyl CoA: dihydroxyacetone phosphate acyltransferase, **408**

Acyl transport, across mitochondrial membrane, 382

Acylated enzyme intermediate, **163**

Acyl-CoA dehydrogenases, **383**

deficiency, 385cc

Acyl-CoA-cholesterol acyltransferase (ACAT), **416**

1-Acylglycerol phosphate acyltransferase, 403

Acylglycerolipids, **397**

Acylglycerols, 363-365, 365f, 1143, 1144

ADA. *See* Adenosine deaminase

ADA-polyethylene glycol (ADA-PEG), 503cc

Adenine, **492**, 679-680

Adenine nucleotide translocator, **245**, 245f

Adenine nucleotides, 492f

Adenosine, 142, 490, 492f

Adenosine deaminase, **501**, 503cc

deficiency, 502

gene therapy, 793cc

Adenosine diphosphate. *See* ADP

Adenosine monophosphate. *See* AMP

Adenosine triphosphate. *See* ATP

Adenosylhomocysteinase, **469**, 470f

S-Adenosylhomocysteine, 405f, **469**

S-Adenosylmethionine, **405**, **469**, **535**, 1124

cysteine synthesis from, 470f

- S-Adenosylmethionine
- (*continued*)
- in methyltransferase reactions, 471-472, 472f
 - in phosphatidylcholine synthesis, 405f
 - synthesis, 469f
- S-Adenosylmethionine decarboxylase, **460**
- Adenovirus DNA, replication, 645, 645f, 658f
- Adenylate cyclase, **293, 323, 327, 327f**, 439, 859, 859f, 861f, **1061**
- Adenylate kinase, **289**, 955-957
- Adenylosuccinate synthetase, **497**
- ADH. *See* Antidiuretic hormone
- Adipose tissue, 1089
- energy reserves in, 537t
 - lipases in, 377
 - in starve-feed cycle, 544-545
 - white, 375, 376
- AdoCys. *See* S-Adenosylhomocysteine
- AdoMet. *See* S-Adenosylmethionine
- ADP, 219f, 238
- ADP-ribosyltransferase, **427**
- Adrenal gland, steroid hormone synthesis in, 898, 990, 991f
- Adrenal hormones, **894**
- Adrenaline. *See* Epinephrine
- α -Adrenergic receptor(s), 328
- β -Adrenergic receptor(s), **328**, 875f, 875-876, 876f
- Adrenocorticotrophic hormone (corticotropin), 842, 846
- actions, 847t, 883t
 - in cortisol secretion, 903f, 903t
 - source, 847t
 - synthesis, 849, 850t
- Adrenodoxin, **989**
- Adult-onset diabetes, in obesity, **1095**
- AE. *See* Anion exchanger
- Aerobic exercise, 551-552
- Affinity chromatography, 73
- Affinity constant (K_a), 137
- Age pigment (lipofuscin), **19**
- Aggrecan, 356
- Agging
- changes that occur in, 547
 - mitochondrial mutations and, 617cc
 - telomerase activity in, 658cc
- Agmatine, **457**, 457f
- Agonist, **201**
- Agriculture, Department of (USDA), food pyramid, 1102, 1103f
- Agriculture, recombinant DNA in, 794-795
- Ah receptor, 913, **985**
- Ah receptor nuclear translocator, **985**
- AIDS, 171, 792-793
- treatment, 661cc
- ALA. *See* Aminolevulinic acid
- Alamethicin, 212t
- Alanine, **25**
- β -Alanine, absorption, 1072
- Alanine cycle, 299-301, 300f, 529-530
- β -Alanylhistidine. *See* Carnosine
- β -Alanylmethylhistidine. *See* Anserine
- Albinism, 467cc, **469**
- Alcaptonuria, 467cc
- Alcohol
- and barbiturates, 281cc
 - cytosolic, **387**
 - drug-nutrient interactions, 1133t
 - effects on liver, 555-556
 - energy content of (kcal), 1088
 - oxidation, 280
- Alcohol dehydrogenase, 129, **154, 280**, 555
- ethanol oxidation by, 129f, 143, 143f
 - isoenzymes, with different pH optima, 167cc
- Alcoholism
- folate deficiency in, **1125**
 - niacin deficiency in, **1121**
 - nutritional considerations in, 1120cc
 - riboflavin deficiency in, **1121**
 - Wernicke-Korsakoff syndrome in, **1120**, 1120cc
 - zinc deficiency in, 1131
- Alcohols, **1137**, 1141
- primary, 1137
 - secondary, 1137
 - tertiary, 1137
- Aldehyde(s), **1137**
- Aldehyde dehydrogenase, **138**, 139cc, **280, 387**, 555
- type I, 934t
- Alditol, **1141**
- Aldohexoses, 1139-1140
- Aldolase, reaction catalyzed by, 273f, 275
- Aldose reductase, **935**
- and diabetes, 551cc
- Aldose-ketose isomerization, **341-342**
- Aldosterone, 894, **896**
- excretion pathway, 902t
 - functions, 895t
 - secretion, 895t, 901, 903r, 904f
 - as stress hormone, 905
 - structure, 895t
 - synthesis, **898**, 901-905, 903t, **990**
- Aldosterone receptor(s), 894
- Alicyclic compound, cholesterol as, 409
- Alkaline phosphatase, 1059t
- Alkalosis, **558, 1041**
- metabolic, **1042**, 1045-1046, 1048-1049, 1051-1052, 1052cc
 - respiratory, **1042**, 1046, 1047f, 1047-1048
 - acute, 1047cc
- Alkyl chains, 26f, 363-365
- Allele-specific probe, 583cc
- Allergy, 440
- Allolactose, **806**
- Allopurinol, for gout (hyperuricemia), **517**
- Allosteric effectors, 491, 497f, **540**
- binding characteristics, 151-152
 - changes in, 541f, 545
 - control of hepatic metabolism, 541f, 542f
 - negative, 153f, 540-541
 - positive, 153f, 540-541
- Allosteric enzyme(s), 153f
- catalytic subunits, 155, 155f
 - K class, **152**, 153f
 - polymeric, 153f
 - rates, 153
 - regulatory subunits, 155, 155f
 - sigmoidal kinetics, 152-153
 - V class, **152**
- Allosteric protein, **807**
- Allosteric site, **129, 151**
- vs. substrate binding site, in gout, 152cc
- Allosterism, 803
- and cooperativity, 154
 - and enzyme activity, 151-155
 - hemoglobin and, 1029-1030
- Allysine, **54**, 54f, 55f, 748
- Alpha (α), conversion factor, **1039**
- Alternative transcription initiation sites, **743**
- Alternative translation initiation sites, **743**
- Alu family, **616, 823**
- Amanita phylloides*, 691, 692cc
- α -Amanitin, 691
- American diet, 1132-1133
- Amides, **1138**
- Amiloride, 1065, 1065f, 1067
- Amines, **1138**
- primary, 1138
 - secondary, 1138
 - tertiary, 1138
- Amino acid(s), **1089, 1146**
- abbreviations, 27t
 - absolute configuration, 28f
 - absorption, 1072-1073
 - acid forms, 30-31, 31r
 - activation, for protein synthesis, 721-724
 - analysis, in diagnosis of disease, 74cc
 - aromatic, 25-26, 554
 - asymmetric center, 28
 - base forms, 30-31, 31r
 - basic, **31**
 - branched-chain, 453, 476-479, 477f
 - metabolism, diseases, 479cc
 - chemistry, 30-39, 39t
 - common, 25, **25**, 25f
 - degradation, 456-485
 - derived, **25**, 30
 - disposition in well-fed state, 528f
 - epithelial transport, **1072**, 1072cc
 - essential, **446**, 447t, **1090**, 1090-1091
 - free, carrier-mediated transport, 1072-1073
 - glucogenic, 304-306, 306r, 1089
 - in gluconeogenesis, 530-533
 - group translocation, 210
 - intermediate polarity, 1146
 - interorgan transport, 453, 453f
 - ionic form, 32
 - ionizable groups, and biological function, 30-39
 - ketogenic, 304-305, 306r, 1089
 - membrane transport, **209**, 1072
 - modification, after incorporation into proteins, 744-746, 745f
 - nitrogen incorporation into, 447-452
 - nonpolar, 38, 1146
 - polar, 38, 1146
 - polymerization, 28-29
 - residue, **29**, 29f
 - separation from proteins based on pI value, 35-36
 - sequence homology in serine protease families, 105
 - side chains, 25-28, 38, 38f
 - structure, 25-28, 26f
 - sulfur-containing, 471cc
 - synthesis, 456-485
 - transport, 209, 211t, 485, 1072
- Amino acid metabolism, 445-488
- enzyme deficiency, 465cc
 - and ketone bodies, 389f
 - by liver, 554
 - overview, 446-447, 447f

D-Amino acid oxidase, 156, **452**

L-Amino acid oxidase, **452**, 452*f*

β -Amino acids, 509-511

α -Amino adipic semialdehyde synthase deficiency, 481cc

Amino group transfer, 448, 448*f*

Amino monosaccharide, **1141**

Amino sugar formation, 344-345

Aminoaciduria, 74cc

Amino-acridine, 594cc

Aminoacyl site, 727

Aminoacylation, of transfer RNA, 721-724, 724*f*

Aminoacyl-tRNA synthetase(s), 721, **722**

Aminoacyl-tRNAs, **529**

p-Aminobenzoic acid, 149-150, 150*f*

γ -Aminobutyric acid. *See* GABA

Aminoglycosides, effects on protein synthesis, 733-734, 734*t*

β -Aminoisobutyric acid, **509**

-Aminolevulinate, **236**

-Aminolevulinate synthase, **236**, **1012**, 1017

Aminolevulinic acid, synthesis, 1014*f*

Aminolevulinic acid dehydratase, 1012-1013

Aminolevulinic acid synthase, 1011-1012, 1017

4-Amino-*N*¹⁰-methyl folic acid. *See* Methotrexate

Aminopeptidase(s), **1070**, 1072

Aminopeptidase A, 1059*t*

Aminopeptidase N, 1059*t*

Aminotransferase(s), **131**, 131*f*, **448**, 448*f*, 449-450, 475*f*

Ammonia

- accumulation
 - in liver disease, 554
 - metabolic disorders caused by, 455-456, 456cc
- elimination, 454-455
- excretion, 1044*f*, **1045**
- incorporation, 450-451
- production, 450, 453

AMP, **287**, 287-290, **289**, 491, **494**, 494-497, 496*f*

5 -AMP aminohydrolase, **500**

AMP deaminase, **500**, **501**

Amphipathic molecules, **5**, **183**

Amplification mechanism, in glycogen phosphorylase regulation, 323-324, **324**

α -Amylase, **314**, **1074**, 1075*f*

- pancreatic, **1073**

Amylo- α -1,6-glucosidase, 318

Amylopectin, **1073**, **1142**

- digestion by α -amylase, 1075*f*
- sources, 1074*t*
- structure, 1074*t*

Amylose, 321, **1073**, 1074*t*, **1142**

Amytal, **259**

Anabolic pathways, **218**

Anaerobic exercise, 551-552

Analbuminemia, 380cc

Anaplerotic reactions (anaplerosis), **304**

Androgen(s), 896, 1145

- aromatization, **992**, 993*f*

Androgen binding protein, **908**, 908-909

Androstenedione, **990**

Anemia

- hemolytic, 337, 338cc, **1008**
- iron-deficiency, 1009cc, **1130**
- macrocytic, **1124**
- megaloblastic, 463cc, 1126
- microcytic hypochromic, **1130**
- pernicious, **1125**
- sideroblastic, **1122**
- spur cell, 195cc
- in vitamin A deficiency, **1111**

Anesthesia, and membrane fluidity, 196

ANF. *See* Atrial natriuretic factor

Angina pectoris, 292cc

Angiotensin I, 932*t*

Angiotensin II, 844*t*, **901**, 901-902, 932*t*

- actions, 848*t*, 884*t*
- source, 848*t*

Angiotensin III, 848*t*, 884*t*, 902

Angiotensin receptor, 902, 904*f*

Angiotensinogen, **901**

Anion(s), **5**, 14, 205, 205*f*

Anion channel, erythrocyte, **190**, 191

Anion exchange protein, **204**

Anion exchanger, **1065**, 1065*f*

Anion gap, **1050**

Anion-exchange resins, **70**

Ankyrin, **191**, 191*f*, 191-192

Anomers, **1139**, **1141**

Anserine, **483**, 483*f*, 1072

Anthracycline, 594cc

Anthranilate synthetase, 808

Anti-association factor, **725**

Antibiotic(s)

- absorption, 1073
- for ammonia buildup, 456
- deafness caused by, 734cc
- effects on protein synthesis, 733-735
- resistance to, 670cc
- and RNA polymerase, 691, 692cc
- and vitamin K deficiency, **1117**

Antibiotic ionophores, 212-213

Antibiotic-resistance genes, transposons containing, 816cc, 817

Antibody(ies), 88-97, 89*f*.

- See also* Immunoglobulin(s)
- classes, functions, 92cc
- maternal, transfer to fetus/neonate, 1073
- nicotinic-acetylcholine receptor, in myasthenia gravis, 929cc
- Rh, 1020cc

Anticoagulant drugs, 350cc

Anticodon sequences, 719

Anticodon triplet, **682**

Anticonvulsants

- drug-nutrient interactions, 1133*t*
- and vitamin requirements, 1118cc, 1125

Antidepressants, mechanism of action, 930

Antidiuretic hormone, 848*t*

Antifolates, **518**, 518-519

Antigen(s), **88**

Antimalarials, and hemolytic anemia, 338

Antimetabolites, **149**, 150, 151, 151*f*, **517**, 517-518

Antimycin A, **259**

Antioxidants, **1110**, **1116**, 1127

Antiparallel DNA strands, **574**

Antiport, **200**, 200*f*, 211*t*, 212*t*

- for anion transport, 204*f*, 204-205
- glutamate-aspartate, **303**

Antiporter

- Ca²⁺, Na⁺, 211*t*

Antipyretics, and hemolytic anemia, 338

Antisense nucleic acids, **790**, 790-793

Antisense RNA, **792**

Antisense strand, 692

Antithrombin III, **975**

Antiviral agents, structure, 520*f*

AP endonuclease, **635**

AP site. *See* Apurinic-apyrimidinic site

Apoenzyme, **128**

Apoferitin, **1004**, 1007, 1007*f*

Apolar edge, **54**, 55*f*

Apolipoprotein(s), **56**, 57*t*, 115

- B, **415**, **1082**, 1082cc
- B-100, **416**
- E, **416**
- intestinal, **1082**
- structure, 60*f*

Apoptosis, **19**, **452**, 751, **915**

- in ovarian cycle, 916cc
- steroid hormones and, 915-916

Apparent mineralocorticoid excess syndrome, 911cc

Apurinic-apyrimidinic site, **635**

Aqueous humor, **932**, 933

araC. *See* Cytosine arabinoside

Arachidonic acid, **433**, 1143

- metabolism, 992, 1099cc

Arachidonic acid-specific acyl CoA

- transacylase, **407**

Arginase, **455**

- deficiency, 457cc

Arginine, **27**, 27*f*

- in children, 448
- guanidinium group, 27*f*
- imidazolium group, 27*f*
- synthesis, 455, 457, 534*f*

Arginine vasopressin. *See* Vasopressin

Argininosuccinate, **454**

Argininosuccinate lyase, **455**, 934*t*

- deficiency, 457cc

Argininosuccinate synthetase, **455**

- deficiency, 457cc

Arnt protein, **985**

Aromatic amino acids, 25-26, 554

Aromatization, **992**, 993*f*

Arrestin, 876, **943**, 944*t*

ARS consensus sequence, **656**

Arsenate

- in glycolysis inhibition, 282, 282*f*
- toxicity, 283cc

Arsenic poisoning, 283cc

Arsenite, **228**

Artificial membrane systems, **189**

Aryl hydrocarbon receptor, 913, **985**, **994**

Ascorbate, in iron absorption, **1005**

Ascorbic acid. *See* Vitamin(s), C

L-Ascorbic acid, **344**, 1141

Asians, sensitivity to alcohol, 139cc

Asparaginase, 174, 452, 452*f*

Asparagine, **27**, **350**, 351*f*, 452, 452*f*

Asparagine synthetase-deficient tumors, treatment, 452

Aspartame (NutraSweet), **544**

Aspartate, **27**, 27*f*, 454

Aspartate proteases, **98**

Aspartylglycosylaminuria, 349cc

4-L-Aspartylglycosamine amidohydrolase deficiency, 349cc

Aspirin, 435, 436

effects on vitamin C serum levels, 1127

Assay(s)

biochemical, for assessment of malnutrition, **1108**

coupled, 168-170

for human immunodeficiency virus, 171

Association constant (K_s), 137, 871

Astrocytes, **921**, 931, 931*f*

Ataxia, **1120**

cerebellar, 387cc

spinocerebellar, 602cc

in thiamine deficiency, **1120**

Ataxia telangiectasia, 639cc

Atherogenesis, 471cc

Atherosclerosis, 56, 56cc, 416cc, 417cc, 471cc

ATP, **142**, **220**, **289**

in active mediated transport, 206, 206*f*

as allosteric effector, 142

in carbohydrate metabolism, 281-282

corneal metabolism, 933

as cosubstrate, 142

and energy-producing and energy-utilizing systems, 218-220, 219*f*, 220*f*

expenditure, gluconeogenesis and, 308

hydrolysis, 594

in muscle contraction, 954-957

production, **920**

regulation of 6-phosphofructo-1-kinase by, 287-290

for retina, source, 935-936

role of, 490

source, 17, 551

structure, 219*f*

synthesis, 219, 231, 231*f*, 238

and transmembrane electrical potential in neurons, 921-923

and ubiquitin-dependent protein degradation, 751*f*, 751-752

ATP cycle, in starve-feed cycle, 526, 526*f*

ATP-ADP translocase, **205**, 205*f*, 205-206

ATP-ADP transport, in mammalian cells, 211*t*

ATPase, **206**

Ca²⁺-, **208**, 211*t*

H⁺, K⁺-, **1069**, 1069*f*

Mg²⁺, 146, 146*f*, 959, 959*f*

myosin, 950, 954-957

Na⁺, K⁺-, **206**, 206-207, 207*f*, 211*t*, **1064**

ATP hydrolysis, 207, 207*f*

contraluminal, in NaCl secretion, 1066*f*, 1066-1067

erythrocyte ghost studies, 207-208, 208*f*

inhibition, 207

vacuolar proton pump as, **927**

ATP-citrate lyase, 371

Atractyloside, 205*f*, 205-206

Atrial natriuretic factor

actions, 848*t*, 885-888, 887*f*

source, 848*t*

synthesis, 905

Atrial natriuretic factor receptor, functional domains, 885, 887*f*

Atrial natriuretic factor receptor-guanylate system, **885**

Atrial natriuretic peptide(s), 885-888, 886*f*

Atriopeptin. *See* Atrial natriuretic factor

Atropine, 1061, 1061*f*

Attenuation, 696

Attenuator site, of tryptophan operon, 810*f*, 810-813

AUG codon, 685, **714**, **719**, 727

Autoactivation, **1070**, 1071

Autocrine hormone(s), **841**

Autolysis, **19**, **105**

Autonomously replicating sequence, **656**

Autophagy, 18*f*, **19**

Autophosphorylation, **879**

Autoregulation, of steroid receptors, **915**

Axon, **921**

Azaserine, **519**

Azathioprine, as immunosuppressant, **517**

3 -Azido-3 -deoxythymidine. *See* Azidothymidine

Azidothymidine, **520**

in AIDS treatment, 661 cc

structure, 520*f*

AZT. *See* Azidothymidine

B

B face, **143**

B peptide, **832**, 833

Bacteria

in carbohydrate digestion, **1075**

expression of foreign genes in, 832-835

expression vector, 783, 784*f*

foreign gene expression in, for encoded protein synthesis, 783, 784*f*

infections, diagnosis, 583cc

metabolism, **450**

synthesis of human growth hormone, 834*f*, 834-835

synthesis of human insulin, 832-833, 833*f*

transcription in, 800-802

transformation, with recombinant DNA, 767

transformed

detection, α -complementation for, 772*f*, 772-773

selection, by loss of antibiotic resistance, 770-773, 771*f*

selection techniques, 768

Bacteriophage(s)

as cloning vectors, 778-779, 779*f*

heteroduplex formation in, 584*f*

in site-directed mutagenesis of single nucleotide, 787-790, 789*f*

Bacteriophage λ , 669*f*, **778**, 779*f*

phage library, **779**

Bacteriophage T7 DNA, replication, 659*f*

Bacteriophage X174, 612*f*

Band 3, **204**

Barbiturates, alcohol and, 281cc

Baroreceptor, **881**

Basal metabolic rate, **1088**, 1088-1089, **1131**

Base(s), 7, 7-12, 1146.

See also Acid(s); Purine(s); Pyrimidine(s)

acid-base pairs, 8*t*

chemical modification, 628-629, 629*f*-631*f*

conjugate, **7**, **1038**

hydrophobic qualities, 569

ionized forms, **629**, 631*f*

methylated, 1147

minor (modified), **1147**

nomenclature for, 1147

Base excess, **1049**, 1051cc

negative, 1049-1050, 1050*f*

positive, 1049-1050, 1050*f*

Base excision repair, **635**

Base pairing, 8*t*, 624*f*

between ionized forms of bases, 631*f*

in RNA, 680, 681*f*

wobble rules, 719, 719*t*

Base substitutions, **628**

Base-exchange reaction, 406, 406*f*

BCAA aminotransferase, **477**

BCAAs. *See* Branched-chain amino acids

B-DNA

major grooves, 109*f*

structure, 571*f*, 573*t*

Beads-on-a-string structure, **603**

Becker muscular dystrophy, 821, 822cc

Beer-Lambert relation, **168**

Behenic acid, **421**

Benz[a]pyrene, **993**, 993-994, 995*f*

Benz[a]pyrene-7,8-dihydrodiol-9,10-epoxide, **994**, 995*f*

Beriberi, **1120**

Betaine, **460**, 460*f*

BH₂. *See* Tetrahydrobiopterin

Bicarbonate. *See also* Base excess; pH-bicarbonate diagram

in blood, 1031-1032

conservation, **453**

distribution, between plasma and erythrocytes, 1035-1036

formation, 1032

for lactic acidosis, 291cc

reabsorption of, **1043**, 1044*f*

secretion, in pancreatic juice, 1066

transport, 204*f*, 204-205

Bicarbonate buffer system, 1038-1041

Bidirectional replication, **646-647**, 648*f*

Bifunctional enzyme, **294**

Bile, **1057**

Bile acids, **410**, **1079**, **1145**

and cholesterol, 417-420

conjugated, 1084

detergent action, 1078

enterohepatic circulation of, **1084**, 1084*f*

glycoconjugates, 1079, 1080*t*, **1084**

metabolism, 1083*f*, 1083-1084

micelles, 1078-1082, **1079**

primary, **1083**

secondary, **1083**

significant, 20

solubility in aqueous solutions, 1079, 1079*f*

structure, 418*f*

synthesis, 410

tauroconjugates, 1079, 1080*t*, **1084**

unconjugated, 1080*t*, 1084

Bile salts, **1079**

deficiency, 1112cc

Bilirubin, **1018**

conjugated, serum, elevation, 1021cc

conjugation, 1018-1019

detoxification, **272**

direct, **1018**

excretion, 346cc

formation, from heme, 1017, 1017*f*

indirect, **1019**

toxicity, 1018

transport, in plasma, 1018-1019

unconjugated, 1018-1019

- Bilirubin diglucuronide, **1018**, 1018-1019, 1019*f*
- Bilirubin UDP-glucuronosyltransferase
 deficiency, 1020cc
 isoenzymes, 1020cc
- Biliverdin IX, **1017**
- Biliverdin reductase, **1017**
- Bimolecular leaf, **189**
- Binding site, asymmetry, 158
- Biochemical assays, in malnutrition, **1108**
- Bioenergetics, 217-266
- Biogenic amines, 853, **1061**
- Biological fluids, 7
- Biopterin, **464-465**, 465*f*
 deficiency, 465cc
- Biotin, 211*t*, **1122**
- 1,3-Bisphosphoglycerate, **225**
- 2,3-Bisphosphoglycerate, **277**, 278*f*, **1029**, 1029*f*, 1034-1036, 1036*f*
- 2,3-Bisphosphoglycerate mutase, **1036**
- 4,5-Bisphosphoinositol glycerophospholipids, **182**
- Blindness, 936cc
- Blood
 acetone in, 389
 bicarbonate concentration, in metabolic acidosis, 12cc
 bicarbonate in, 1031-1032
 buffering line of, **1040**, 1041*f*, 1049-1050, 1050*f*
 carbon dioxide in, forms, 1031-1032
 clearance of drugs from, 134
 clot dissolution, 960
 clotting. *See* Blood coagulation
 enzymes, short half-life, 174
 gas concentration in, respiratory anatomy and, 1027
 properties, in humans at rest, 1032, 1033*t*
 steroid hormone transport in, 908-909
- Blood coagulation, 91cc, 436, **960**
 amplification factor and, 963
 autocatalytic action, 963
 calcium in, **1128**
 clot dissolution, 960-961, 961*t*, 975*f*, 975-976.
See also Fibrinolysis
 control, allosteric role of thrombin in, 974*f*, 974-975
 extrinsic (tissue factor) pathway, 960-961, 961*t*, 963*f*, 963-964, 974*f*, 974-975
 factors, 103*f*, 960-961, 961*t*
 and heparin therapy, 350cc
 intrinsic (contact) pathway, 960-961, 961*t*, 961-963, 962*f*
 defects, 963cc
 mechanism, 960-976
 as membrane-mediated process, 960-961
 and plasmin, **172**
 platelets in, 966, 967, 968*f*
 proteins, properties of, 968-969
 signal amplification in, 920
 and streptokinase, **172**
 and tissue plasminogen activator, **172**
- Blood gases, in humans at rest, 1032, 1033*t*
- Blood groups, sugars determining, 347, 348cc
- Blood pressure, **436**, 1129
- Blood-brain barrier, **920**, **921**
- Bloom syndrome, 639cc
- Blue pigment, 937
- BMI. *See* Body mass index
- Body fluids, 537*t*, 1036-1037, 1037*f*
- Body mass index, 378cc
- Body surface area, and energy expenditure, 1088
- Bohr effect, **123**, 123-124, **1031**, 1034, 1035
- Bombesin, 848*t*
- Bone
 in acid-base homeostasis, 1042cc
 demineralization, 1114, 1131
- Bongkreic acid, 205*f*, 205-206
- Boron, **1132**
- Botulinum toxin, binding to vesicle-associated membrane protein, 927
- BPG. *See* 2,3-Bisphosphoglycerate
- BPG mutase, **1036**
- BPG shunt, 278*f*
- Bradykinin, 848*t*
- Brain, **920**
 carbohydrate metabolism in, 269-270, 272
 complex lipids in, **921**
 composition, 920, 921
 energy source for, **920**
 gangliosides in, 426
 protein turnover rate, **921**
- Branch migration, **664**, **667**
- Branched-chain acids, **364**
- Branched-chain amino acids, **226**, 453, 476-479, 477*f*
 metabolism, diseases, 479cc
- Branched-chain α -keto acid dehydrogenase, **544**
- Branching enzyme, **319**, 320*f*
- Breast milk, micronutrients in, 1117cc
- Brevican, 356
- Bronchopulmonary dysplasia, 399
- Brush border, **1059**
 transport systems, **1073**
- Buffering (buffers), **10**, 10-12, 11*f*, 12cc
 acid dissociation constants, 1037, 1037*t*
 bicarbonate, in metabolic acidosis, 12cc
 capacity, **10**
 carbon dioxide-bicarbonate system, 1038-1041
 of cells, 1036-1038
 hemoglobin, **1033**, 1033-1034, 1041, 1041*f*
 hydrogen ion, **1043**, 1044*f*
 of interstitial fluid, 1036-1038
 of metabolic acids, 1038, 1038*t*
 of plasma, 1036-1038
 problems with, 11*f*
 in urine, 1044
- Buffering line of blood, **1040**, 1041*f*, 1049-1050, 1050*f*
- α -Bungarotoxin, **203**
- Burn(s), metabolic effects, 553
- Buthionine sulfoximine, **485**, 485*f*
- Butyrate, **559**
- C**
- C peptide, 743
- C regions, **91**
- Ca²⁺. *See* Calcium
- CAAT box, **699**
- Cachexia, **453**
 cancer, 553cc
- Caffeine, 688-689, 689*f*
- Cahn-Ingold-Prelog system, 1140
- Calbindin, 1114
- Calciferol. *See* Vitamin(s), D₂
- Calcitonin, 849*t*
- Calcitriol. *See* 1- α ,25-Dihydroxycholecalciferol
- Calcium, **1128**
 in aldosterone secretion, 902-904
 binding to calmodulin, 323
 in blood coagulation, 968-969
 and blood pressure, 1129
 deficiency, **1128**
 dietary requirements, and protein intake, 1094
 in glycogenolysis, 328-329, 329*f*
 and hepatic glycogenolysis, 328, 328*f*
 homeostasis, vitamin D in, 1112-1114, 1115*f*
 intracellular, **996**
 as intracellular messengers, **208**
 and membrane fluidity, **195**
 metabolism, 1112-1114, 1115*f*
 in renal osteodystrophy, 1113cc
 in muscle contraction, 954
 and osteoporosis, 1128-1129
 physiological roles, 1128-1129
 primary active transport, 208-209
 in regulation of smooth muscle contraction, 959, 959*f*
 release, from intracellular stores, 862-865, 865*f*
 requirements, **1128**
 as second messenger, **208**, 323
 in steroid synthesis, **896**, 901
 transport, in mammalian cells, 211*t*
- Calcium fluxes, 440
- Calcium ionophore, 212, 212*f*, 212*t*
- Calcium-binding proteins, helix-loop-helix motif, 209, 209*f*
- Calcium-calmodulin complex, 208-209, 209*f*, **926**
- Calcium-calmodulin kinase I/II, **925**
- Calmodulin, **155**, **208**, **323**, **996**
 calcium binding, 208-209, 209*f*
- Calmodulin-like proteins, 950
- Caloric homeostasis, 536-538, **537**
- Calories, 222, **1088**
- CaM kinase. *See* Calcium-calmodulin kinase
- cAMP. *See* Cyclic adenosine monophosphate, **224**, **293**, 490, 540
 and catabolite repression, 807
 control of *lacP* by, 807, 808*f*
 in glycogenolysis, 328-329, 329*f*
 intracellular levels of, increase in, 295
 in protein kinase A activation, 294*f*, 294-295, 862, 862*f*
 in steroid hormone synthesis, **896**
 structure, 293*f*
- cAMP phosphodiesterase, **295**
- cAMP receptor protein, 807
- cAMP response element-binding protein, **312**
- cAMP-dependent protein kinase, **925**.
See also Protein kinase A
- cAMP-response element, **312**
- Camptothecin, 594cc
- Cancer
 colon, 602cc
 diagnosis, 583
 DNA mutation and, 633cc
 mismatch DNA repair and, 641cc
 prevention, **1127**

Cancer

(continued)

- risk, 1097, 1110
- telomerase activity in, 658cc
- treatment, DNA amplification and, 671cc

Cancer cachexia, 553cc

CAP-binding protein, 805*f*, 806-807Capillary electrophoresis, 70-71, 71*f*Capillary fragility, **1127**Carbamation, 1032-1033, 1033*f*Carbamino groups, **1032**Carbaminohemoglobin, 1031, **1032**, 1032-1033, 1033*f*Carbamoyl phosphate, **454**, 454*f*Carbamoyl phosphate synthetase

- deficiency, 456cc
- I, **454**, **505**
- II, **454**, **505**, **506**, 506*f*

Carbohydrate(s), **1139**.

- See also* Carbohydrate metabolism; Sugar(s)
- complex, biosynthesis, 346-348
- energy content of (kcal), 1088
- in glycoproteins, 348-349
- linkages
 - with glycoproteins, 349-350
 - with protein, 61, 61*f*
- of membranes, 187, 187*f*
- oxidation states, comparison with lipids, 222, 222*f*
- sleep-inducing effect, 476

Carbohydrate, dietary, 1056-1057, 1074*t*, 1095

- absorption, 1073-1076, 1075*f*
- contribution to daily nutrient supply, 1056, 1056*t*
- digestion, 1073-1076, 1075*f*
- intake, 1056*t*
 - and athletic endurance, 1096cc
 - and diabetes mellitus, 1096cc
 - and glycogen stores, 1095, 1096cc
 - and protein sparing, 1091
 - and serum triacylglycerols, 1100, 1100cc
- metabolic fate, 1095
- refined, intake, 1100

Carbohydrate intolerance, **1095**.*See also* Diabetes mellitus

Carbohydrate loading, 551

and athletic endurance, 1096cc

Carbohydrate metabolism

- clinical correlations
 - aspartylglycosylaminuria, 349
 - blood group substances, 348
 - fructose intolerance, 342
 - galactosemia, 343
 - hemolytic anemia, 338
 - heparin as anticoagulant, 350
 - jaundice, 346
 - mucopolysaccharidoses, 352
 - pentosuria, 345
- and ketone bodies, 389*f*
- major pathways, 267-333
- special pathways, 335-359

Carbon, 1139, 1140

 α -Carbon atom, **25**, 93*f*

Carbon dioxide

- in blood, forms, 1031-1032
- isohydric carriage of, **1034**, 1034*f*, 1034-1035
- partial pressure, 1026, 1027*t*
- total, **1032**
- total plasma, **1049**
- transport, 1026, 1031-1035, 1034*t*

Carbon dioxide-bicarbonate buffer system, 1038-1041, 1039cc

Carbon monoxide, 1017, **1017**

Carbon monoxide difference spectrum, 986

Carbonic acid, **8**, 8-9, 1039Carbonic anhydrase, **144**, **302**, **1032**Carbonylcyanide-*p*-trifluoromethoxy phenylhydrazone, 260-261 γ -Carboxyglutamic acid (Gla), **103**, 103*f*, **1116**, 1116-1117 γ -Carboxyglutamyl protein(s), 961*t*, 963, 968-969, 969*f*, 971-972, 972*f*

Carboxyl groups, 363-365

Carboxylation, 1122

prothrombin, **1116**, 1116-1117Carboxylic acids, **1137**Carboxypeptidase(s), **144**, **1070**A, 156, **1071**, 1071*t*, **1072**B, **1071**, 1071*t*, **1072**pancreatic, **1071**, 1072Carcinogen, **994**

Carcinogenesis, transcription factors and, 701cc

Cardiac enzymes, release after myocardial infarction, 167*f*Cardiolipin, **398**, 398*f*.*See also* Phosphatidylglycerol phosphoglycerideCardiotonic steroids, **207**Carnitine, **535**

- in acyl group transport, 382
- source, 535, 536*f*
- synthesis, 481, 482*f*
- transport, deficiency, 384cc

Carnitine palmitoyltransferase

deficiency, 384cc

I and II, 382

Carnosine, **483**, 483*f*, 1072 β -Carotene, **938**, 939*f*, 1110, **1110**Carotenoids, **1109**, 1109-1110

Carrier-mediated transport, 1072-1073, 1076

Catabolic pathways, **218**

defects in, 427-431

Catabolic response, **1092**

protein and energy requirements in, 1092, 1093cc, 1094

Catabolite activator protein, **807**Catabolite repression, 807, 807*f*Catalase, 19, **131**, **251**, 390

Catalysis

- acid-base, 160
- covalent, in active site of chymotrypsin, 162*f*
- environmental parameters, 165-166
- mechanism, 159-166
- temperature dependence, 165-166, 166*f*

Catalyst, **128**Catalytic antibody, 165*f*Catalytic constant, **136**

Catalytic subunits, and regulatory subunits, 155

Catalytic triad, of acetylcholinesterase, 928

Cataracts, **934**, 934-935diabetic, **935**senile, **935**Catechol oxygenase, **130**, 130*f*Catecholamines, **553**.*See also* Epinephrine

activation of pyruvate dehydrogenase, in cardiac tissue, 231

degradation pathways, 930, 930*f*as neurotransmitters, **929**, 930*f*synthesis, 466, 466*f*, 468, 929-930Catechol-*O*-methyltransferase, **930**Catenation, **594**Cation(s), **5**, 14Cation-exchange resins, **70**CBG. *See* Corticosteroid-binding globulin

CD44, 356

CDKs. *See* Cyclin-dependent kinasescDNA. *See* Complementary DNACDP-choline, biosynthesis, from choline, 404*f*CDP-ethanolamine, in phosphatidylethanolamine synthesis, 405*f*CDRs. *See* Complementarity-determining regions

Celiac disease, 463cc

Cell(s)

- animal, structure, 13*f*
- buffering (buffers) of, 1036-1038
- and cellular compartments, 2-4
- cellular environment, 4-12
- chemical composition, 4*t*, 13-15
- coincidental alterations in, **513**
- cycle, **511**, 512*f*
- cytoskeleton, 19-20
- distribution of nucleotides, 491
- division, and nucleotide-metabolizing enzymes, 511-513
- eukaryotic, 1-22, 608
- fluid, chemical constituents, 14*t*
- growth, inhibition, 520
- membrane, **12**
- metabolism, *de novo* pathways, 517-518
- plasma membrane, 16
- rapidly dividing, glutamine catabolism in, 532
- regulation, and hormone secretion, 859-866

Cell death, planned (programmed), **452**.*See also* Apoptosis

Cellobiose, structure, 1142

Cellulose, **1056**, **1097**, 1098*t*, **1142**

Central dogma, of molecular biology, 678

Central nervous system, 426-427, 921.

See also BrainCentromere, **603**

Cephalin(s), 1144.

See also PhosphatidylethanolamineCeramic trihexoside, **425**Ceramide(s), **184**, 184*f*, 421, 421*f*, 422, 422*f*, 1144

Ceramide oligosaccharides, 1145

Cerebellar ataxia, 387cc

Cerebrocan, 356

Cerebrosides, **184**, 184-185, 422-425, 1145Ceruloplasmin, **1008**

deficiency, 1008cc

cGMP, 942

- role of, 490
- structure, 885, 885*f*
- synthesis, 885

cGMP-activated channel, in phototransduction, 944*t*

Channels

membrane, **197**, 197*t*, 197-198, 201-204.*See also* Membrane transport

- functions, 201, 201*f*
- ionophores and, 212, 212*t*
- regulation, 201-203, 202cc
- structure, 201, 201*f*
- voltage-gated, **201, 921, 922**, 923
 - disorders, 956cc-957cc
- Chaperone protein(s), **63**, 1011
- Chaperonins, **63**, 64*f*
- Cheilitis, **1118**
- Chelates, **144**, 145
- Chelation, modes, 145
- Chemical reactions. *See* Reaction(s)
- Chemical synapses, **923**
- Chemical-coupling hypothesis, 261-263
- Chemiosmotic-coupling mechanism, **262**, 262-263, 263*f*
- Chemotaxis, mediation, 439
- Chemotherapeutic agents, 517-521
- Chemotherapy, DNA repair and, 639cc
- Chenic acid. *See* Chenodeoxycholic acid
- Chenodeoxycholic acid, **418**, 1080*r*, **1083**
- Chi form, **664**
- Chi sites, **612**
- Children
 - nitrogen balance in, 448
 - urea synthesis in, 454
- Chiral compounds, 158
- Chloramphenicol, effects on protein synthesis, 734-735
- Chloride
 - in acid-base imbalance, 1050-1052
 - transport, 204*f*, 204-205
- Chloride channels
 - in cystic fibrosis, 201, 202cc, 1067cc.
 - See also* Cystic fibrosis transmembrane conductance regulator
 - intestinal epithelial, 1066
- Chloride shift, **1035**, 1035*f*
- p*-Chloromercuribenzoate, **149**
- Cholanic acid, 418, 418*f*
- Cholecalciferol. *See* Vitamin(s), D₃
- Cholecystokinin, **1062**, **1071**
 - actions, 848*t*
 - as secretagogue, 1061*t*, 1062
 - source, 848*t*
 - structure, 1062, 1062*t*
- Cholera, treatment, 1068cc
 - toxin, 1068cc
- Cholesterol, **186**, **1145**
 - in bile, 409-420
 - and bile acids, 418
 - and bile salts, 410
 - disposal, by liver, 415
 - distribution, in body, 409-420
 - elimination, 417
 - estimation, by Liebermann-Burchard reaction, 409
 - excretion, 410, 417-420
 - feedback inhibition of HMG CoA reductase, 415*f*
 - formation, from farnesyl pyrophosphate, 413-415
 - intake, and serum level, 1098-1100, 1099cc
 - and membrane fluidity, **195**, 195cc
 - in membranes, 186, 410
 - in mixed micelles, 1079, 1081cc
 - plasma/serum levels, 409-420
 - diet and, 1098-1100, 1099cc
 - elevated, **416**
 - esterified, 417
 - tests for, 409
 - vegetarian diets and, 1100
 - side chain cleavage, 896, **990**, 991*f*
 - in steroid hormone synthesis, 410, **894**, 896-901, 899*f*, 900*f*
 - structure, 186, 186*f*, 894*f*
 - synthesis, 410-415, 415*f*, 415-417, 1098
- Cholesterol (5-cholester)-3β-ol, structure, 409*f*
- Cholesterol esters, **409**, 409*f*
- Cholesterol ester-storage disease, 19cc
- Cholesterol gallstones, 1081cc
- Cholestyramine, 416cc
 - drug-nutrient interactions, 1133*t*
- Cholic acid, **418**, 1079*f*, **1083**
 - acidity, effect of conjugation on, 1080*t*
 - structure, 1145
 - transport, in mammalian cells, 211*t*
- Choline, 404*f*, **460**, 460*f*, 1123
- Choline acetyltransferase, **928**
- Choline glycerophospholipid. *See* Phosphatidylcholine
- Choline phosphotransferase reaction, 404*f*
- Choline plasmalogen, 183, 183*f*, 408*f*
- Chondroitin sulfate(s), 354, 355*f*, 356-357
- Chorionic gonadotropin, 847*t*, 870
- Chorionic somatomammotropin, **829**
- Chromaffin granules, **853**
- Chromatin, **16**, **601**, 604, 697
- Chromatosomes, **605**, 605*f*, **607**
- Chromium, **1132**
 - deficiency, **1132**
 - recommended dietary allowances, 1132
- Chromophores, **79**, 79*f*
- Chromosome(s), **601**
 - folded, 609*f*
 - lampbrush, **607**
 - linear, DNA replication at end, 657*f*, 657-660, 658cc
 - polynucleosomes and, 604*f*
 - polytene, **607**
- Chromosome 11, 826
- Chromosome 16, 826
- Chromosome walking, **781**, 781-783, 782*f*
- Chronotropic control, of hormone secretion, 866
- Chylomicrons, **56**, 379, 528, 529, **1082**, 1082-1083
- Chymotrypsin, **75**, 79*f*, 100*t*, 162*f*, 1071, 1071*t*
 - α-Chymotrypsin, 79*f*, 100*t*
- Circular dichroism (CD) spectroscopy, **80.**, 80-81, 81*f*
- Circular DNA, 586, **586**, 587-595
- Cirrhosis, **554**
- Cisternae, **16**
- Citrate, **232**, 234*f*; 244-245, 245*f*, 292
- Citrate synthase, 232, **232**, 232-233, **237**, **306**
- Citric acid cycle. *See* Tricarboxylic acid cycle
- Citrulline, **454**, 455, 534
- Clathrin, **416**, **877**, 877*f*; 877-878
- Cl⁻/HCO₃⁻ exchanger, **204**, **1065**, 1069
- Cloning vector(s), 766
- Closed complex, **695**
- Clotting factors, activation, **1116**
- Cloverleaf, transfer RNA, 682*f*, 683
- CMP-*N*-Acetylneuraminic acid, biosynthesis, 346, 347*f*
- CNS. *See* Central nervous system
- CoA. *See* Coenzyme A
- Coagulation. *See* Blood coagulation
- Coated pits, **877**
- Coated vesicles, **877**, 877*f*
- Cobalamine. *See* Vitamin(s), B₁₂
- Cobalt, in vitamin B₁₂, 1125
- Cobratoxin, **203**
- Cockayne's syndrome (CS), 638cc
- Codon(s), deletion, in cystic fibrosis, 752cc
- Codon-anticodon interactions, 719*f*, 719-721
- Codons
 - in mRNA, 718*t*, 718-719
 - nonsense, **719**
 - nonuniversal usage, 719, 719*t*
 - termination, **719**
 - disorders of, 722cc
 - universal usage, 719
- Coenzyme A, 228*t*, 514-515, 515*f*
- Coenzyme binding-site, mutations, disease caused by, 142
- Coenzyme Q, **253**, 253-255, 255*f*
- Coenzymes, **142**
 - binding, in cystathioninuria, 142cc
 - components, 491
 - derived from B vitamins, 142
 - structure and function, 142-147
- Cofactors, **128**
- Cognate receptors, **840**
- Colestipol, 416cc
- Colicin E3, effects on protein synthesis, 735
- Colipase, **1078**
- Colitis, 559
- Collagen
 - amino acid composition, 50*f*, 50-51, 51*t*
 - chicken, 821
 - covalent cross-link formation, 54, 54*f*, 55*f*
 - distribution in humans, 50
 - and elastin, comparison, 51*t*
 - glycine requirement, 53*f*
 - maturational, 747-748
 - structure, 52-54, 746, 747*f*
 - disorders of, 748*t*
 - synthesis
 - abnormal, 50cc
 - defects, 748*t*, 749cc
 - posttranslational modifications in, 746-748
 - types, 52*t*, 746
- Colon
 - cancer, 602cc
 - energy salvage by, 559
- Color blindness, 945
- Color vision, **944**, 944-945
- Committed step, regulation, **174**
- Common cold, 1127-1128
- Compartmentation of enzymes, **174**
- Compensated acid-base state, **1046**
- Competitive inhibition, 148
- Competitive inhibitors, **148**
- Complement pathway, classical, 91cc
- Complement proteins, 91cc
- Complementarity-determining regions (CDRs), **90**
- Complementary DNA, **777**, **824**
 - globin, cloning, 824-827, 825*f*
 - library, 777-778, 824
 - modification, for cloning, 778, 778*f*

Complementary DNA

*(continued)*synthesis, 777*f*, 777-778using reverse transcriptase PCR, 778, 779*f*Complementary strands, and DNA replication, 642-649, 643*f* α -Complementation, 772, 772*f*, 772-773Complex lipids, in brain, **921**Composite transposons (Tn), **670**Concatemers, **652**Concatenated chromosomes, **652**Cones, **936**, 937*f*, 937-943

in color vision, 944-945

physicochemical properties, 945-946

types, 944

Conformational-coupling hypothesis, **262**Confusion, in thiamine deficiency, **1120**Conjugase, **1123**Conjugate acids and bases, 7-10, 8*t*, **1038**

Connective tissue disease, autoimmunity in, 706cc

Connexin, **203**Consensus sequence, 690, 690*f*

Conservation of energy, in biochemical systems, 220

Conservative site-specific recombination, **662**

Control elements, 801

Convergent evolution, **106**Cooperative hydrogen bonding, **576**Cooperativity, **154**

and allostery, 154

models, 154, 154*f*, 155*f*Cooperativity index, **119**, 119*t*

Copper

absorption, 1131

in activation of molecular oxygen, 147, 147*f*

as cofactor, 1131-1132

deficiency, **1131**, 1132

recommended dietary allowances, 1131

requirements, 1131

Copper metalloenzymes, 1131

Coprotoporphyrinogen oxidase, 1015-1016

Coprotoporphyrinogens, **1011**

Core enzyme, 691

Corepressor, 808, 809

Corepressors, **802**Cori cycle, 299-301, 300*f*, 529, **529**

Cori's disease, 317cc

Cornea, 270, **932**, 933

Corpus luteum, 868-870, 896-898, 906, 916cc

Corticosteroid(s), 435, 1127, 1133*t*Corticosteroid-binding globulin, **908**

Corticotropin-like intermediary peptide, 846

actions, 847*t*source, 847*t*synthesis, 849, 850*t*Corticotropin-releasing hormone, 842, 844*t*actions, 847*t*, 883*t*source, 847*t*structure, 857*t*Cortisol, 842, 894, **896**

actions, 905

excretion pathway, 902*t*functions, 895*t*

and human growth hormone gene expression, 830

secretion, 895*t*structure, 895*t*synthesis, **898**, 903*t*

Cortisol receptor(s), 894

COS cells, foreign gene expression in, 786, 786*f*cos sites, **779**

Cosmid vectors, 780-781

Cot-a-half value, **580**, 581*f*Cotransfection, **785**

Cotransporter(s)

Na⁺,K⁺-2Cl⁻, **1066**Na⁺-monosaccharide, **1076**

Coupled assays, 168-170

Covalent bond, bond strength, 65*t*Covalent catalysis, 162, **163**Covalent modification, **294**, **541**, 541-545C-peptide, **39**, 40*f*C-protein, 948*t*CPT. *See* Carnitine palmitoyltransferaseCreatine, 483, **483**, 534*f*, 535

Creatine (phospho)kinase, 146, 955-957

reactions, **225**, 225*f*types, **172**Creatine phosphate, **225**, 225*f*Creatinine, **483**, 484*f*, **535**

Crigler-Najjar syndrome, 346cc, 1020cc

Cristae, **17**Critical micelle concentration, **187**, **1079**, 1079*f*Cross-linked polyacrylamide, **72**

Cross-links, allysine-generated, 54

Crossover theorem, **287**, 287-290, 288*f*Cross-regulation of enzymes, **175**, 175*f*Cross-stranded intermediate, **663**Crown gall plasmids, **794**CRP. *See* cAMP receptor proteinCrystallins, **933**, 934*t*CTP, 219*f*, 220, 505*f*CTP cyclohydrolase I, **500**CTP synthetase, **505**, 505*f*, 506*f*

Cushing's disease, 378cc

Cushing's syndrome, and obesity, 526cc

Cutis laxa, 748*t*

Cyanide

detoxification, 474*f*

poisoning, 259cc

Cyanogen bromide, **75**

Cyanosis, 1028cc

Cyclic AMP. *See* cAMPCyclic control system, **294**, 295*f*Cyclic GMP. *See* cGMPCyclic hemiacetals, **1140**Cyclin(s), **657**, **751**Cyclin-dependent kinases (CDKs), **657**Cyclooxygenase, **431**, 433*f*, 433-435, **434**Cyclopentanoperhydrophenanthrene, **894**Cyclopentanophenanthrene ring, 409*f*CYP, **982**Cystathionase, **470**

catalytic reaction, 142cc

lack, 471cc

reactions catalyzed by, 474

Cystathionine synthase, **470**

deficiency, 471cc

Cystathioninuria, 471cc

Cysteic acids, formation, by oxidation of disulfide bonds, 74*f*Cysteine, **27**

in children, 448

synthesis, 469, 470*f*, 473*f*, 473-474Cysteine proteases, **98**Cysteinesulfinate, **473**, 473*f*Cystic fibrosis, 202cc, **751**, 752cc, 1067cc

chloride channel in, 201, 202cc

nutritional considerations for, 1112cc

Cystic fibrosis transmembrane conductance regulator, 752cc, 1067cc

activation, 1068cc

Cystine aminopeptidase, **858**Cystine, 30, 30*f*

Cystinosis, 471cc

Cystinuria, 212cc, 471cc

Cytochalasin B, 1077*f*, 1077*t*Cytochrome(s), **147**, 252-253*b*₅, **372**, **988***c*, 69*f*, 253*f*, 254*f*Cytochrome *c* oxidase, **129**, 129*f*, **255**, 257*f*, 1131Cytochrome P450, **17**, 981-999, **982**carbon monoxide-bound, absorbance spectrum, 982, 982*f*

cross-reactivity, 986

CYP11B1, **992**CYP11B2, **992**CYP17, **992**CYP21, **991**

CYP21A2, deficiency, 992cc

distribution, 982

in eicosanoid oxygenation, 990-992

electron transport systems, 987-989

exogenous lipophilic substrates, oxidation, 992-995

forms of, 984-986

gene subfamilies, **982**gene superfamily, **985**

genes, 984-986

human, forms, 982, 983*t*induction, **985**, 985-986

drugs and, 986cc

posttranscriptional mechanisms, **985**, 985-986transcriptional mechanisms, **985**, 985-986

inhibitors, 986-987

mitochondrial, **989**, 989*f*

nomenclature, 982-984

physiological functions, 989-995

polymorphisms, 986, 987cc

protoporphyrin IX prosthetic group, **983**, 983*f*reaction catalyzed by, 982, 989, 990*f*sequence of reactions at, 984, 984*f*

in steroid synthesis, 896, 898, 990-992

structural homology, 986

substrate specificity, **985**

substrates, 982

Cytochrome P450 steroid 21-hydroxylase deficiency, 992cc

Cytoglutamic acid, **857**

Cytomegalovirus, human, in expression vector, 785

Cytoplasm, **16**Cytosine, **493**, **628**, 679-680Cytosine arabinoside (araC), 517*f*, **518**, 518*f*Cytoskeleton, **19**, 19-20Cytosol, **20**, 371*f*, 382*f*

D

- DAM methylase, **565, 639, 649**
- DCLHb. *See* Hemoglobin, diaspirin cross-linked
- dCMP deaminase, **509, 509f**
- ddNTP. *See* Dideoxynucleoside triphosphate
- Deacetylases, **356**
- Deafness, antibiotic-induced, 734cc
- Deamination, **226**
- Deamination of cytosine, **628**
- Debranching enzyme, **317-318, 318f**
- Decarboxylase(s), **132**
- Decarboxylation, **344**
- Decoding region, 727
- Degenerative diseases, mitochondrial mutations and, 617cc
- Dehydratase(s), **132**
- Dehydrocholesterol, **420**
- 7-Dehydrocholesterol, photochemical conversion, 419f
- Dehydroepiandrosterone, **896, 992**
- functions, 895f
 - secretion, 895f
 - structure, 895f
 - synthesis, **898**
- Dehydrogenase(s), **129**
- 3 β -ol-Dehydrogenase, **896**
- Dehydrogenation, 336-338, 337f, **381**
- Deletion mutation, 786-787, 788f
- DEM methylase, **565**
- Denaturation, 68f, 577-580, **578, 579f**
- Dendrites, **921**
- Densitometer scans, 173f
- Deoxyadenosine, structure, 492f
- Deoxycholate, **1083**
- Deoxycholic acid, 211f, 1080f, **1083**
- 1-Deoxycorticosterone, **991, 991-992**
- 2-Deoxyglucose, **282, 282f**
- Deoxyhemoglobin
- salt bridges between subunits in, 122f
 - steric hindrance between proximal histidine and porphyrin in, 120f
 - transition to oxyhemoglobin, 122f
- Deoxyhexoses, **344**
- Deoxymonosaccharide, **1141**
- Deoxynucleoside triphosphate, **763, 763f**
- Deoxyribonucleotides, 491, **507, 507-511, 509f**
- Deoxyribopyrimidine nucleosides, 509
- Deoxythymidylate, synthesis, 508-509, 519f, 1123
- Deoxyuridine monophosphate, 508
- Depurination, **629, 635**
- Derepression, 808
- Dermatan sulfate, **354**
- Dermatitis, **1118**
- Desaturase, **372**
- ⁹-Desaturase, 1131
- Desmosine, **55, 55f**
- Detergents, biological, **1077, 1078**.
- See also* Bile acids
- Deuteranopia, **945**
- Dextrins, α -limit, **1075**
- DFP. *See* Diisopropylfluorophosphate
- DHAP, in choline plasmalogen biosynthesis, 408f
- DHEA. *See* Dehydroepiandrosterone
- Diabetes mellitus, 41cc, 62cc, 287cc, 362, **1095**
- adult-onset, in obesity, **1095**
 - complications, 537, 537cc, 551cc
 - dietary treatment, 1096cc
 - and hyperglycemic hyperosmolar coma, 537cc
 - insulin-dependent (IDDM), 550cc, 550-551
 - noninsulin-dependent (NIDDM), **548, 548-549, 549cc**
- Diabetic cataracts, **935**
- Diabetic ketoacidosis, 390, 390cc, 1044
- Diacylglycerol(s), 182, 184, **325, 364, 397-398, 400, 1060, 1144**
- activation of protein kinase C pathway, 865-866
 - formation, **862, 865f**
 - in phosphatidylethanolamine synthesis, 405f
 - in phospholipid synthesis, 404-406
 - as second messenger, 862, 865f
- 1,2-Diacylglycerol 3-phosphate. *See* Phosphatidic acid
- Diagnosis
- of bacterial infections, 583cc
 - of cancer, 583
 - of disease
 - amino acid analysis in, 74cc
 - plasma proteins in, 37cc
 - use of DNA probes in, 583cc
 - of Gaucher's disease, 430f, 430cc
 - of genetic disorders, 583
 - direct DNA sequencing for, 766cc
 - of infectious disease, 583
 - isozyme measurement and, 172
 - of sphingolipidoses, enzyme assays for, 429-431
 - of Tay-Sachs disease, 430
- Diarhea, 427
- bacterial toxigenic, 1068cc
 - electrolyte replacement therapy in, 1068cc
 - in vitamin deficiency, **1118**
- Diaspirin hemoglobin, 1026cc
- Diastereomers, **1139**
- Diazepam, structure, 923, 923f
- 6-Diazo 5-oxo-L-norleucine (DON), 519, 519f
- Dibase monocarboxylic acids, **27**
- Dibasic acids, 1146
- Dicarboxylic acid, **387**
- Dicarboxylic acids, transport, in mammalian cells, 211f
- Dicarboxylic monoamino acids, **27**
- Dicumarol, **971, 1117**
- Dideoxyhexoses, **344**
- Dideoxynucleoside triphosphate, **763, 763f, 763-765, 764f**
- Diet
- American, 1132-1133
 - iron-fortified, hemochromatosis and, 1011cc
 - and nitrogen balance, 447-448
 - and osteoporosis, 1129cc
 - vegetarian. *See* Vegetarian diet(s)
- Dietary fiber, **1097, 1097-1098**
- Dietary Goals for the United States*, 1101-1102, 1102f
- Dietary intake studies, in malnutrition, **1108**
- Diffusion, **196**.
- See also* Membrane transport
 - facilitated, **204**
 - Fick's first law of, **197**
 - of molecules, through membranes, 189, 196-197, 197f
 - of proteins and lipids, in membranes, 193-196
 - rate of, **196, 196-197, 197f**
- Digestion, 1059-1063
- of carbohydrates, 1073-1076, 1075f
 - intracellular, **17, 17-19, 18f, 1059**
 - intraluminal, **1059**
 - knowledge of, historical perspective on, 1056
 - of lipids, 1077f, 1077-1083
 - overview, 1056-1057
 - of peptides, 1072
 - of protein, 1070f, 1070-1073
- Digestive enzyme(s)
- proenzymes, 1059-1060
 - secretion, 1059-1060, 1060f
- Digestive vacuoles, **19**
- Digitalis, **207**
- Dihydrobiopterin reductase deficiency, 465cc
- Dihydrofolate reductase, 150-151, 1123
- gene, as selectable marker for transfected cells, 785
- Dihydrolipoyl dehydrogenase, 234
- Dihydrolipoyl transsuccinylase, **234**
- Dihydropyrimidinase, **511**
- Dihydropyrimidine dehydrogenase, **511**
- Dihydroquinone, formation, 971
- Dihydrosphingosine, **184, 184f, 422**
- Dihydrotestosterone, **901**
- Dihydrouracil, 1147
- 1,25-Dihydroxy vitamin D₃ (1 α ,25-dihydroxycholecalciferol), **907, 1112, 1112-1114**
- excretion pathway, 902f
 - functions, 895f
 - mechanism of action, 907, 907f
 - in renal failure, 1113cc
 - secretion, 895f
 - structure, 895f
 - synthesis, 894, **907, 908, 992**
- Dihydroxyacetone, structure, **339, 1139**
- Dihydroxyacetone phosphate, 375f, 376, 377f
- Dihydroxyacetone phosphate synthase, **408, 408f**
- Dihydroxyphenylalanine (DOPA)
- for Parkinson's disease, 467cc
 - production, 466
- Diisopropylfluorophosphate (DFP), reaction with serine protease, 98f
- Diisopropylphosphofluoridate, 1071
- Dimerization
- photochemical, **629, 632f**
 - of steroid receptor monomers, **912, 912f**
- 2,4-Dinitrophenol, **260**
- Dioxygenase(s), 129, 129f, 130
- Dipalmitoyllecithin, 398-399, 408f
- Dipeptidase(s), **1059, 1072**
- Dipeptide(s), **28**
- carrier-mediated transport, 1072-1073
- Dipeptidyl aminopeptidase IV, 1059f
- Diphenylhydantoin, and vitamin requirements, 1118cc
- Diphosphatidylglycerol, 184f
- See also* Phosphatidylglycerol phosphoglyceride
- Diphtheria toxin, effects on protein synthesis, 735
- Dipole, 4, 4f
- Dipole-dipole interactions, **576**

Dipole-induced dipole interactions, **569**

Direct bilirubin, **1018**

Directional cloning, 766-767, 767*f*

Disaccharidase(s), **1059**

- deficiency, 1075cc

Disaccharides, 1073-1076, 1142

Dissociation, 5-9

Dissociation constant (K_d), 8*r*, **30**, 30-31, 31*r*, 32*r*, 32-33

Dissociation constant (K_d), of

- hormone-receptor complex, 871-872

Distal histidine, **115**

Disulfide bond, **1139**

Disulfide isomerase, 744

Diuretics, drug-nutrient interactions, 1133*r*

Diurnal variations, of hormone secretion, 866

DKA. *See* Diabetic ketoacidosis

D-loop, **663**

DNA, **16**, 678, 708.

- See also* Complementary DNA; Gene(s); Transcription
- A conformation, **570**
- alkaline denaturation, **579**
- Alu family, **616**
- amplification
 - and drug resistance, 671cc
 - by polymerase chain reaction, **759**, 759*f*, 759-760
- anisomorphic, **595**
- annealing, **580**
- antiparallel strands, **574**
- average helical repeat, 589*f*
- B conformation, 108*f*, **570**
- bacterial, cleavage, 610-611
- base composition, **565**
- base pairing, 624*f*
- base-pair stacking energies, 577*f*
- bases, 565, 566*f*.
 - See also* Base(s)
- B-DNA, 109*f*, 571*f*, 573*r*
- bending, **595**, 606
- blunt end, 765
- bZip Gcn4, structure, 111*f*
- C conformation, **570**
- catenates, **586**
- cell content, species differences, 584*r*
- cell transformation by, **564**
- circular, **586**, 587-595
 - evolutionary advantage, 586
- cloning
 - directional, 766-767, 767*f*
 - versus polymerase chain reaction, 768-770
- coding effectiveness, **565**
- complementarity, **570**
- complexity, **585**
- conformations, **570**, 595-601
- conserved sequences, 690
- cruciform, **595**, 595-596, 596*f*
- DAM methylase in, **565**
- damage, reversal, 640-641
- defined, ordered sequence (dos), **595**, **616**
- defined segments, preparation, 761-762
- DEM methylase in, **565**
- denaturation, 577-580, **578**, 579*f*
- depurination, **629**
- dipole-dipole interactions, **576**
- direct repeats, **595**, 596*f*
- discontinuous synthesis, **646**, 646*f*, 646-647
- double helix, **570**, 570-575
 - anti form, **573**, 573-574
 - disruption, 577-580
 - dynamic state, **578**
 - endo form, **573**
 - geometry, **570**
 - major groove, **571**
 - minor groove, **571**
 - structure, 572*f*, **573**, 573-574
 - syn form, **573**, 573-574
 - syn-anti equilibrium, **573**
 - zipper model for, 578*f*
- double-strand
 - circles, 586-587
 - hydrogen bond formation in, 570
 - and temperature, 578*f*
- end-group labeling procedure, 586*f*
- equilibrium centrifugation, 585*f*
- Escherichia coli*, nucleotide sequence, 611*f*
- eukaryotic, 613-614
 - negative supercoiling, 606*f*
 - proteins coded for, 820
 - reassociation kinetics, 581*f*
- flanking regions, study using deletion and insertion mutations, 786-787, 787*f*
- four-stranded, 599*f*, 599-601
- fragments, Southern blotting, 774*f*, 774-775
- function, 564-565, 609-617
- G-quartet, **599**
- G-rich regions, **595**
- helical turns or twists, number (T), **589**
- helix-to-coil transformation, **578**
- helix-turn-helix motif, lac repressor protein association with, 109*f*
- homology, evolutionary relatedness determined by, **582**
- homopurine-homopyrimidine regions, **597**
- homopurine-homopyrimidine sequences, **595**
- hybridization, **582**, 582-583
 - D_f method, **582**
 - R_f method, **582**
 - in situ*, **582**
- hydrogen-bonding specificities, **570**, 570*f*
- hypochromic effect, **579**
- information capacity, 565
- interaction with protein, and *lac* operon transcription, 807
- interlocking circles, **586**
- interspersion pattern, **615**
- inverted repeats, **595**, 596*f*
- junk, 613
 - , circularization, 587*f*
- linker, **606**
- linking number L , **589**, 589*f*, 592
- London dispersion interactions, **576**
- long interspersed repeats, **615**, 615*f*
- long stretches, analysis, 781-783
- mammalian, organization of genes in, 820-822
- melting curve, **579**
- midpoint temperature, 579*f*
- mirror repeat symmetry, **598**
- mirror repeats, **595**, 596*f*
- mitochondrial, 617, 830-831, 831*f*
 - mutations, 617cc
- mobile elements (transposons), **614**
- mutations, 627*f*, 627-632, **628**, 628*f*, 633cc.
 - See also* Mutations
 - deletion, 786-787, 788*f*
 - expressed, **628**
 - frameshift, 601, 603*f*, **628**, 721, 723*r*
 - phenotypically silent, **628**
- nascent, **647**
- negative spherical form, **648**
- negative superhelical, **587**
- NF- κ B homodimer, structure, 113*f*
- nodule variant, **599**, 599*f*
- nucleosome positioning, **606**
- origin of replication, **603**
- overwinding, **588**
- packing, **603**
- palindromes, **595**, 596*f*
- phased A tracts, **595**
- polynucleotide segment, structure, 567*f*
- precursor fragments, **647**
- prokaryotic
 - coding for specific proteins, 611-613
 - genome size, 614
- quadruplex, **595**, 599*f*, 599-601
 - antiparallel, 601
- radiation damage to, 629-630
- random coils, **569**
- random primer labeling of, 773
- random-coil regions, **579**
- reannealing, 580-582
- reassociation kinetics, 581*f*
- recombinant. *See* Recombinant DNA
- recombination, **661**, 661-670
 - and immunoglobulin genes, 663cc
 - types, 662-663
- characteristics, 662*r*
- regulatory sequences, enzymatic
 - modification, 788, 788*f*
- reiteration of nucleotide sequences, 580, **585**
- relaxed, **587**, 587*f*
- renaturation, 580-582
- REP elements (repeated extragenic palindromic elements), **612**
- repeated sequences, 614-617
- repetitive, **614**
 - in eukaryotes, 822-823
 - highly repetitive, **822**, 822*f*
 - moderately repetitive, **822**, 822-823
- replication, **511**, 642-661
 - bidirectional, **646-647**
 - coordination, 660-661
 - in *E. coli*, 649, 649*f*, 650*f*
 - at end of linear chromosomes, 657*f*, 657-660, 658cc
 - eukaryotic, 653-657, 659-660
 - initiation, 656-657
 - in mammals, 655*f*
 - and mutation, 627*f*
 - prokaryotic, 658*f*, 659, 659*f*
 - rolling circle model, **652**, 652-653, 653*f*
 - semiconservative, 643-644, 644*f*
 - telomerases, 659-660
 - types, 643*f*
- restriction enzyme cleavage sites, 610*r*
- restriction maps, 760-762, **761**, 761*f*
- satellite, **614**
 - sequences, **616**
- sensitivity to shearing forces, 585
- sequences and genetic information, 25*f*

- highly reiterated, **614**, 616
- inverted repeats, **614**, 616-617
- locating, 582
- moderately reiterated, **614**, 615-616
- rates of reassociation, **614**
- satellite, **616**
- single copy, **614**
- sequencing, 671-672, 762-765
 - chemical cleavage method
- (Maxam-Gilbert procedure), 762-763, 763*f*
 - direct, 765
- for diagnosis of genetic disorders, 766cc
 - interrupted enzymatic cleavage method
- (Sanger procedure), 763-765, 764*f*, 765*f*
 - short interspersed repeats, **615**, 615*f*
 - simple sequence, **616**
 - single strand, 587
 - structures, **570**
 - single-copy, 615
 - size, 584-586
 - determination, 585-586
 - slipped, mispaired (SMP-DNA), **601**, 602
 - SOS postreplication repair, **634**, 642, 642*f*
 - splicing, **613**
 - stacking interactions, **576**
 - sticky ends, 765
 - strands
 - polarity, **574**, 576*f*
 - separation, 647-649
 - structure, 133*f*, 565-584, 573*t*, 609-617
 - conformational variations, **571**, 572*f*
 - hairpins, **617**
 - and histones, **603**
 - interwound circular, **591**
 - interwound turn, 591
 - plectonemic coil, **591**
 - secondary, 568-575
 - stability, 575-584
 - stabilization, 575-584
 - symmetry elements, 596*f*
 - toroidal turn, **591**
 - types, 584-609
 - variation of base plane orientation, 573-574
 - subcloning, 781
 - supercoils, **587**, 587*f*
 - equilibrium in, 591*f*
 - negative, 588
 - (or writhing) number (*W*), **589**
 - positive, 588, **593**
 - superhelical, 589*f*, 590*f*
 - geometric description, 589-592
 - linking number *L*, determination, 589*f*
 - superhelix, 587-595
 - symmetrical inverted repeats, **595**, 596*f*, **610**
 - synthesis, 16, 512-513
 - discontinuous, 646*f*, 646-647
 - DNA templates in, 646, 646*f*
 - initiation, 649-651, 650*f*
 - progression, 649-651
 - ribonucleotide reductase in, 508*f*
 - RNA template in, 660
 - termination, 651-652, 653*f*
 - using reverse transcriptase PCR, 778, 779*f*
 - tandem arrays, **616**
 - telomeres, **599**
 - temperature-optical density profile, 579*f*
 - template, for RNA synthesis, 689, 690, 690*f*
 - topology, **587**
 - torsional tension, **587**
 - triple helices, 598*f*
 - triple repeats, expansion, and disease, 602cc
 - triple-stranded, **595**, 596-599, **597**, 597*f*
 - triplexes
 - base pairing in, 598*f*
 - therapeutic potential, 600cc
 - unwinding, **588**, 689
 - wrapping, 606-608
 - Z-DNA, **574**
 - structure, 571*f*, 573*t*
 - DNA glycosylases, **635**
 - DNA ligase, **765**, **832**
 - action, 635*f*, 639cc
 - DNA methyltransferase, **656**
 - DNA polymerase(s), 622-625
 - α , **644-645**, **655**
 - β , **654**
 - γ , **655**
 - in DNA synthesis, 652*f*
 - DNA-dependent, **622**, 622*t*, 622-625
 - errors, 630-631
 - eukaryotic, 625-627, 626*t*, 654-656
 - I, **624**
 - III, 623*t*, **625**, 626*f*
 - proofreading activity, 624
 - structure, 624-625, 625*f*
 - synthetic activity, 623*f*, 623-624
 - DNA probes, **582**, 583, 770, 773-774
 - diagnostic use, 583cc
 - DNA repair, 633-642, 639cc
 - coordination, 660-661
 - lesions requiring, 634*t*
 - mismatch, **627**, 630, **638**, 638-640, 640*f*, 641cc
 - postreplication, 641, 641*f*
 - DNA topoisomerase(s), properties, 593*t*
 - DNA vaccines, 565, 565cc
 - dnaA, **649**
 - dnaB, **650**
 - DNA-binding proteins, **88**, 108-114, 109*f*
 - structural motifs, 108-111
 - Xfin, zinc-finger motif in, 109*f*, 110*f*
 - dnaC, **650**
 - dnaG, **650**
 - DNase I hypersensitivity, 696*f*, **697**
 - DNase protection, **806-807**
 - DOC. *See* 11-Deoxycorticosterone
 - Docking, of synaptic vesicles, **927**
 - Docking protein, **735**
 - cis-Docosahexaenoic acid, 364*f*
 - Dolichol phosphate, **350**, 350-351, **737**
 - Domains, **46**, 46-48
 - all- β -domain, **48**, 48*f*
 - β -barrel, **48**, 48*f*
 - α -folded, 48*f*, 49*f*
 - β -folded, **48**, 48*f*, 49*f*
 - Greek key β -barrel, **48**, 48*f*
 - twisted β -sheet, **48**, 48*f*, 49*f*
 - DON. *See* 6-Diazo 5-oxo-L-norleucine
 - Donor atom, **66**
 - Donor molecule, **80**
 - Donor site, **669**
 - DOPA. *See* Dihydroxyphenylalanine
 - DOPA decarboxylase, **466**
 - Dopamine, 211*t*, **466**, 467cc, 468*f*, **929-930**
 - Dopamine β -hydroxylase, **147**, 853, 1131
 - Dopaquinone, production, 468
 - Double helix/helices
 - intercalation between base pairs, 632*f*
 - interlocked, separation, 648*f*
 - stretching, 631-632
 - Double-reciprocal plot. *See* Lineweaver-Burk plot
 - Double-stranded RNA-dependent kinase, **748**
 - Drosophila virilis*, repetitive DNA sequences, 822, 822*f*
 - Drug(s)
 - antipyretic, 436
 - clearance from blood, 134
 - and cytochrome P450 induction, 986cc
 - delivery, liposomes for, 189cc
 - detoxification, **272**
 - as enzyme inhibitors, 149-151
 - Drug resistance. *See also* Multidrug resistance
 - biological basis for, 520-521
 - DNA amplification and, 671cc
 - Drug-nutrient interactions, 1133, 1133*t*
 - dTMP. *See* Deoxythymidylate
 - Dubin-Johnson syndrome, 1021cc
 - Duchenne's muscular dystrophy, 821, 822cc
 - Ductus arteriosus, 436
 - dUMP. *See* 2-Deoxyuridine 5'-monophosphate
 - Duodenum, iron absorption in, 1005cc
 - Dyad symmetry, **806**
 - Dynein, **20**
 - Dystonia, 237cc
 - Dystrophin
 - gene, 821, 821*f*
 - Duchenne/Becker muscular dystrophy and, 822cc
 - structure, 821, 821*f*
 - E**
 - E site, 730
 - ECC. *See* Enterochromaffin-like cells
 - Edema, 398
 - Editing, **723**
 - Edman cycles, 75
 - Edman reaction, **74**, 75*f*
 - EF (elongation factors). *See* Elongation factor(s)
 - EF hand, **209**
 - Effectors, 151
 - Ehlers-Danlos syndrome, 748*t*, 749cc
 - Eicosanoids, **433**
 - oxygenation, cytochrome P450 in, 990-992
 - Eicosapentaenoic acid, **440**, 1099cc
 - Eicosatrienoic acids, **440**
 - eIF (eukaryotic initiation factor), **725**
 - Elastase(s), 1071, 1071*t*
 - reactivity toward substrates, 100*t*
 - Elastin, **54**, 54-55
 - Elderly
 - niacin deficiency in, **1121**
 - nutritional needs of, 1133, 1134cc
 - Electrical synapses, **923**
 - Electrogenic sodium flux, **1064**, 1065*f*
 - Electrolyte replacement therapy, in diarrhea, 1068cc

Electrolytes, **5**, 5-7

- activity, **6**
- intestinal epithelial secretion, 1066, 1066*f*
- non-, **5**
- weak, **6**, 6-7

Electromotive force, **247**

Electron distribution, **77**

- Electron interactions, 67*f*

Electron microscopy, **585**, 585-586

Electron transport, **241**, **246**

- in inner mitochondrial membrane, 241, 246-261

Electron transport systems, 206, **983**

- cytochrome P450, 987-989

Electron transport-oxidative phosphorylation sequence, 231, 231*f*

Electron-density map, **77**, 78*f*

Electro-osmotic flow, 71*f*

Electrophoresis, **69**, **585**, 585-586

Electrostatic interactions, 66, 66*f*.

- See also* Ionic interactions

α - β -Elimination, 450*f*

ELISA, 171

- in HIV envelope protein detection, 171*f*

Elongation

- in protein synthesis, 727-730, 728*f*-729*f*
- in transcription, **689**, **695-696**

Elongation factor(s), 727-730, 814

- EF-1, 727
 - in elongation cycle, 730, 731*f*
- EF-1 α , 727
- EF-1 β , 730, 731*f*
- EF-2, 730, 745, 745*f*
- EF-G, 730, 731*f*, 814
- EF-Ts, 731*f*
- EF-Tu, 730, 731*f*, 814

Elongation reactions, 372-373

- in mammalian fatty acid synthase, 370*f*

ENaC. *See* Epithelial sodium channel

Enantiomers, **1139**, 1140

Encephalomyelopathy, subacute necrotizing, 258cc

Encephalopathy, 237cc

Endergonic reaction, **221**

End-group labeling procedure, 586*f*

Endo conformation, **573**

Endocrine abnormalities, and cancer, 553cc

Endocrine cells, epithelial, **1062**

Endocrine hormone(s), **841**

Endocytosis, **18**, 18*f*, **877**, **878**

Endonuclease, **665**

- RuvC, **667**

Endonuclease(s), **709**.

- See also* Restriction endonuclease(s)
- specificities, 569*t*

Endopeptidase(s), 1059*t*, **98**, **1070**, **1071**, 1072

Endoplasmic reticulum, **16**, 16-17, **982**

- hydroxylases, in steroid synthesis, 898
- membranes, protein topology at, 741-742, 742*f*
- microsomal cytochrome P450 system, 988, 988*f*
- procollagen formation in, 746-747

Endorphin(s), **932**, 932*t*

β -Endorphin, 846, 847*t*, 849, 850*t*

Endothelin, 849*t*

Enediols, 1142

Energy

- dietary sources, 528
- expenditure
 - age-related changes in, 1088
 - exercise and, 1089
 - factors affecting, 1088-1089
 - sex differences in, 1089
 - starvation and, 1089
- free. *See* Free energy
- intake, excess, 1094-1095
- metabolic reserves, 536, 537*t*
- metabolism, 490, 1088-1089
- requirements, in illness and recovery, 1092, 1093cc, 1094
- source, for brain, **920**
- sources, 312-330
- utilization and storage, 361-393
- in work, 220-222

Energy-producing systems, 218-220

- ATP and, 218-220, 219*f*, 220*f*

Energy-rich components, 220-225

- classification, 223*t*
- hydrolysis and, 222-224, 223*t*, 224*f*

Energy-utilizing systems, 218-220

- ATP and, 218-220, 219*f*, 220*f*

Enhancer sequences, 697

Enhancers, **690**, **696**, 697

Enkephalin(s), **932**, 932*t*

- genes encoding, 852
- structure, 852
- synthesis, 852*f*, 852-853

Enol phosphates, as energy rich compounds, 223*t*

Enolase, reaction catalyzed by, 273*f*, 277

Enterochromaffin-like cells, **1061**

Enterocytes, **531**, **1059**

- glucose transport systems in, 1076, 1077*t*

Enterohepatic circulation, **418**, **1084**, 1084*f*

Enterokinase. *See* Enteropeptidase

Enteropeptidase, 1059*t*, **1071**

Entropy, **220**

Entropy effect, 163-164

Enzyme(s), **128**.

- See also* Restriction enzyme(s)
- active site, 129
- allosteric control, 151-155
- allosteric effector, binding, 152
- allosteric site, 129
- bacterial, in carbohydrate digestion, **1075**
- binding site
 - asymmetry, 158
 - lock-and-key model, 156*f*
- cardiac, release after myocardial infarction, 167*f*
- catalysis of reversible reactions, 140
- catalytic ability, comparison, 136
- catalyzed vs. non-catalyzed reactions, energy diagrams for, 159*f*
- in chemical reactors, 174
- classifications, 129-133, 130*t*
- clinical applications, 166
- committed step catalysis, **174**
- compartmentation of, **174**
- competitive inhibitors, **148**
- complementarity with substrate, 156-158
- covalent modification, 149, 541-545
- cross-regulation, **175**, 175*f*
- and decrease of activation energy, 160-164
- deficiency
 - identification and treatment, 169cc
 - in Lesch-Nyhan syndrome, 169cc
 - in orotic aciduria, 169cc
- dephosphorylation, 543*f*, 545
- digestive, 1057, 1059*t*, 1059-1060, 1060*f*
- drug-metabolizing
 - genetic polymorphisms, 987cc
 - induction, 986cc
- feedback inhibition, **175**, 175*f*
- function, 24
- glycation, 538cc
- in gout, 138cc
- immobilized, as reagents, 170
- immunoassays, indicators in, 170-171
- induction in liver
 - in fasting, 546*f*
 - in fed state, 546*f*
- inhibition
 - by covalent modification of active center cysteine, 149*f*
 - in drug therapy, 149-151
- as integral membrane proteins, 191
- interaction with substrate, 136-137.
 - See also* Reaction(s), enzyme-catalyzed
- lipid-hydrolyzing, 17*t*
- long-term changes in, 545-547
- lysosomal, 17*f*
- in gout, 18cc
- sphingolipid catabolism by, 428
- and substrates, 17*f*
- lysosome-targeted, 739-742, 741*f*
- mechanism of action, 137, 139
 - biphasic nature, 138, 138cc
- metal cofactors, 144-147
- modulation by ligands, 151-152
- monomeric, 152
- multisubstrate reactions, 140-142
- mutated, assay of, ambiguity in, 169cc
- nomenclature, 129
- nucleic acid-hydrolyzing, 17*t*
- oligomeric, 152, **152**
- pancreatic, **1059**
 - activation, 1071-1072, 1072*f*
 - deficiency, 1112cc
 - essential serine residue, **1071**
 - secretion, 1071-1072, 1072*f*
- phosphorylation, **294**, 294*f*
- in lipogenic liver, 543*f*
- pH-velocity profile, 166
- plasma
 - activities, time dependence of, 167, 167*f*
 - types, 166
- polysaccharide-hydrolyzing, 17*t*
- product inhibition, 140
- protein-hydrolyzing, 17*t*
- proteolytic, binding characteristics, 101*f*
- rate-limiting, **174**, 175
- in reaction rate enhancement, 165*f*
- RecBCD, **612**
- regulation, 174-175, 540-541
- regulatory protomer, 155
- reversible noncompetitive inhibition,
 - double-reciprocal plot for, 149, 149*f*
- saturation kinetics, 136-140
- secretion, 1059-1060, 1060*f*
- specific activity, **136**

- specificity, 128-129
 - active site, 155-158
- subclasses, 129, 130*t*
- substrate-binding site, 128-129
- symmetrical substrate, three-point
 - attachment to asymmetrical substrate, 159*f*
- temperature vs. velocity, 166, 166*f*
- terminology, 136
- as therapeutic agents, 172-174
- units (U), 136
- velocity vs. temperature, 166, 166*f*
- xenobiotic-metabolizing, 993, 994*t*
- Enzyme-binding site
 - induced fit model, 156, 156*f*
 - lock-and-key model, 156, 156*f*
- Enzyme-linked immunosorbent assay. *See* ELISA
- Eosinophil function, regulation, 439
- Epidermal growth factor
 - actions, 848*t*
 - source, 848*t*
- Epidermal growth factor-like domains, **960**, 969
- Epimerase(s), **133**
 - reactions catalyzed by, 133*f*
- Epimerization, **343**
- Epimers, **1139**, 1140
- Epinephrine, **231**, **533**, **929-930**
 - actions, 323, 327-328, 853, 883*t*, 884*t*
 - activation of pyruvate dehydrogenase, in cardiac tissue, 231
 - in cardiac glycolysis, 296-298
 - formation, 466-467
 - in hepatic glycolysis, 295, 296*f*
 - secretion, 853, 855*f*
 - synthesis, 853, 854*f*, 855*f*
 - urinary excretion products, 468*f*
- Epithelial endocrine cells, **1062**
- Epithelial sodium channel, **1064**
- Epithelial transport, 1063*f*, 1063-1069
 - paracellular, 1063*f*, 1063-1064
 - transcellular, 1063*f*, 1063-1064
- Epoxide, **989**
- Epoxide hydrolase, **994**
- Equilibrium centrifugation, **585**, 585-586
 - of DNA, 585*f*
- Equilibrium constant, **221**
 - and standard free-energy change, 221, 221*t*
- Equilibrium constant(s), **284**
 - for glycolytic enzymes of liver, 284*t*
- Equilibrium constant (K_{eq}), 6, 135, 137
 - equation for, 118
- Equilibrium electrical potential, **921**
- Erabutoxin, **203**
- Ergocalciferol. *See* Vitamin(s), D₂
- Ergosterol, **410**
 - structure, 410*f*
- Erythrocyte(s)
 - anion channel, **190**, 204-205
 - domains, 191
 - band 3, **204**
 - bicarbonate in, 1033*t*, 1035-1036
 - carbohydrate metabolism in, 270-272
 - glucose transport, 204
 - inhibitors, 204, 204*f*
 - life span, 1017
 - oxygen dissociation curve for, 1029, 1029*f*
 - plasma membrane
 - asymmetric distribution of lipids in, 192-193, 194*f*
 - fluidity, cholesterol and, 195cc
 - structure, 192, 193*f*
 - senescent, 1017
 - transketolase, 1119
- Erythrocyte ghosts, **207**
- Erythromycin, effects on protein synthesis, 734*t*, 735
- Erythropoietic porphyria, **1014**
- Erythropoietic protoporphyria, 1012*t*
- Erythropoietin
 - actions, 848*t*
 - source, 848*t*
- Erythrose 4-phosphate, formation, 339
- Escherichia coli*
 - biosynthetic operons, leader peptide
 - sequences, 813*t*
 - chromosome, 609*f*
 - diarrhea caused by, 1068cc
 - DNA replication in, 649, 649*f*
 - termination, 653*f*
 - DNA-dependent DNA polymerases, 622*t*, 622-625
 - excision repair in, 635-636
 - genetic map of, 801*f*
 - heat-stable toxin, 1068cc
 - homologous DNA recombination in, 665-666, 666*f*
 - lactose operon, 802*f*, 802-807
 - large ribosomal subunit, assembly map for, 716, 717*f*
 - primosome, 651*f*
 - protein synthesis in, stringent control of, 815, 815*f*
 - pyruvate dehydrogenase complex derived from, 228, 228*f*
 - RNA polymerase, 691, 691*t*
 - structure, 3*f*
 - synthesis of human growth hormone, 834*f*, 834-835
 - tryptophan operon, 807-813
 - genes of, 808, 809*f*
- Essential amino acid(s), **1090**
 - requirements for, 1090-1091
- Essential fatty acids (EFA), deficiencies, **1097**
- Essential serine residue, **1071**
- Esterase(s), **1059**
- Esterification, 1138
- Esters, **1138**
- 17 β -Estradiol, 894, **896**, **905**
 - excretion pathway, 902*t*
 - functions, 895*t*
 - secretion, 895*t*, 903*t*, 905*f*, 905-906
 - structure, 895*t*
 - synthesis, 903*t*, 905*f*, 905-906, **990**
 - hormonal regulation, 903*t*
- Estradiol, actions, **868**, 868-870
- Estrogen(s), 896, 1145
 - androgen aromatization to, **992**, 993*f*
 - drug-nutrient interactions, 1133*t*
 - and tyrosine metabolism, 467
- Ethanol
 - catabolism, 555
 - ingestion, and gluconeogenesis, **312**, 312cc
 - and membrane fluidity, 195cc
- Ethanolamine, **460**, 460*f*
- Ethanolamine glycerophospholipid. *See* Phosphatidylethanolamine
- Ethanolamine kinase, **405**
- Ethanolamine phosphotransferase, **405**
 - in phosphatidylethanolamine synthesis, 405
- Ethanolamine plasmalogen, 183, 183*f*
- Eukaryotes
 - genes, structure, 613*f*
 - repetitive DNA sequences in, 822-823
 - transcription in, 696-699
- Eukaryotic cells, **2**
 - compartments and functions, 15*t*, 15-20
 - composition, 12-15
 - expression vectors in, 784-786
 - nucleoproteins, 601-608
 - organization, 3*f*, 12-15
 - structure and function, 3*f*, 4*t*, 12-22, 13*f*
 - transfected
 - foreign gene expression in, 786, 786*f*
 - selectable markers, 785-786
- Eukaryotic initiation factor(s), **725**
- Evolution, restriction mapping and, 762cc
- Evolutionary relatedness, determined by DNA homology, **582**
- Excinuclease. *See* Excision nuclease
- Excision nuclease, **636**, 636*t*
- Excision repair, **635**, 636-638
 - base, **635**
 - in *E. coli*, 635-636
 - eukaryotic, 636-638
 - nucleotide. *See* Nucleotide excision repair
- Excitation energy transfers, **80**
- Excitatory neurotransmitters, **923**, 924
- Exciton system, **79**
- Exercise, **551**
 - aerobic, 551-552
 - anaerobic, 551-552
 - and energy expenditure, 1089
 - fuel for, 551-552
 - and glycogenolysis, 313
- Exergonic reaction, **220**
- Exocrine cells, **1060**
- Exocrine secretion, **1060**
 - of digestive enzymes, 1060, 1060*f*
- Exocytosis, **927**, **1060**
 - fusion process, **927**
 - of neurotransmitters, 925, 926*f*
- Exogenous substrates, **992**
- Exon-intron patterns, **104**, 104*f*
- Exons, **613**, **703**, 820
- Exonuclease(s), 569*t*, **709**
- Exopeptidase(s), **98**, **1070**
- Expressed (retained) sequences, **703**.
 - See also* Exons
- Expression system, **985**
- Expression vector(s), 783, **783**, 784*f*, 784-786
- Extended active site, **101**
- Extracellular fluid, 1037, 1037*f*
- Extrinsic factor, **1125**
- Eye(s), 932-946
 - anatomy, 932, 933*f*
 - diseases, 481cc

F

- Fab fragment, **94**, 95*f*
- Fabry's disease, 429*t*, 430
- Facilitated diffusion, **204**
- F-actin, **951**, 951-952

- Factor III, **961**, 961*r*, 964*f*.
See also Tissue factor
- Factor V, 965, 966, 968*f*
- Factor VII, 963-964, 969
- Factor VIIa, 964, 965*f*
- Factor VIIIa, 963, 966
- Factor VIII, 966, **967**, 968*f*
 deficiency, 967, 969cc
- Factor IX, activation, 963, 969
- Factor X, 961*r*, 963, 969
- Factor Xa, 965, 965*f*
- Factor Xa-Va, 964-966, 965*f*
- Factor XI, 961*r*, 961-963
- Factor XII, 961, 961*r*, 963
- Factor XIII, 967
- FAD. *See* Flavin adenine dinucleotide
- Familial hyperproinsulinemia, 743cc
- Familial lysinuric protein intolerance, 481cc
- Fanconi's anemia, 639cc
- Farnesyl pyrophosphate
 formation, 412*f*
 mevalonic acid and, 412
 in squalene formation, 413*f*
- Fasciculus, 946, 947*f*
- Fast axonal transport, **931**
- Fast food, 1133
- Fasting state, 530-533, 531*f*.
See also Starvation
 early, 529-530, 530*f*
- Fat, dietary, 1097.
See also Lipid(s)
 contribution to daily nutrient supply, 1056, 1056*t*
 energy content of (kcal), 1088
 intake, 1056*t*, 1077
 and cancer risk, 1097
 and diabetes mellitus, 1096cc
 excess, 1097
 inadequate, 1097
 and protein sparing, 1091
- Fat malabsorption, **1114**
 and vitamin K deficiency, **1117**
- Fat storage, 321
- Fats, 1144
- Fatty acid desaturase, **988**
- Fatty acid synthase, **366**, 369, 374
- Fatty acids, **362**, **1143**
 abbreviations for, 364*t*
 activation by conversion to fatty Acyl CoA, 381-382
 addition of water, 1143
 asymmetrical distribution, in phospholipids, 406-408
 availability to tissue, 380-381
 bound to serum albumin, 379
 branched chain, 374
 catabolism, 306*f*
 chemical nature, 363-365
 desaturation, positions for, 373*f*
 diet and, 365-366
 elongation and desaturation, specific example, 373
 elongation reactions, 372-373
 mitochondrial elongation, 372*f*
 energy yield from β oxidation of, 383
 essential, deficiencies, **1097**
 free
 in obesity, **1095**
 in triacylglycerol digestion, **1078**, 1081
 function in the body, 362-363
 gluconeogenesis from, 306-307
 in glycerophospholipids, 182, 183*r*
 in human metabolism, 364*t*
 hydroxy, formation, 373-374
 hydroxylation, **387**
 long-chain, 181*f*, 364*f*, 182-183, 183*f*, 1082-1083, 1143-1144
 medium-chain, **1082**, 1082-1083
 metabolism, 362, 384-387
 nomenclature, 364
 omega, 1099cc, 1143
 omega (ω)-oxidation, 387
 α -oxidation, 384-387
 β -oxidation, 384-387
 comparison with palmitate biosynthesis, 383
 genetic impairment in, 385cc
 modification, 384-387
 palmitate, 385*t*
 oxidation, 382*f*, 384-387, 390*f*, 390-391, 532, 1143
 palmitate precursor, 371-374
 patterns, **376**
 in phosphatidylcholine, 182
 in phosphatidylethanolamine, 182
 polyunsaturated, **372**, **1098**
 formation and modification, 372-373
 linoleic, 1099cc
 linolenic, 1099cc
 omega-3, physiologic effects, 1099cc
 omega-6, physiologic effects, 1099cc
 and risk of heart disease, 1099, 1099cc
 and prostaglandin synthesis, 432*f*
 reduction, 1143
 saturated, **1098**, **1143**
 and risk of heart disease, 1099, 1099cc
 short-chain, 1143-1144
 sources, 365-366
 storage, 375-377
 straight chain, β -oxidation, 381-383
 synthesis, **272**
 commitment step, 366-368
 palmitate biosynthesis, 367*t*
 regulation, 367*t*
 release of palmitic acid, 369*f*
 stoichiometry, 369
 transfer through mitochondrial membrane, 382*f*
 triacylglycerols, 364-365, 377*f*
 unsaturated, 1143
 utilization for energy production, 381-387
- Fatty acyl CoA
 in phosphatidic acid synthesis, 402-403
 reduction to fatty alcohols, 374-375
 as source for triacylglycerols, 376
- Fatty alcohols, **375**, 375*f*
 in plasmalogen synthesis, 408-409
 reduction from fatty acyl CoAs, 374-375
- Fe fragment, **94**, 95*f*
- FCCP. *See* Carbonylcyanide-*p*-trifluoromethoxy phenylhydrazone
- Feedback inhibition, **175**, 175*f*, 808
- Feedback loops, in hormonal cascade, **842**, 842-844, 843*f*
- Feedback stimulation, of hormone secretion, 869
- Fermentation, **269**
- Ferredoxin(s), **1004**, 1004*f*, 1004-1005
- Ferritin, **1004**
- Ferrochelatase, **1016**
- Ferroxidase I/II, **1008**
- Fetus, **552**
 nutrient requirements, 552
 protein absorption, 1073
- Fever-inducing agents. *See* Pyrogens
- Fiber, dietary, 1056, **1097**
 intake, 1098-1101
 metabolic fate, 1097-1098
 mucilaginous, **1097**, 1098*t*
 properties, 1097-1098, 1098*t*
 sources, 1097-1098
 types, 1097-1098, 1098*t*
 water-soluble, **1097**, 1097-1098, 1098*t*
- Fibrin, **960**
 formation, 964-966, 965*f*
 in myocardial infarct, 98cc
 soft clot, 966, 967*f*
- Fibrinogen, 964-966, 974*f*
- Fibrinolysis, 975-976.
See also Blood coagulation, clot dissolution
- Fibrous material, **1056**.
See also Fiber
- Fibrous protein(s), 50-55
- Fick's first law of diffusion, **197**
- FIGLU. *See* Formiminoglutamate
- First order reactions, **134**
- Fischer projection formulas, 1140
- Flagella, bacterial, **818**
- Flagellin gene, of *Salmonella*, 818-819, 819*f*
- Flavin, **251**
- Flavin adenine dinucleotide, **143**, 144*f*, 514-515, 988, 1121
 coenzyme function, in succinic
 dehydrogenase reaction, 143-144, 144*f*
 isoalloxazine ring of, 987, 988*f*
 optical properties, 168-170
 and pyruvate dehydrogenase reaction, 228*t*, **234**
 structure, 251*f*
 synthesis, 514*f*
- Flavin coenzymes, absorption spectrum, 168*f*
- Flavin mononucleotide, **143**, 144*f*, 251*f*, 987, 988, 988*f*, 1121
- Flavin-linked dehydrogenases, 251, 251*r*
- Flip-flop movement, 189, 191, 193
- Fluid compartments, composition, 1036-1037, 1037*f*
- Fluid mosaic model, of membranes, **189**, 190*f*, 196*f*
- Fluid secretion, intestinal epithelial, 1066, 1066*f*
- Fluidity
 membrane, **193**, 194-195
 abnormalities, 195cc
 factors affecting, 195cc, 195-196
 plasma membrane, cholesterol and, 195cc
- Fluorescence spectroscopy, 79-80
- Fluorescent emission, 79, 80*f*
- Fluoride, **282**, **1132**
- 5-Fluoro-2 -deoxyuridine 5 -monophosphate (FdUMP), **518**
- Fluoroacetate, **233**
- Fluorophore, **80**
- 5-Fluorouracil (Fura), 151, **517**, 517*f*
- Fluoxetine hydrochloride (Prozac), 930
- FMN. *See* Flavin mononucleotide

- Folate
- components, 461*f*
 - deficiency, 463cc, 481-482, **1124**, **1125**
 - fully reduced (coenzyme) form, 150
 - metabolism, diseases, 483cc
 - transport, in mammalian cells, 211*r*
- Folic acid, **1123**
- as coenzyme, 150
 - deficiency, 463cc
 - functions, in one-carbon metabolism, 1123-1125
 - metabolic role, in one-carbon metabolism, 1123*f*, 1123-1125
 - requirements, and anticonvulsant therapy, 1118cc, 1125
 - structure, 1123*f*
 - and methotrexate structure, comparison, 518*f*
- Follicle-stimulating hormone, 846, 903*r*, 905-906
- actions, 847*r*, **868**, 868-870, 883*r*
 - hormone-receptor interactions, 872-873
 - secretion, regulation, 883-885, 884*f*
 - source, 847*r*
- Follicular hyperkeratosis, in vitamin A deficiency, **1111**
- Food(s)
- contribution to daily nutrient supplies, 1056, 1056*r*
 - energy content of (kcal), 1088
 - fast, 1133
 - glycemic index, 1096cc, 1101*r*
 - imitation, 1133
- Food pyramid, USDA, 1102, 1103*f*
- Formiminoglutamate (FIGLU), **481**, 481-482
- N*¹⁰-Formyl H₄folate, **494**, 496*f*
- Fourier synthesis, **77**
- Fovea centralis, **935**
- Fragile X syndrome, 602cc, 697cc
- Frameshift mutations, 601, 603*f*, **628**, **631**, 721, 723*r*
- Free energy, **200**, **220**, 220-222
- standard change, 221*r*, 221-222, 222*r*
 - in coupled enzyme reactions, 224-225
 - and equilibrium constant, 221, 221*r*
 - in redox reactions, 248-249
- Free fatty acids, **1078**, 1081, **1095**
- Fructokinase deficiency, 342cc
- Fructolysis, **307**
- Fructose, **286**
- formation, 308*f*
 - gluconeogenesis from, 307, 308*f*
 - intolerance, 285cc, 342cc
 - malabsorption, 212cc
 - sources, 1074*r*
 - structure, 1074*r*, 1140
 - synthesis, 935
 - transport, in mammalian cells, 211*r*
- Fructose 1,6-bisphosphatase, 289, **303**, 303*f*
- Fructose 1-phosphate, **307**
- Fructose 1-phosphate aldolase, 342
- deficiency, 342cc
- Fructose 2,6-bisphosphatase, **544**
- bifunctional nature, 295-296
 - cardiac isoenzyme, 298*f*
 - covalent modification, 295*f*
 - hepatic isoenzyme, 296*f*
 - intracellular concentration, 295, 296*f*
- Fructose 2,6-bisphosphate, **287**, **292**, 292-294, 293*f*, **310**, 310-312
- degradation, 293*f*
 - formation, 293*f*
 - structure, 292*f*
- Fructose 4-phosphate, formation, 339-340
- Fructosuria, essential, 342cc
- FSH. *See* Follicle-stimulating hormone
- Fucosidosis, 349cc, 429*r*
- Fumarase, 132, 132*f*, **237**
- deficiency, 237cc
- Fumarate, **236**, 454, 455*f*
- Functional groups, 1137-1138
- Furanose rings, 1140
- Furosemide, **1066**, 1066*f*
- Fusion proteins, **783**
- G**
- G factor, 730
- G subunit, **325**, 325*f*
- G6P. *See* Glucose-6-phosphate
- GABA (gamma-aminobutyric acid), **457**, 923
- degradation, 931
 - metabolism, 931, 931*f*
 - neurotransmitter function, 931
 - structure, 923, 923*f*
 - synthesis, 457*f*
 - transport, in mammalian cells, 211*r*
- GABA receptor, **923**, 923-924, 924*f*
- GABA shunt, **931**
- G-actin, **951**, 951-952
- G-actin-ATP-Mg²⁺ complex, 951-952
- Galactitol, 343cc
- Galactocerebrosidase deficiency, in Krabbe's disease, 425
- Galactocerebroside(s), **184**, 184-185, 185*f*, **422**, 424*f*, **425**
- Galactocerebroside sulfate, structure, 424*f*
- Galactokinase deficiency, 343cc
- Galactolipid. *See* Galactocerebroside
- Galactose, **307**
- and blood type, 347
 - gluconeogenesis from, 307
 - interconversion, 343, 343cc
 - structure, 1140
- Galactose 1-phosphate, accumulation, 343cc
- Galactose 1-phosphate uridylyltransferase, **307**
- deficiency, 343cc
- Galactosemia, **307**, 343cc
- β -Galactosidase, 611*f*, 800, 807, 807*f*, **1075**, 1076*r*
- Galactosyltransferases, **425**
- Gallbladder, functions, 1057, 1058*f*
- Gallstones, cholesterol, 1081cc
- Ganglioside(s), **185**, **426**, 426*r*, 426-427, **1145**
- in brain, 426
 - receptor function, 427
 - structure, **426**, 426*f*, 426*r*
- Gangliosidosis
- generalized, 429*r*
 - GM₁, 349cc, 427
 - GM₂, **430**
 - variant O, 349cc
- Gap junctions, **203**, 203*f*
- Gardner's syndrome, 639cc
- Gas exchange, pulmonary, 1027
- Gas transport, 1026
- Gastric acid, secretion, **436**
- Gastric juice, 1070
- Gastrin, **1062**
- actions, 848*r*, 1061*r*, 1062
 - source, 848*r*
 - structure, 1062, 1062*r*
- Gastrointestinal tract, 1057, 1058*f*, 1066, 1066*f*
- Gaucher's disease, 429*r*, 430-431
- diagnosis, 430*r*, 430cc
 - gene therapy, 793cc
- GDP, 942
- Gene(s) *See also* DNA; Gene expression
- activation, **699**
 - active, **608**
 - cloning, 824-827
 - intervening sequences (introns) in. *See* Introns
 - inversion, in *Salmonella*, 818-819, 819*f*
 - mitochondrial, 830-831
 - mutations, 169cc.
 - See also* DNA, mutations
 - organization, in mammalian DNA, 820-822
 - regulatory, 801
 - reporter, 787
 - repressed, **608**
 - silencers, 912
 - structural, 613, 801
 - for vision, chromosomal location, 944-945, 946cc
- Gene duplication, **96**, **984**
- Gene expression
- bacterial, of foreign genes, 832-835
 - coordinate, 803
 - foreign, in transfected cells, 786, 786*f*
 - regulation, 799-838
- Gene library, **768**
- Gene superfamily, cytochrome P450, **985**
- Gene therapy, **793**, 793cc, **836**
- General transcription factor TFIIH, **638**
- Genetic code, 718, 718*r*
- breaking of, 720
 - degeneracy, 719
 - four-letter alphabet of, 718, 718*r*
 - punctuation, 719
 - universal, 719
- Genetic complementation groups, **636**
- Genetic disease, 828
- diagnosis, 583
- Genetic diversity, **661**
- Genetic information, transcribed into amino acid sequence, 25*f*
- Genetic polymorphisms, **986**
- of drug-metabolizing enzymes, 987cc
- Genome(s)
- complexity, **580**
 - human, 608, 672cc
 - sequencing, 611
 - intervening sequences, **613**
 - repetitive classes, **580**
- Gentamicin, effects on protein synthesis, 734, 734*r*
- Geranyl pyrophosphate, **412**
- Gilbert's syndrome, 1020cc
- Glaucoma, 936cc
- Glial cells, 921
- Globin(s)
- cDNA, cloning, 824-827, 825*f*
 - chains, production, age-related change in, 114*f*
 - genes, 824-829, 826*f*
 - subunits

- Globin(s)
- (*continued*)
- genes, 824
 - in thalassemia, 828-829
- Globoid leukodystrophy, 425, 429*t*
- Globosides, 425, 1145
- γ_2 -Globulins, **901**, **1021**
- Glomerular filtration rate, 436
- Glossitis, **1118**
- Glucagon, **270**, **533**
- actions, 295, 296*f*, 311, 311*f*, 312, 323, **327**, 848*t*
 - source, 848*t*
 - synthesis, 293
- 1,4- α -Glucan branching enzyme, **319**
- D-Gluconic acid, 1141
- Glucoamylase, 1059*t*, 1076*t*
- Glucocerebrosidase deficiency, in Gaucher's disease, 430cc, 793cc
- Glucocerebrosidase(s), **184**, **422**
- excess, in Gaucher's disease, 425
 - structure, 424*f*
 - synthesis, 424*f*
- Glucocorticoid(s), 894, 911, 1145
- Glucocorticoid receptor(s), 911
- Glucocorticoid response elements, 911, 911*t*
- Glucogenic amino acids, 304-306, 306*t*, 447
- Glucokinase, 131, **142**, 284*t*, 284-286, 286*f*
- reaction catalyzed by, 142, 284
 - specificity, 156
 - substrate saturation curve for, 285*f*
- Gluconeogenesis, **245**, **272**, **299**, 299-312, 300cc, 310*f*, **530**, 530-533
- abbreviated pathway, 299*f*
 - from amino acid carbon chains, 304-306
 - and ATP expenditure, 308
 - ethanol ingestion and, **312**, 312cc
 - from fatty acids, 306-307
 - glycolytic enzymes in, 303-304
 - hormonal regulation, 310-312
 - from lactate, 301, 302*f*
 - regulation sites, 308-310, 310*f*
 - from sugars, 307
- Gluconic acid, 1141
- Glucono-5-lactone, 1141
- Glucosamine, structure, 402*f*
- Glucosamine 6-phosphate, synthesis, 344
- Glucose
- absorption, epithelial, **1067**, 1068*f*
 - activated, **319**
 - blood (serum)
 - factors affecting, 1100
 - and glycemic index of foods, 1101*t*
 - source, 529-530
 - steady-state level, 138
 - and carbohydrate metabolism pathways, 268*f*
 - catalysis, 170
 - conformations, 158, 158*f*
 - dietary sources, 1074*t*
 - disposition, in well-fed state, 528*f*
 - homeostasis, 538, **538**, 539*f*
 - interconversion to galactose, 343
 - intolerance, **546**
 - malabsorption, 212cc
 - membrane transport, **209**, 209*f*, 209-210
 - metabolism, 270*f*-271*f*, 270-272
 - in early refeed state, 533-534
 - as energy source for brain, **920**
 - free-energy changes associated with, 222*t*
 - glycolysis and, 269*f*
 - sodium-dependent transport, 209*f*, 209-210
 - storage, 321
 - structure, 1074*t*, 1140
 - synthesis. *See* Gluconeogenesis
 - transepithelial transport, 1067, 1068*f*
 - transport, 204, 204*f*, 211*t*
 - UDP-, **307**
 - oxidation, 280, 344, 344*f*
 - synthesis, 343
- Glucose 1-phosphate uridylyltransferase, **319**
- Glucose 6-phosphatase, **286**, 286*f*, **316**, **545**
- deficiency, in von Gierke's disease, 498cc
 - reactions catalyzed by, 274, 303*f*, 303-304*f*
- Glucose 6-phosphate, 170, **225**, 304*f*
- complete oxidation, **340**, 340*f*, 340-341
 - dehydrogenation, 336-338, 337*f*
 - in pentose phosphate pathway, 336-338
- Glucose 6-phosphate dehydrogenase, **337**
- deficiency, 338cc
- Glucose dehydrogenase, UDP-, **344**
- Glucose oxidase, **129**, 129*f*
- Glucose permease, **204**
- Glucose tolerance factor, 1132
- Glucose transport protein(s). *See* Glucose transporter(s)
- Glucose transporters(s), 204, **272**, **330**, 1068*f*, **1069**, 1076, 1077*t*
- Glucose-fatty acid cycle, 545
- Glucosidase, **319**
- α -Glucosidase(s), **1075**.
- See also* Maltase
- β -Glucosidase, 1059*t*, 1076*t*
- exo*-1,4- α -Glucosidase. *See* Glucoamylase
- Glucosyltransferase(s), **132**, **425**
- Glucuronic acid, **344**, 344*f*, 345*f*, 1141
- copolymer, 353-354
 - and glucuronide formation, 346cc
 - UDP-, formation, **280**, 344*f*
- Glucuronic acid pathway, **272**
- β -Glucuronidase deficiency, 352cc
- β -Glucuronidase(s), **280**, 280-281
- GLUT. *See* Glucose transporter(s)
- Glutamate, **27**, 34*f*
- in amino acid synthesis, 450, 450*f*, 457-458
 - metabolism, 931, 931*f*
 - ornithine conversion into, 535
 - side chains, 27*f*
 - transport, in mammalian cells, 211*t*
- Glutamate dehydrogenase, 235, **450**, 450*f*, 451, 453
- Glutamate-aspartate antiport, **303**
- Glutamate-oxaloacetate transaminase, 235
- Glutamate-pyruvate aminotransferase reaction, 448*f*
- Glutamic semialdehyde, **458**, 458*f*
- Glutaminase, **450**, 451*f*, **546**
- Glutamine, **27**, **450**
- in acid-base balance, 556-559
 - in ammonia production, 450-451
 - antagonists, 519*f*, 519-520
 - catabolism, 532*f*
 - cycle, **451**, 451*f*, **554**, 558
- Glutamine PRPP amido-transferase, **497**, 497*f*, **500**
- Glutamine synthetase, **450**, 451*f*
- Glutaminolysis, **531**
- γ -Glutamyl cycle, **210**, 210*f*, **485**, 485*f*, 1059*t*
- γ -Glutamylcysteinylglycine. *See* Glutathione
- γ -Glutamyltranspeptidase, **210**, **485**
- Glutaredoxin, **507**
- Glutathione, **210**, 210*f*, **272**, **484**, 484-485, **535**
- composition, 457
 - drug conjugation by, 484, 484*f*
 - production, 535*f*
 - synthesis, 485, 485*f*
- Glutathione peroxidase, **460**, 1132
- Glutathione reductase, **507**, **933**
- Glutathione transhydrogenase, **858**
- Glutathione-dependent peroxidase, **434**
- Gluten, **1057**
- Glycan, **192**
- Glycyrhethinic acid, 911cc
- Glycemic index, 1096cc, 1101*t*
- Glyceraldehyde, structure, 1139
- Glyceraldehyde 3-phosphate, 149*f*, 339-340
- Glyceraldehyde-3-phosphate dehydrogenase
- inactivation, 282, 282*f*
 - mechanism of action, 276*f*
 - and noncompetitive inhibition, 149, 149*f*
 - reaction catalyzed by, 275-276
- D-Glyceric acid, 1141
- Glycerol
- gluconeogenesis from, 307, 308*f*, 530-533
 - stereospecific numbering, 396*f*
 - structure, and sphingosine structure, comparison, 420*f*
- Glycerol 3-phosphate, 376, 376*f*, 403*f*
- L-Glycerol 3-phosphate, structure, 181*f*
- Glycerol ether phospholipids, **183**, 183*f*
- Glycerol kinase, 158, **307**
- Glycerol phosphate shuttle, **243**, **279**, 279*f*
- Glycerol phosphate:acyltransferase, 403
- Glycerol-3-phosphate dehydrogenase, 280
- Glycerophosphate, in phosphatidic acid synthesis, 402-403
- Glycerophospholipids, 180, **181**, 397
- amphipathic, **183**
 - charge on, 183-184, 184*t*
 - fatty acids in, 182, 183*t*
 - structure, 181, 181*f*
- Glycine, **25**, **460**, 461cc, 923, **1078**
- in heme synthesis, 1012
 - metabolism, free-energy changes associated with, 222*t*
 - oxidation, 460, 461*f*
 - structure, 923, **923*f***
 - synthesis, 1123
- Glycine cleavage complex, **460**, 461*f*
- deficiency, 461cc
- Glycine receptor(s), **923**
- Glycocholic acid, **418**, 419*f*
- Glycoconjugates, 1079, 1080*t*, **1084**
- Glycogen, **270**, 316*f*, **1073**, **1142**
- digestion and absorption of, 1073-1074, 1075*f*
 - glucose storage as, 321
 - metabolism, effector control of, 326
 - stores, **313**, **1095**
 - and carbohydrate intake, 1095, 1096cc
 - and food intake, 313, 313*f*
 - synthesis, 132, 132*f*
 - enzymes for, 319, 319*f*
 - negative feedback control of, 326

- primer for, **321**, 321*f*
- regulation, 322, 326
- Glycogen branching enzyme, **319**, 320*f*
- Glycogen debranching enzyme, **317-318**, 318*f*
- Glycogen phosphorylase, **314**, 314-317, **322**, 322*f*, 322-323, **544**
- Glycogen storage disease, **316**, 317cc, **318-319**
- Glycogen synthase, **319**, 319-320, 322, **324**, 324*f*, 324-325
- Glycogenesis, **269**, **312**, 312-330, **313**
- Glycogenin, **321**, 321*f*
- Glycogenolysis, **269**, **299**, **312**, 312-330, 316*f*, 322, 327*f*, 327-328
- Glycolaldehyde, active, **338**
- Glycolysis, **268**, 269*f*, 269-283, **921**
 - balanced equation for, 269*f*
 - excessive, 291cc
 - inhibition, 282-283
 - oxidoreduction-phosphorylation stage, **274**, 275-278
 - and pentose phosphate pathway, 336
 - reversible link with, **338**
 - priming stage, **274**, 274-275
 - regulation, 283-299
 - splitting stage, **274**, 275
 - stages, 273*f*, 274
- Glycolytic intermediates, in pentose phosphate interconversion, 338-340
- Glycopeptide bonds, 61*f*, 350, **350**, 351*f*
- Glycophorin, 190, **190**, 191
- Glycoproteins, **187**, **348**, 348-351
 - carbohydrate in, 348-349
 - and covalently bound carbohydrate, 60-61
 - functions, 348
 - microheterogeneity, **349**
 - N*-linked, synthesis, 350-351
 - structure, 349-350
 - SV-2, 927
 - synthesis, 1110
- Glycosaminoglycan(s), **352**, 355*f*, 356-357
- Glycosaminoglycan chain, repeat units, 353*f*
- Glycosidases, **356**, 737
 - defects in, 349cc, 350cc
- β -*N*-Glycosidic bond, **492**
- Glycosidic linkage
 - α -1,4-, 1142
 - N*-, **61**, 61*f*, 737
 - O*-, **61**, 61*f*, 738
- Glycosphingolipids, **184**, 422-427, 1145
- N*-Glycosyl bonds, 350
- O*-Glycosyl bonds, 350
- Glycosyl donor, **1110**
- Glycosyl phosphatidylinositol anchors, 192, **192**, 192*f*, 192*t*, **401**, 401-402
- Glycosylated 5-hydroxycytosine, **565**
- Glycosylated hemoglobin, 62cc
- Glycosylation, 736-739
 - N*-linked, **61**, 61*f*, 737
 - O*-linked, **61**, 61*f*, 738
- Glycosyltransferase(s), 346, **346**, 737, 737*t*
- Glycyrrhizic acid, 911cc
- Glyoxalate, **460**
- GMP. *See* Guanosine 5'-monophosphate
- GMP reductase, **500**
- GnRH. *See* Gonadotropin-releasing hormone
- GnRH-associated peptide, 852
- Goiter, **1131**
- Golgi apparatus, **17**
 - procollagen formation in, 746-747
- Gonadotropes, **868**, **906**
- Gonadotropin, secretion, 906
- Gonadotropin release-inhibiting factor, 844*t*
- Gonadotropin-releasing hormone, 844*t*, 905
 - actions, 847*t*, 867*f*, 867-870, 883-885, 884*t*
 - gene, 852
 - source, 847*t*
 - structure, 857*t*
- Gout, 152cc, 490, 498, 498cc, 517
- GPI. *See* Glycosyl phosphatidylinositol anchors
- G-protein(s), **859**, 859-860, 860*t*, 942
 - subunits, **859**
- G-quartet DNA, **599**
- Gramicidin A, 212*t*, **213**
- Gratuitous inducers, 804
- Green pigment, 937
- Group translocation, **198**, **210**, 211*t*
- Growth hormone, **553**, 829, 846
 - actions, 847*t*
 - deficiency, 830
 - human, synthesis in recombinant bacteria, 834*f*, 834-835
 - rat gene, introduction into mice, 835*f*, 835-836
 - recombinant, therapy with, 830
 - source, 847*t*
- Growth hormone release inhibiting hormone.
 - See* Somatostatin
- Growth hormone-like proteins, genes, 824, 829-830
- Growth hormone-releasing hormone (somatocrinin), 844*t*
 - actions, 847*t*
 - source, 847*t*
 - structure, 857*t*
- GTF. *See* Glucose tolerance factor
- GTP-binding proteins, **927**
- Guanine, **492**, 679-680
- Guanine nucleotide exchange factor, **727**
- Guanosine 5'-monophosphate, **494**
 - synthesis, 494-497, 496*f*
- Guanosine pentaphosphate, synthesis, 815
- Guanosine tetraphosphate, synthesis, 815
- Guanosine triphosphate, **219**, 490-491, **500**, 501*f*, 942
 - as energy source, 219, 219*f*
- Guanylate cyclase, 885, 886*f*, **943**, 944*t*, **1061**
- Guanylin, 1061*t*, 1062, **1062**, 1062*t*, 1068cc
- Gums, **1097**, 1098*t*
- Gustin, **1131**
- Gyrase(s), **592**, **648**
 - reverse, **593**
- H**
- H band, **948**
- Hairpin structure(s), 680
- Half life of reaction ($t_{1/2}$), 134
- Half-chair configuration, 161*f*
- Halothane, and malignant hyperthermia, 291cc
- Hammerhead ribozyme, 686, 688*f*
- Hapten, **88**
- Haptoglobins, **1021**
- Hartup disease, 212cc, 1072cc
- Haworth formulas, 1140-1141
- HbH disease, 828-829
- HDL. *See* High-density lipoproteins
- Heart
 - glycogen degradation in, regulation, 328
 - glycolysis in, 296-298, 298*f*
- Heart attack. *See* Myocardial infarction
- Heart disease, risk factors for, 1098-1100, 1099cc
- Heat shock proteins, **63**, **910**, 934*t*
- Heavy filaments, **948**
- Heavy meromyosin, **950**
- Helicase(s), **636**, **648**
 - in homologous recombination, 665, 666*f*
- II, **648**
- Helices, **568**
 - α -Helix, 43-44, 44*f*, 55*f*, 79*f*
- Helix pitch (p), **43**, 43*f*
- Helix-loop-helix motif, of calcium-binding proteins, 209, 209*f*
- Helix-turn-helix (HTH) motif, **108**, 109*f*, 912
- Hematin, **1003**
- Hematocrit, 1036
- Heme, **1003**
 - catabolism, 1017*f*, 1017-1021
 - environment, movement of residues in, 122*f*
 - structure, 115*f*, 115-116, 1009, 1009*f*
 - synthesis, 1009-1017
 - enzymes in, 1011-1016
 - pathway, 1009, 1010*f*
 - rate-limiting step, ALA synthase in, 1017
- Heme a, 252*f*-253*f*, 253
- Heme b, 253
- Heme c, 252*f*-253*f*, 253
- Heme iron, 147, 983-984
- Heme oxygenase, **1017**
- Heme proteins, **982**, 983-984, 1003-1005
- Heme-regulated inhibitor kinase, **748**
- Hemiacetals, **1138**
- Hemicellulose, **1097**, 1098*t*
- Hemiketals, 1140
- Hemochromatosis, **1130**
 - idiopathic, **1008**
 - and iron-fortified diets, 1011cc
 - molecular genetics, 1011cc
- Hemoglobin, **88**, **1026**
 - and allosterism, 1029-1030
 - amino acid sequence, 117*t*
 - buffering capacity, **1033**, 1033-1034, 1041, 1041*f*
 - chemically modified, 1030cc
 - diaspirin cross-linked, 1026cc
 - fetal. *See* Hemoglobin F
 - glycosylated, 62cc
 - human, chains, by developmental stage, 114*t*
 - and intravascular hemolysis, 1020-1021
 - isohydric carriage of carbon dioxide, **1034**, 1034*f*, 1034-1035
 - ligands, interrelationships, 1036, 1036*f*
 - α -like genes, 826, 827*f*
 - β -like genes, 826, 827*f*
 - missense mutations, 721cc
 - molecular aspects, 114-124
 - oxygen affinity
 - abnormalities, 1032cc
 - plasma pH and, 1031, 1031*f*
 - temperature and, 1031, 1031*f*
 - oxygen binding, 115-116, 119*f*, 119-124, 1028, 1031, 1031*f*

Hemoglobin

(*continued*)

- oxygen dissociation curve for, 1029, 1029*f*
 - postnatal changes, 1030, 1031*f*
 - oxygen saturation curve, 1028cc, 1028*f*, 1028-1029
 - oxygen-binding curve, 119*f*
 - oxygen-carrying capacity, 1026
 - oxygen-induced changes in, 154
 - R state, **1029**, 1029*f*
 - structure, 114-124, 115*f*, 121*f*, 122*f*, 824
 - subunits
 - genes, 821
 - α -globin, 824
 - β -globin, 824
 - T state, **1029**, 1029*f*
 - types, 114, 114*t*
- Hemoglobin A₁
- β chain, comparison with myoglobin, 118*f*
 - Hill plots for, 119*f*
- Hemoglobin A_{1c}, **1030**
- Hemoglobin A₂, **1030**
- Hemoglobin F, **1030**
- hereditary persistence of (HPFH), 599, 600cc, 829
- Hemoglobin Kenya, **829**
- Hemoglobin Lepore, **828**
- Hemoglobin S, 828
- and sickle cell anemia, 42cc, 828, 828cc
- Hemoglobinopathy, 721cc, **1030**
- Hemolysis, intravascular, iron scavenging with, 1020-1021
- Hemolytic anemia, 166cc, **1008**
- drug-induced, 337, 338cc
- Hemopexin, **1021**
- Hemophilia, 967
- B, diagnosis, direct DNA sequencing for, 766cc
 - classic, 969cc
- Hemorrhagic disease of the newborn, 1117cc, 1118cc
- Hemosiderin, **1004**
- Hemostasis, **960**, 960-961, 961*t*
- Henderson-Hasselbalch equation, **9**, 9-10, 12cc, 32*f*, 32-33, **1038**, 1038*f*, 1039, 1046
- Heparin, **354**
- anticoagulant activity, 350cc
 - structure, 353*f*
- Heparin binding protein, 968
- Heparin sulfamidase deficiency, 352cc
- Heparin sulfate, **355**
- Hepatic glycogenolysis, 529-530
- Hepatocytes
- mitochondria in, 239*f*, 241
 - periportal, **558**
 - perivenous, **558**
- Hepatorenal tyrosinemia, 467cc
- Heptose, formation, 338, 339*f*
- Hereditary coproporphyrin, 1012*t*, **1016**
- Hereditary persistence of fetal hemoglobin, 599, 600cc, 829
- Hereditary protoporphyria, 1012*t*
- Herpes simplex virus, **709**
- type I, glycoprotein D, site-directed mutagenesis, 789cc
- Herpesvirus, 517, **520**
- Heteroduplex DNA, **663-664**, 669
- Heteroduplexes, **583**, 583-584, 584*f*
- Heterogeneous nuclear RNA, 678*t*
- Heterophagy. *See* Phagocytosis
- Heterotetrameric protein, **942**
- Heterotropic effect, **1029**
- Heterotropic interactions, **152**
- Heterozygote detection, 430
- HETEs. *See* Hydroxyeicosatetraenoic acid(s)
- Hexokinase(s), **138**, **156**, 273*f*, **274**
- with glucose bound, 47*f*
 - glucose-induced conformational change, 157*f*
 - properties, 284*t*, 284-286, 285cc
 - reaction catalyzed by, 282*f*
 - reactions, **225**
 - regulatory features, 283, 283*f*
 - specificity, 156
 - substrate saturation curve for, 285*f*
 - unliganded form, 47*f*
- Hexosaminidase, 428, 431*f*
- Hexose(s), 338, 339*f*, 342*f*
- Hexose monophosphate pathway, **933**
- Hexose monophosphate shunt, **516**.
- See also* Pentose phosphate pathway
- HGPRTase. *See* Hypoxanthine-guanine phosphoribosyltransferase
- High mobility group protein(s). *See* Protein(s), HMG
- High molecular weight kininogen, 961, 962*f*
- High-density lipoproteins, **57**, **379**.
- See also* Lipoproteins
- High-energy bonds, **219**, 222, 225, 225*f*
- High-performance liquid chromatography, 72-73
- Hill coefficient (n_{H}), 119*t*, **1029**
- Hill equation, **119**
- Hippurate, **456**, 456*f*
- Histamine, **482-483**, 483*f*, 1061, **1061**, 1061*t*
- Histamine H₂-receptor antagonists, 1061
- Histidase, **481**
- deficiency, 482cc
- Histidine, **27**, 27*f*, 481-483
- acid and base forms, 160*f*
 - distal, **115**
 - guanidinium group, 27*f*
 - imidazolium group, 27*f*
 - invariant sequences, 105*t*
 - metabolism, 481-483, 482*f*
 - proximal, **115**
- Histidine decarboxylase, **482**
- Histidinemia, 482cc
- Histone(s)
- and DNA structure, **603**
 - messenger RNA, 685
 - in nucleoproteins of eukaryotes, 601-608
 - structure, 604*t*
- Histone acetylase, **608**
- Histone deacylase, **608**
- HIV, 520, **520**, 792
- detection, 171, 171*f*
 - screening for, polymerase chain reaction and, 760cc
- HIV protease, structure, 78*f*
- HMG proteins. *See* Protein(s), HMG
- HMWK. *See* High molecular weight kininogen
- H-NS protein, **609**
- Holliday intermediate, **669**
- Holliday junction, **663**, 666, 668*f*
- Holoenzyme, **128**, 691
- Holoprotein, **115**
- Homeodomain transcription factors, 830
- Homocysteine
- accumulation, 471cc
 - production, 470-471
- Homocysteine desulfhydrase, 471, 472*f*
- Homocysteine methyltransferase, **472**
- Homogentisic acid, production, 465
- Homologous alignment, **663**, **667**
- Homologous DNA sequences, pairing, **666**
- Homologous recombination, **662**, 662-668, 664*f*
- characteristics, 662*t*
 - enzymes, 665-668
 - proteins in, 662*t*, 665-668
- Homotropic interactions, **152**, 1029
- Hormonal cascade system, **840**, 841*f*, 841-846, 843*f*
- cyclic, 866-871
- Hormone(s), **841**
- adrenal, **894**
 - amino acid-derived, **840**, 853-856
 - autocrine, **841**
 - derived from 5-hydroperoxyeicosatetraenoic acids, 437-439
 - endocrine, **841**
 - gonadotropic, in ovarian cycle, 867*f*, 867-870
 - intracellular action, 878-888
 - paracrine, **841**
 - peptide. *See* Peptide hormone(s)
 - polypeptide. *See* Polypeptide hormone(s)
 - progesterational, 894, **894**, 896
 - release
 - pulsatile, **842**
 - rhythmic cyclical, **842**
 - serum levels, 537*t*
 - sex, 894, **894**, 896
 - in ovarian cycle, 867*f*, 867-870
 - synthesis, 898, 900*f*
 - steroid. *See* Steroid hormones
- Hormone response elements, **910**, 911*t*
- Hormone-receptor complex, 871
- Hormone-receptor interactions, 859-860, 861*f*, 871-874
- multiple hormone subunits in, 872-873
- Hormone-sensitive lipase, 545
- activity, in obesity, **1094**
- Hormone-sensitive triacylglycerol lipase, in triacylglycerol hydrolysis, 380-381, 381*t*
- Hot spots, for recombination, **666**
- HPETEs. *See* 5-Hydroperoxyeicosatetraenoic acids
- HPFH. *See* Hereditary persistence of fetal hemoglobin
- HPLC. *See* High-performance liquid chromatography
- HREs. *See* Hormone response elements
- HU protein, **609**, **650**
- Human genome. *See* Genome(s), human
- Human growth hormone, synthesis in recombinant bacteria, 834*f*, 834-835
- Human growth hormone gene family, 829*f*, **829-830**
- Human growth hormone-like proteins, genes, 829-830
- Human immunodeficiency virus. *See* HIV
- Human serum albumin, titration curve, 35*f*
- Hunter disease, 352cc

Huntington's disease, 823cc

Hurler-Scheie disease, 352cc

Hyaluronate, **353**, 353*f*, 353-354

Hydration, **381**

Hydrochloric acid secretion, 1056, **1069**, 1069*f*, 1070*f*

Hydrogen bond(s), **4-5**, 5*f*, **66**, 66*f*, 576-577, **1139**

- bond strength, 65*t*
- of water molecules, 4*f*, 4-5

Hydrogen ions

- in 6-phosphofructo-1-kinase regulation, 290-291
- buffering, **1043**, 1044*f*
- excreted, fates of, 1043-1045
- transport, in mammalian cells, 211*t*

Hydrogen peroxide, **19**

Hydrolase(s), **132**

Hydrolysis, 222-224, 223*r*, 224*f*, 376-377, **1138**

5-Hydroperoxyeicosatetraenoic acids, 437*f*, 437-439, 438*f*

Hydrophobic bond, bond strength, 65*t*

Hydrophobic interaction(s), **64**, 65*f*, 569, 575-584, **1139**

Hydrophobic molecules, **362**

Hydrophobicity, **38**, 38*f*

Hydrops fetalis, **828**

α -Hydroxy fatty acids, **373**

Hydroxy methylglutaryl (HMG) CoA, 388, **411**, 411*f*, **478-479**

Hydroxy methylglutaryl (HMG) CoA reductase, 411*f*, 415*f*

Hydroxy methylglutaryl (HMG) CoA synthase, **389**, 411*f*

25-Hydroxy vitamin D, (25-hydroxycholecalciferol), 907, **907**, **1112**

1,25-Hydroxy vitamin D, synthesis, hormonal regulation, 903*r*

3-L-Hydroxyacyl CoA, **383**

β -Hydroxybutyrate, **227**, 379, 379*f*, 388-389, 1044-1045

β -Hydroxybutyrate dehydrogenase, 191, 250

5-Hydroxycytosine, **565**

- glycosylated, **565**

Hydroxyeicosatetraenoic acid(s), 437*f*, 437-440

Hydroxyindole-*O*-methyltransferase, **866**

Hydroxylalysine, 748

Hydroxylase(s), in steroid synthesis, **898**

α -Hydroxylating enzyme, genetic deficiency, 387cc

Hydroxylation, **984**

5-Hydroxylsine, **350**, 351*f*

p-Hydroxyphenylpyruvate oxidase, **465**

Hydroxyproline, **458**, 458*f*

- synthesis, in scurvy, 749cc

11 β -Hydroxysteroid dehydrogenase, **911**

5-Hydroxytryptamine, **1061**.

- See also* Serotonin
- neurotransmitter function, 930-931
- structure, 1062*f*
- synthesis, 930

Hydroxyurea, **520**, 520*f*

Hyperammonemia, 456cc

Hyperbilirubinemia, **1019**

- hereditary, 346cc
- neonatal, 1020cc

Hypercholesterolemia, 362, **1131**

- familial (genetic), **416**
- treatment, 416cc

Hyperchylomicronemia, **549**

Hyperglycemia, nonketotic, 461cc

Hyperglycemic hyperosmolar coma, 537cc

Hyperhomocystinemia, 471cc, **1122**, **1124**

Hyperkalemic periodic paralysis, 956cc-957cc

Hyperleucine-isoleucinemia, 479cc

Hyperlipidemias, 56cc, 380cc

Hyperlysinemia, 481cc

Hyperphagia, 378cc

Hyperpolarization, **924**

- of rod cell membrane, **941**

Hyperproinsulinemia, familial, 743cc

Hyperthermia, malignant, 291cc

Hypertriglyceridemia, **286**, 549, 549cc, **550**

Hyperuricemia, 499cc

Hypervalemia, 479cc

Hypervariable regions, **90**

Hypoglycemia, 300cc, 385cc

- and alcohol intoxication, 312cc

Hypokalemia, and metabolic alkalosis, 1051-1052

Hypopituitarism, 846cc

Hypotension, 398

Hypothalamic gastrin-releasing peptide, 844*t*

Hypothalamic-pituitary axis, 842, 843*f*, 849-851, 851*f*

Hypothalamus

- and appetite regulation, 526cc, 528
- hormonal systems and, 842, 843*f*
- hormones, 847*t*
- in ovarian cycle, 867*f*, 867-870
- releasing hormones, 842, 844*t*, 845*f*, 857, 857*t*
- tumors, 378cc

Hypothyroidism, 378cc

- and obesity, 526cc

Hypoxanthine, 492

Hypoxanthine-guanine phosphoribosyltransferase deficiency, 499cc, 770cc

Hypoxic injury, 261cc

Hypusine, **473**, 473*f*

I

I band, **948**

IBW. *See* Ideal body weight

I-cell disease, 740, 740cc

IDDM. *See* Diabetes mellitus, insulin-dependent

Ideal body weight, 378cc

Idiopathic hemochromatosis, **1008**

IDL. *See* Intermediate-density lipoprotein(s)

Iduronate sulfatase deficiency, 352cc

L-Iduronic acid, 354

α -L-Iduronidase deficiency, 352cc

I-FABP. *See* Intestinal fatty acid-binding protein

Illness, nutritional considerations in, 1133

Immune system, and protein-energy malnutrition, 1093-1094

Immunization, 92cc

Immunoassays, enzyme-linked, 170-171

Immunocompetence, decreased, in iron deficiency, 1130

Immunoglobulin(s), **88**, 88-97, 89*f*, 90*f*

- A, 90*t*, 92cc
- abzymes, 164-165
- amino acid sequences, 92
- artificially synthesized, 164-165
- classes, 90*t*
- D, 90*t*
- deficiency, 92cc
- DNA recombination and, 663cc
- E, 90*t*, 92cc
- fold, 93, 93*f*, 97
- G, 89*f*, 90*f*, 90*t*, 92*f*, 92cc
- heavy chain, 96*f*
- hydrolysis, 95*f*
- isotopes, **96**
- structure, 93*f*, 94*f*
- genetics, 96-97
- hypervariable loops in, 95*f*
- M, 90*t*, 92*f*, 92cc
- molecular mass, 90*t*
- in mucosal secretions, 92cc
- in plasma, 92cc
- structure, 89-92, 95*f*, 97, 97*f*

Immunological domains, of receptors, **875**, 875*f*

IMP. *See* Inosine 5'-monophosphate

IMP dehydrogenase, **497**

Indicators, in immunoassays, enzymes used as, 170-171

Indirect bilirubin, **1019**

Induced fit model, 156, 156*f*

Inducers, **802**

- gratuitous, 804

Induction, **801**

Infantile bilateral striatal necrosis, 831

Infection(s)

- diagnosis, 583
- iron overload and, 1003cc
- metabolic effects, 553

Inflammation, 435, 440

Inflammatory mediators, 436

Inhibin, 847*t*, **906**

Inhibitor 1, **325**

Inhibitory neurotransmitters, **923**, 924

Inhibitory site, 152

Initial velocity (v_0), of enzyme-catalyzed reaction, **137**, 137*f*

Initiation, **689**, **695**, 725-727, 726*f*

Initiation codon, 685

Initiation complex, 727

Initiation factors, **725**

Initiation sequence, 685

Initiation sites, **63**

Initiator tRNA, **725**

Injury, metabolic effects, 553

Inner mitochondrial membrane, **983**

Inorganic ion transport, in mammalian cells, 211*t*

Inorganic pyrophosphate (PP_i), 404

Inosine 5'-monophosphate, 493, 494-497

Inosinic acid, 719

Inositides, role in signal transduction, 399-401

Inositol, **182**, 400

Inositol triphosphate, **328**, 328*f*, **400**, **1060**

- generation, 400*f*
- intracellular, removal, 401*f*
- as second messenger, 862-865
- in steroid hormone synthesis, **896**

Insertion sequences (IS), **669-670**

Insertional inactivation, of recombinant plasmids, 770, 771*f*

Insulin, **39**, 40*f*, **230**, **270**, **286**

actions, 295-296, 297*f*, 311, 323, 325-326, 329-330, 330*f*, 848*r*

signal transduction in, 879-880, 880*f*, 881*f*

activation of pyruvate dehydrogenase, in adipose tissue, 230-231

effects on protein phosphorylation, 879-880, 880*f*

human, synthesis in recombinant bacteria, 832-833, 833*f*

primary structure, 41cc

source, 848*r*

structure, species differences, 41*r*, 41cc

synthesis, 743, 800

Insulin receptor(s), **879**, 879-880

in obesity, **1094**

Insulin resistance, 547-548

Insulin-like growth factor(s)

actions, 847*r*

IGF-I, **554**

source, 847*r*

Insulin-response element, **312**

Integrase (Int), **668-669**

Integration host factor (IHF), **668**

Intercalation, **631**

Intercellular glutamine cycle, **451**, 451*f*

Interleukin(s), 553, **553**

Intermediate-density lipoprotein(s), **58**

Internal promoter, **690**

International Union of Biochemistry and Molecular Biology (IUBMB), 129

Interstitial fluid, 1036-1038, 1037*f*

Intervening sequences, **613**, **703**.

See also Introns

Intestinal fatty acid-binding protein, **1082**

Intestinal mucosa, triacylglycerol synthesis, 376

Intestine(s)

diseases, 463cc

function, 457, 529

Intracellular digestion, **17**, 17-19, 18*f*, **1059**

Intracellular messengers, calcium ions as, **208**

Intraluminal digestion, **1059**

Intrinsic factor, 963, **1125**

Introns, **613**, 613*f*, **703**

in eukaryotic genes, 820-822

group I, 686

group II, 686

removal, 700, 702*f*

self-splicing, 686

Iodide, in thyroid hormone synthesis, 854-856

Iodine, dietary, **1130**

Iodoacetate, **282**

Ion channels

isolation, 923

subunits, transmembrane organization, 956cc-957cc

voltage-gated, **921**, **922**, 923

disorders, 956cc-957cc

Ion exchange chromatography, 70, 70*f*

Ion product of water, **6**

Ionic bond, bond strength, 65*r*

Ionic forces, in DNA stabilization, **577**

Ionic interactions, **1139**

Ionic linkages. *See* Electrostatic interactions

Ionophores, **211**, 211-213, 212*r*

IP₃. *See* Inositol trisphosphate

IPTG. *See* Isopropylthiogalactoside

IREs. *See* Iron-responsive elements

Iron

absorption, 1005cc, **1005-1006**, 1006*f*, **1127**

duodenal, 1005cc

intestinal, **1005-1006**, 1006*f*

binding

to milk, 1003-1004

to transferrin, 1003

biochemistry, 1002

deficiency, **1005**, 1009cc, 1130

distribution, 1007-1008, 1008*r*

excretion, 1005

ferric ions, **1002**

ferrous ions, **1002**

metabolism, 1002, 1007-1008, **1130**, 1130*f*

overload (excess), **1005**, **1130**

and infection, 1003cc

oxidation states, **1002**

physiological roles of, 1130

recommended dietary allowances, 1130

requirements, in newborn, 1117cc

scavenging, with intravascular hemolysis, 1020-1021

storage, 1004

transfer, 1002

transport, in serum, 1003

utilization, molecular regulation of, 1006-1007

Iron regulatory proteins, **1006**

IRP-1, 1006, 1006*f*

IRP-2, **1007**

Iron-binding proteins, 1002

Iron-containing proteins, 1003-1005

Iron-deficiency anemia, 1009cc, **1130**

Iron-responsive elements, 750, 1006*f*, **1007**

mutant, 1007cc

Iron-sulfur center, 233, 252*f*

Iron-sulfur protein(s), 146-147, **237**, **987**

IRPs. *See* Iron regulatory proteins

Irreversible inhibition, 149, 150

IS. *See* Insertion sequences

Isoacceptors, **682**

Isoalloxazine ring, 987, 988*f*

Isobutyrate, **559**

Isocitrate dehydrogenase, **233**, 233-234

Isodesmosine, **55**

Isoelectric focusing, **70**, 70*f*

Isoelectric pH, **33**

Isoelectric point, 1146

Isoenzymes. *See* Isozyme(s)

Isohydic carriage, of carbon dioxide, **1034**, 1034*f*, 1034-1035

Isoleucine, 26*f*, 453, 476-477, 478*f*.

See also Branched-chain amino acids

Isomaltase, 1076*r*

Isomaltose, 1142

^{4,5}-Isomerase, **896**

Isomerase(s), **133**

cis-trans-prolyl, **63**

protein disulfide, **63**

Isomerism, *cis-trans*, **1139**

Isomerization

aldose-ketose, **341-342**

in carbohydrate interconversion, 341-342

of ribulose 5-phosphate, **338**

Isomers, 1140-1141

resonance, **28**

stereoisomers, **1139**

Isoniazid, 450, 1133*r*

Isoprene, **1145**

Isopropylthiogalactoside, 803-804, 833

Isovaleric acid, structure, 364*f*

Isozyme(s), **129**, 172, **172**, 450-451

IUBMB. *See* International Union of Biochemistry and Molecular Biology

J

Jaundice

neonatal, 1020cc

nonhemolytic, 346cc

physiological, 346cc

Junk DNA, 613

K

K class enzymes, **152**

*k*₁ (rate constant), 134, **134**

Kallikrein, 963

Kasugamycin, effects on protein synthesis, 734

Katal, **136**

Kennedy syndrome, 602cc

Keratan sulfate, 353*f*, 355, **355**

Keratin, 55, 55*f*, **1111**

Kernicterus, **1018**

β -Keto acid, formation, 381

Ketoacidosis, 362, 480cc

β -Ketoacyl-ACP synthase, **368**

3-Ketodihydrospingosine, 420*f*, 421*f*

Ketogenic amino acids, 304-305, 306*r*, 447

α -Ketoglutarate, **233**, 233-234

α -Ketoglutarate dehydrogenase, 234-235, 1119

Ketone bodies, **227**, **380**, 532

in diabetic ketoacidosis, 390

as energy source for brain, **920**

formation, 387-390

and lipid, carbohydrate and amino acid metabolism in liver, 389*f*

as lipid-base energy source, 379-380

structure, 379*f*

in triacylglycerol transport, 379

utilization by nonhepatic tissue, 389

Ketones, **1137**

Ketopentose, 1139

Ketosis, 380, 389-390

β -Ketothiolase, 388

Kidney(s)

in acid-base balance, 1043

function, 556-557

medulla, carbohydrate metabolism in, 270

in metabolic alkalosis, 1045-1046

in nitrogen metabolism, 453, 457

Kidney disease

chronic, zinc deficiency in, 1131

low-protein diets and, 1092cc

nitrogen metabolism abnormalities and, 555

Kilocalories, **1088**

Kilojoule, 1088

Kinase(s), **131**, 131*f*, 146*f*, 511

Kinesin, **20**

Kinetics, 133-142

Klenow fragment, **624**, 625*f*, **762**

*K*_m (Michaelis constant), 137-139, 152

abnormal, 169cc

changes in, physiological effects, 139cc

determination, using Lineweaver-Burk plot, 137-138

graphic estimation, 137-138, 138*f*

significance, 138

Krabbe's disease, 425, 429*t*

Krebs cycle. *See* Tricarboxylic acid cycle

Kringle domains, 975

Kwashiorkor, 527cc, **1093**

Kynuramine, **476**

Kynureninase, 475*f*, **476**

Kynurenine formamidase, 475*f*

Kynurenine hydroxylase, 475*f*, **476**

L

lac repressor, 803-805

LACI. *See* Lipoprotein-associated coagulation inhibitor

β -Lactam antibiotics, absorption, 1073

Lactase, 1059*t*, **1075**, 1076*t*

insufficiency (deficiency), 1075cc, **1095**

Lactate, 10*f*, 290, 290*f*

gluconeogenesis from, 301, 302*f*

metabolism, free-energy changes associated with, 222*t*

transport, in mammalian cells, 211*t*

Lactate dehydrogenase

in gluconeogenesis, 301

reaction catalyzed by, 273*f*, 278

retinal, 935-936

subunit composition, 172

type B, 934*t*

types, 172

Lactation, **552**, 552-553

folic acid requirements in, 1125

Lactic acidosis, **290**, 291cc

Lactoferrin, **1003**, 1003-1004

Lactone(s), **1138**, **1141**

Lactose, **307**, **552**, **1057**

intolerance, 1075cc, 1095

sources, 1074*t*

structure, 1074*t*, 1142

synthesis, 552-553

Lactose operon, 802*f*, 802-807

control elements, 805*f*, 805-806

control of, 803-805, 804*f*

operator sequence, 805-806

promoter sequence, 805*f*, 806-807

repressor, 803-805

Lactosylceramide, structure, 425*f*

Lagging strand, **647**, 652*f*

phage. *See* Bacteriophage

Lambert-Eaton myasthenic syndrome, 927cc

Lampbrush chromosomes, **607**

Lanosterol, 413*f*, 414*f*

Large intestine, functions, 1057, 1058*f*

Lariat RNA, 706, 707*f*

LCAH. *See* Lipoid congenital adrenal hyperplasia

LDL. *See* Low-density lipoprotein(s)

Lead poisoning, 1012*t*, **1013**

Leader sequence(s), **810**, 810*f*, 811, 813, 813*f*

Leading strand, **647**, 652*f*

Leber's hereditary optic neuropathy, 617cc, 831, 831cc

Lecithin(s), 1144.

See also Phosphatidylcholine

Lecithin-cholesterol acyltransferase, **417**, 417*f*

Lens, crystalline, 932, **933**

age-related changes in, 934, 934*f*, 935*t*

carbohydrate metabolism in, 270

composition of, 933-935

metabolic interrelationships in, 935, 935*f*

Leptin

gene, **528**

in obesity, 378cc

Lesch-Nyhan syndrome, 169cc, **499**, 499cc, 770cc

Leucine, **25**, 26*f*.

See also Branched-chain amino acids

and gluconeogenesis, 304-305

ionic form, 32*f*

metabolism, 453, 476, 478*f*, 478-479

titration curve, 33*f*

Leucine aminopeptidase, 1059*t*

Leucine zipper motif, **110**, 110*f*, 111*f*

Leucovorin, **519**

Leukemia treatment, 174, 517, **517**

Leukocyte(s), carbohydrate metabolism in, 270

Leukotriene(s), 437-439, 1143, **1144**

derived from 5-HPETE, 438

LTA₄, **438**

LTB₄, 992

LTC₄, conversion to LTD and LTE, 439*f*

physiological effects, 439-440

structure, 1144

Levulose, for ammonia buildup, 456

Lewis acid, 144-146

LexA, **642**

LH. *See* Luteinizing hormone

LHON. *See* Leber's hereditary optic neuropathy

Licorice, 911cc

Liebermann-Burchard reaction, 409

Ligand, **151**.

See also Hormone-receptor interactions

Ligand gated receptors, 954

Ligand gated sodium channels, 942

Ligand-binding domains, of receptors, **875**, 875*f*

Ligandin, **1018**

Ligase(s), **133**, 135.

See also DNA ligase

Light meromyosin, **950**

Lignin, **1097**, 1098*t*

Limit dextrins, **317**, **1075**

Lineweaver-Burk plot, **138-139**

Linoleic acid, 366, 366*f*, 433, 1143

Linolenic acid, 366, 366*f*, 1143

Linoleoyl CoA, oxidation, 386*f*

Lipase(s)

acid-stable, **1078**

in adipose tissue, 377

hydrolysis of blood triacylglycerols, 380-381

in lipid digestion, 1078

mechanism of action, 1078, 1078*f*

pancreatic, **1078**, 1078*f*

deficiency, 1112cc

Lipid(s), **362**, **396**, **1143**

absorption, 1077*f*, 1077-1083

amphipathic, 1143

asymmetric distribution, **192**

biological function, 365

complex, in brain, **921**

digestion, 1077*f*, 1077-1083

functions, 362-363

hydrophobicity, 365

membrane, 180, 180*f*, 181-184, 186, 186*f*

asymmetric distribution, **192**

diffusion, 193-196

mobility, 188, 188*f*

transverse movement, 193

metabolism, 361-393, 389*f*, 395-443

nonpolar, **396**

nonsaponifiable, 1143

oxidation states, comparison with carbohydrates, 222, 222*f*

polar, **396**, 396*f*, 396-443

saponifiable, 1143

solubilization during digestion, 1077, 1078-1082

vesicular structures, 187-188.

See also Micelles

Lipid bilayer

fluidity, 188-189, 193-194, 194*f*

integral membrane proteins in, 190-191, 191*f*

phase transition temperature, 194, 194*f*

stability, 188-189

structure, 188, 188*f*

Lipid esterase, specific, **1078**

Lipid storage disorders, 427, **429**, 429*t*

Lipid-energy transport, genetic abnormalities, 380cc

Lipid-hydrolyzing enzymes, 17*t*

Lipid-linked oligosaccharide, **350**, 351*f*

Lipofuscin, **19**

Lipogenesis, 528*f*, **529**

Lipoic acid, 228*t*, **234**

Lipoid congenital adrenal hyperplasia, 896

Lipolysis, **532**

Lipophilin, 187

Lipoprotein lipase, 166, 380cc, 380-381, 381*t*, **529**

Lipoprotein-associated coagulation inhibitor, **975**

Lipoproteins, **56**, 56-60, **187**

blood, 375

chemical composition, 59*t*

density, 57*f*

high-density (HDLs), **57**, **379**

hydrated density classes, and electrophoretic mobility, 57*t*

in hyperlipidemias, 56cc

in hypolipoproteinemias, 59cc

intermediate-density (IDLs), **58**

low-density (LDLs), **57-58B**, **379**

plasma, and triacylglycerol transport, 379

structure, 58*f*

very low density (VLDLs), **58**, **379**, 529

in obesity, **1095**

Liposomes, **188**

for drug delivery, 189cc

preparation, 189

structure, 188*f*, 188-189

β -Lipotropin, 842, 846, 849, 850*t*

γ -Lipotropin, 849, 850*t*

Lipoxygenase, 436-440, 437*f*

Lipoxygenase pathways, **431**

Lithium

and phosphatidylinositol cycle, 863, 865*f*, 893cc

therapy, for manic-depressive illness, 863, 893cc

Lithocholate, **1083**

Lithocholic acid, **1084**

- Liver
- acetyl CoA in, excess, 231
 - in amino acid metabolism, 453, 454
 - bilirubin conjugation in, 1018-1019
 - cirrhosis, **554**
 - Cori cycle in, 552
 - damage, amino acid metabolism and, 448
 - and dietary glucose, 528
 - disease, metabolic derangements caused by, 554
 - energy reserves in, 537*t*
 - enzyme induction in, 546*f*, 547*f*
 - ethanol oxidation in, 555-556
 - glucogenic phosphorylation of enzymes in, 543*f*
 - gluconeogenesis in, 300*f*
 - glycogen granules in, **314**, 315*f*
 - glycogen in, 313, 313*f*
 - glycogenolysis in, 327*f*, 327-328
 - glycolysis in, 293, 293*f*, 295, 296*f*, 297*f*
 - glycolytic enzymes, 284*t*
 - in insulin-dependent diabetes mellitus, 550
 - intercellular glutamine cycle, 558
 - lipogenic phosphorylation of enzymes in, 543*f*
 - metabolism, switching between well-fed and starved state, 539-547
 - phospholipid metabolism in, 409
 - phosphorylase *a* in, 326-327
 - in regulation of blood pH, 558
- Lock-and-key model, 156, 156*f*
- London dispersion forces, **66-67**, 67*f*, 576*f*
- Long-chain fatty acids. *See* Fatty acids, long-chain
- Loop-sheet-helix motif, **112**, 113*f*
- Lovastatin, 416cc
- Low-density lipoprotein(s), **57-58**, **379**.
- See also* Lipoprotein(s)
 - oxidation, **1116**
- Low-density lipoprotein receptor(s), **416**, 973
- downregulation, **416**
- LTA, synthase, **438**
- Luteinizing hormone, 846, 903*t*, 906
- actions, 847*t*, **868**, 868-870, 883*t*
 - hormone-receptor interactions, 872-873, 874*f*
 - secretion, regulation, 883-885, 884*f*
 - source, 847*t*
- Luteinizing hormone-releasing hormone, 932*t*
- Luteolysis, 916cc
- Lyase(s), **132**
- Lymphocytes, **531**
- Lysine, **27**, 55*f*, **479**, 479-481
- and gluconeogenesis, 304-305
 - metabolism
 - disorders, 481cc
 - minor product, 481*f*
- Lysine amino oxidase, **55**
- Lysinuric protein intolerance, familial, 481cc
- Lyso-compounds, 1144
- Lysolecithin exchange, in phosphatidylcholine synthesis, 407*f*
- Lysolecithin-lecithin acyltransferase (LLAT), **407**, 407*f*
- Lysophosphatidylcholine, in phosphatidylcholine synthesis, 407*f*
- Lysosomal acid lipase
- in cholesterol ester-storage disease, 19cc
 - deficiency, 19cc
 - in Wolman's disease, 19cc
- Lysosomal enzymes, 17*f*
- in gout, 18cc
 - sphingolipid catabolism by, 428
- Lysosomal storage diseases, 427-431
- Lysosomes, **17**, 17-19, **857**
- active site, hexasaccharide binding, 158
 - in lipase deficiency, 19cc
 - protein digestion in, 750-751
 - proteins targeted to, 739-742, 741*f*
- Lysozyme, 156-158, 158*f*, 160*f*, 161*f*
- Lysyl hydroxylase deficiency, 749cc
- Lysyl oxidase, 748, 1131
- M**
- Macrominerals, 1128-1129
- Macromolecular binding specificity, **108**
- Macromolecular structures, 1139
- Macronutrients, 1087-1106.
- See also* Carbohydrate(s); Carbohydrate metabolism; Energy; Fiber; Protein; dietary
- Macula degeneration, 936cc
- Magnesium, **1129**
- in active site of kinases, 146*f*
- Malabsorption, 1133
- due to loss of membrane transport systems, 212cc
 - fat, **1114**
 - and vitamin K deficiency, **1117**
 - fructose, 212cc
 - glucose, 212cc
 - niacin deficiency in, **1121**
- Malaise, in vitamin deficiency, **1118**
- Malaria, 828
- Malate, **237**
- Malate dehydrogenase, **237**, **280**, **371**
- Malate-aspartate shuttle, **243**, **279**, 279*f*, **312**
- Malignant hyperthermia, 291cc
- Malnutrition, **1108**.
- See also* Nutrition
 - assessment of, 1108
 - biochemical assays for, **1108**
 - clinical symptoms in, **1108**
 - dietary intake studies, **1108**
 - protein-energy, **1093**, 1093-1094
- Malonate, **237**
- Malonyl CoA, formation, 366-368
- Maltase, 1059*t*, 1076*t*
- Maltose, **1075**, 1142
- Maltotriose, **1075**
- Mammalian fatty acid synthase, 369, 370*f*
- Mammalian synthase, **369**
- Mammary gland, **374**
- Manganese, **1132**
- Manic-depressive illness, lithium therapy for, 863, 893cc
- Mannose, 307, 1140
- Mannose 6-phosphate, 341-342, 740
- Mannosidosis, 349cc
- Marasmus, 527cc, **1093**
- Maroteaux-Lamy disease, 352cc
- Mass-action ratio(s), **284**, 284*t*
- Matrix, **13**
- Maxam-Gilbert procedure, for DNA sequencing, 762-763, 763*f*
- Maximum velocity (V_{max}), **136**
- McArdle's disease, 317cc
- Mechanism-based inhibitors, **986**
- Mechanochemical proteins, **20**
- Mediated transport system, **198**
- Megaloblastic anemia, 463cc
- Melanin, 468*f*, 468-469, **469**
- Melanocyte-stimulating hormone, 846
- actions, 847*t*
 - source, 847*t*
 - synthesis, 849, 850*t*
- Melatonin, **476**
- secretion, 866
 - structure, 476*f*
 - synthesis, 866, 866*f*
- Membrane(s), **12**, 12-13
- asymmetry, 191
 - carbohydrates, 187, 187*f*
 - cellular, 180, 186, 186*f*
 - channels, **197**, 197*t*, 197-198, 201-204
 - functions, 201, 201*f*
 - regulation, 201-203, 202cc
 - structure, 201, 201*f*
 - chemical composition, 180-187
 - cholesterol in, 186
 - depolarization, 328-329
 - diffusion of molecules, 189, 196-197, 197*f*.
 - See also* Membrane transport
 - diffusion of proteins and lipids in, 193-196
 - electron microscopy, 180, 180*f*
 - eukaryotic, 180
 - fluidity, **193**, 194-195
 - abnormalities, 195cc
 - factors affecting, 195cc, 195-196
 - functional role, 15-20
 - hyperpolarization, **941**
 - integral (intrinsic) proteins, **187**
 - domains, 191
 - in lipid bilayer, 190-191, 191*f*
 - transmembrane segment, 190, 191*f*
 - intracellular, 180
 - lipids, 180, 180*f*; 181-184, 186, 186*f*
 - asymmetric distribution, **192**
 - diffusion, 193-196
 - mobility, 188, 188*f*
 - transverse movement, 193
 - molecular movement through, 196-201.
 - See also* Membrane transport
 - facilitated, 197-198
 - movement, 180
 - peripheral (extrinsic) proteins, **186**, **191**, 191-192
 - phase transition temperature, **194**, 194*f*
 - plasma. *See* Plasma membrane(s)
 - pores, **197**, 197*t*, 197-198, 201-204
 - prokaryotic, 180
 - proteins, 180*f*, 189
 - classification, 186-187
 - diffusion, 193-196
 - distribution, 192
 - functions, 187
 - mobility, 196, 196*f*
 - removal, 186-187
 - sphingolipids, 184-185
 - structure, 189-196
 - erythrocyte as model, 192, 193*f*
 - fluid mosaic model, **189**, 190*f*, 196*f*
 - trilaminar appearance, 180, 180*f*
- Membrane potential, 200, **201**
- in neurons, 921-923

Membrane transport, 180, 196-201

- active, 198, **200**
 - mediated, 199*t*, 206-210
 - primary, of calcium ions, 208-209
 - secondary, 209*f*, 209-210
- of amino acids, **209**
- by diffusion, **196**, 196-197, 197*f*
- electrogenic mechanism, 200, 212*r*
- electroneutral (electrically silent)
 - mechanism, 200, 212*r*
- energetics of, 200-201
- free energy change in, **200**
- of glucose, **209**, 209*f*, 209-210
- by group translocation, **198**
- in mammalian cells, 210, 211*r*
- mediated, 199*f*, 199-200
- passive, 198, **200**
- passive mediated, 199*t*, **204**
- rate of diffusion in, **196**, 196-197, 197*f*
- saturation kinetics, 197*f*, **199**
- steps of, 199-200
 - recognition, **199**
 - recovery, **200**
 - release, **200**
 - translocation, **199**, 199*f*
- systems, **197**, 197*t*
 - characteristics, 198-199, 199*r*
 - loss of, diseases caused by, 212cc
 - saturation kinetics, 197*f*, **199**
 - specificity, 199
- transporters for, **198**.
 - See also* Cotransporter(s); Membrane transport, systems; Transporter(s)

Menkes' syndrome, 750cc, **1132**

Menstrual cycle, mood variations during, 467

Menstruation, 868

Mental retardation, 456cc, 461cc

β -Mercaptoethylamine, 226

6-Mercaptopurine, **151**, 151*f*, 517, **517**, 517*f*

MERRF. *See* Myoclonic epilepsy and ragged-red-fiber disease

Messenger RNA, 25*f*/679

- blocking of 5' terminus, 704, 704*f*
- cap structure, 684*f*, 685, 685*f*, 704, 704*f*
- in cDNA library construction, 777
- codons in, 718*r*, 718-719
- cytoplasmic, 678*r*
- enrichment, 777
- eukaryotic, 684, 684*f*, 714
- functions, 678*r*, 684-685, 714-715
- histone, 685
- leader sequence, 685
- mitochondrial, 678*r*, 685-686
- monocistronic, 684, 714
- polycistronic, 684, 714, 800
- poly(A) synthesis, 704, 705*f*
- poly(A) tail, 685
- precursors, intron removal from, 705-706, 706*f*
- processing, 703-708, 704*f*
- prokaryotic, 714
- properties, 678*r*
- synthesis
 - defects in, 705cc
 - promoters for, 699
- synthetic, polypeptide products, 720, 720*r*
- trailer sequence, 685
- turnover, 709

Metabolic disorders

- of branched-chain amino acids, 479cc
- of tyrosine synthesis, 467cc
- of urea synthesis, 455-456

Metabolic stress, nutritional considerations in, 1133

Metabolism

- in acidosis, 557*f*
- bile acid, 1083*f*, 1083-1084
- in ethanol ingestion, 557*f*
- in exercise, 551*f*
- in illness and recovery, 1092, 1093cc, 1094
- in insulin-dependent diabetes mellitus (IDDM), 548*f*
- interorgan interactions in, 534-536
- interrelationship of tissues, 525-562
- of iron, 1002, **1130**, 1130*f*
- in kidney failure, 556*f*
- in lactation, 553*f*
- in liver disease, 555*f*
- in noninsulin-dependent diabetes, 548*f*
- and obesity, 548*f*, 1094-1095
- oxidative. *See* Oxidative metabolism
- pathways, regulation, 540
- in pregnancy, 552*f*
- in stress, 553, 554*f*
- substrate availability and, 540

Metachromatic leukodystrophy, 425, 429*r*

Metal(s)

- in activation of molecular oxygen, 147
- in oxidation and reduction, 146-147
- structural functions, 145-146

Metal cofactors, in enzymes, 144-147

Metal-bridged complexes, 146

Metalloenzymes, **146**

- copper, 1131
- zinc, 1131

Metalloproteases, **98**

Metallothionein, **1131**

Metarhodopsin, **941**

Methemoglobin, 1030cc

Methionine, **27**, 469*f*, 469-472, 472*f*, 1124, 1125

Methionine adenosyltransferase, **469**

Methotrexate, 150, **518**

- inhibition, 519*f*
- mechanism of action, 150
- structure, and folic acid structure, comparison, 518*f*

Methylase(s), **611**

Methylation, **651**, 745

Methylene groups, **363**

N^5,N^{10} -Methylenetetrahydrofolate

- in deoxythymidylate synthesis, 508-509
- production, **460**, 461*f*
- structure, 508*f*

β -Methylglutaryl coenzyme A. *See* HMG CoA

7-Methylguanosine, **714**

Methylmalonate metabolism, diseases, 480cc

Methylmalonyl CoA, **236**, 374, 479*f*, 1125-1126

Methylmalonyl mutase, **479**

N^5 -Methyltetrahydrofolate, **472**, 1123, 1123*f*, 1126

5-Methylthioadenosine, **499**

5-Methylthioadenosine phosphorylase, **499**

5-Methylthioribose-1-phosphate, **499**

O-Methyltransferase, **468**

Mevalonic acid, 411-412, 412*f*

Micelles, **187**

- bile acid, 1078-1082, **1079**
- in cholesterol transport, 1078, 1081cc, 1082
- formation, 187-188, 1143
- mixed, **1079**, 1080*f*
- structure, 187-188, 188*f*
- in vitamin transport, 1082

Michaelis constant. *See* K_m

Michaelis-Menten equation

- derivation, 139-140
- formulation, **137**, 137-138
- linear form, 138-139

Microbodies, **19**

Microcytic hypochromic anemia, **1130**

Microenvironments, **4**

Microheterogeneity, of glycoproteins, **349**

Micronutrients, 1107-1136.

See also Minerals; Vitamin(s)

Microsomes, **16**, 717, **982**

Microtubules, **20**

Microvilli, 1059

Milk, iron binding to, 1003-1004

Milk intolerance, 1075cc

Mineralocorticoid receptor(s), 911

Mineralocorticoids, 1145

Minerals

- macrominerals, 1128-1129
- trace, 1130-1132

Mismatch repair, **627**, 630, **638**, 638-640, 640*f*

- and cancer, 641cc

Mispairing, in DNA synthesis, **624**, 624*f*

Missense mutations, **721**, 721cc

Mitochondria, **17**

- anion transport systems, 205, 205*f*
- ATP synthesis in, 231, 231*f*
- ATP-ADP translocase, **205**, 205*f*, 205-206
- biosynthesis in, 369-371
- in cardiac cells, 239*f*, 241
- electron transport in, 241, 246-249
 - Complex I of, **256**
 - Complex II of, **258**
 - Complex III of, **258**
 - Complex IV of, **258**
 - flavin-linked dehydrogenases and, 251, 251*f*, 251*r*
 - free-energy changes and, 248-249
 - inhibition, 259, 259*f*
 - as multicomponent system, 249-255
- location in inner membrane, 255-258, 256*f*, 258*f*
 - NAD-linked dehydrogenases and, 249*f*, 249-250, 250*r*
 - oxidation-reduction reactions and, 247-248, 257*f*
 - oxidative phosphorylation and, 260*f*, 260-263
 - reversal, 259, 260*f*
- elongation of fatty acids in, 372*f*
- inner membrane
 - adenine nucleotides in, 245, 245*f*
 - calcium transport across, 246, 246*f*
 - citrate in, 244-245, 245*f*
 - composition, 241
 - phosphate in, 245, 245*f*
 - substrate transportation systems in, 243*f*, 243-244, 244*f*
- in liver cells, 239*f*, 241, 257*f*
- in Luff's disease, 16cc

Mitochondria

(*continued*)

- membrane
 - compartmentation and, 240*f*, 241*t*
 - enzymatic composition, 241*t*
 - separation, 242, 242*f*
 - structure, 238-246
 - transport across, 381-383, 384*cc*
- messenger RNA in, 685-686
- mutation
 - and aging, 617*cc*
 - and degenerative disease, 617*cc*
- protein import to, 742
- protein synthesis in, 733
- transport systems, 205*f*, 205-206

Mitochondrial cytochrome P450, **989**, 989*f*

Mitochondrial DNA, 617, 830-831, 831*f*, 617*cc*

Mitochondrial F₁F₀-ATPase, **262**, 263*f*

Mitochondrial genes, 830-831

Mitochondrial matrix targeting signal, 742

Mitochondrial myopathies, 247*cc*

Mitochondrial receptor, 742

Mitoplast, **242**

Mitosol, **17**

Mixed function oxidases, **372**

Mixed micelles, **1079**, 1080*f*

MLCK. *See* Myosin light chain kinase

Mobile carriers, **212**

Mobilferrin, 1005*cc*

Modifiers, 151

Modulators, 151

Molar absorptivity, **79**

Molar extinction coefficient (ϵ), **79**

Molecular cell biology, 919-979

Molecular dynamics, **68**

Molecular exclusion chromatography, 72, 72*f*

Molecular weight, and Svedberg coefficient, 71*f*

Molten-globular state, **63**

Molybdenum, **1132**

Monensin, 212*t*

Monoacylglycerol hydrolase, in triacylglycerol hydrolysis, 380-381

Monoacylglycerols, **364**, 1078, **1078**, 1081, 1144

Monoamine oxidase, **468**, **930**, 931, 931*f*

Monoamino dicarboxylic acid, titration, 33-34

Monocarboxylic acids, 211*t*, 431-436

Monoenoic acids, formation, 372

Monofluoroacetyl coenzyme A, **233**

Monofluorocitrate, **233**

Monohydroxyeicosatetraenoic acids, 440

Monomeric enzyme, 152, 153*f*

Monomers, **1057**

Monoxygenase(s), 129, 129*f*, 130, 130*f*, **982**

Monoxygenation reaction, **984**

Monophosphate kinase reactions, **220**, 220*f*

Monosaccharide acid, 1141

Monosaccharide alcohol, **1141**

Monosaccharides, **1073**, **1139**

- absorption, 1076
- derivatives, 1141
- esters, 1141-1142
- reactions, 1141-1142
- structure, 1139-1140
- in sugar transformation, 336

Morquio syndrome, 352*cc*

6-MP. *See* 6-Mercaptopurine

M-protein, 948*t*

mRNA. *See* Messenger RNA

MRP (multidrug resistance protein), 521

MSD. *See* Multiple sulfatase deficiency

MSH. *See* Melanocyte-stimulating hormone

mtDNA (mitochondrial DNA). *See* DNA, mitochondrial

Mucilaginous fibers, **1097**, 1098*t*

Mucopolidosis

- type I, 349*cc*
- type VII, 352*cc*

Mucopolysaccharides, 1142.

- See also* Proteoglycan(s)

Mucopolysaccharidoses, 352*cc*, **356**

Mucosal secretions, immunoglobulins in, 92*cc*

Multidrug resistance, 521

- transmissible, 816*cc*

Multilamellar vesicles, 189

Multiple nonsimilar domains, **101**, 102*f*

Multiple sulfatase deficiency, 352*cc*, 746*cc*

Multiplex strategy, for PCR, **769**, 769*f*

Multiprenylmenaquinone. *See* Vitamin(s), K₂

Muscarine, 1061, 1061*f*

Muscle. *See also* Skeletal muscle

- cells, 947, 948*f*
- contraction, 946-959
 - calcium in, 954
 - electrical to chemical to mechanical path for, 946-948
 - energy for, source, 954-957
 - model for, 957-959, 958*f*
 - sliding filament model, **946**
- energy reserves in, 537*t*
- fibers
 - carbohydrate metabolism in, 270
 - red, **313**, 315*f*
 - white, **313**, 315*f*
- glycogen in, 313

Muscular dystrophy, 821, 822*cc*

Mutagenesis

- inverse PCR, **790**, 791*f*
- site-directed. *See* Site-directed mutagenesis

Mutarotation, 1141, 1142

Mutases, **133**

Mutations, **721**

- cis-dominant, 805
- deletion, 786-787, 788*f*
- disease caused by, 142, 705*cc*, 706, 707*f*, 828-829
- frameshift, 721, 723*t*
- insertion, 786-787, 787*f*
- missense, **721**, 721*cc*
- mitochondrial, 617*cc*
- nonsense, 721
- operator-constitutive, 805
- perpetuated by replication, 627*f*
- point, **721**
- read through, 721, 722*t*, 723
- repressor-constitutive, 804
- silent, **721**
- suppressor, **723**
- in thalassemia, 828-829
- trans-dominant, 805

MutH, **639**

MutL, **639**

MutS, **639**

MutU, **639**

Myasthenia gravis, 929*cc*

Myelin, lipoproteins, 187

Myoblast cells, **946**

Myocardial infarction, 98*cc*, 292*cc*

- atherosclerosis and, 417*cc*
- enzymes released after, 167*f*
- LDH isozymes and, 172*f*, 173*f*
- serum CPK and, 172*f*
- treatment, efficacy, 168, 169*cc*
- troponin subunits as markers for, 954*cc*

Myoclonic epilepsy, 831

Myoclonic epilepsy and ragged-red-fiber disease (MERRF), 617*cc*

Myofibrils, 946, 947*f*, 948*f*

Myoglobin

- amino acid sequences, 117*t*
- binding characteristics, 115, 115*f*
- comparison with β chain of HbA¹, 118*f*
- Hill plots for HbA₁, 119*f*
- molecular aspects, 114-124
- oxygen binding, 117-119, 119*f*
- oxygen dissociation curve for, 1029, 1029*f*
- oxygen-binding curve, 119*f*
- structure, 114-124, 115*f*, 115-117, 118*f*

Myokinase. *See* Adenylate kinase

Myopathy, 247*cc*

Myosin, **20**, **948**, 948*t*, 949, 949*f*

- actin binding, 950-951
- active site, 950
- amino acid sequences, 950
- essential light chain, 950-951
- light chains, 948*t*, **949**
 - in smooth muscle contraction, 959, 959*f*
- regulatory light chain, 950-951
- subfragment 1 (S-1), 950, 950*f*
- symmetrical tail-to-tail aggregate, 950
- in thick filaments, 949-951

Myosin light chain kinase, 959, 959*f*

Myosin phosphatase, 959

Myotonic dystrophy, 602*cc*

Myristic acid, 191*f*, **192**

N

Na⁺. *See* Sodium

nAChR. *See* Nicotinic-acetylcholine channel

NAD. *See* Nicotinamide adenine dinucleotide

NADH, **227**, 249-250, 250*f*, 273*f*, 278-279, 476

- reoxidation, 279-280

NADH peroxidase, 130

NADH-cytochrome *b*, reductase, **988**

NAD-linked dehydrogenases, 249*f*, 249-250, 250*t*

NAD⁺/NADH ratio, alteration, 555-556

NADP. *See* Nicotinamide adenine dinucleotide phosphate

NADP-linked malic enzyme, **371**

NADPH

- oxidation, 463
- synthesis, 336-338, 337*f*, 341

NADPH-adrenodoxin reductase, **989**

NADPH-cytochrome *b*, reductase, 372

NADPH-cytochrome P450 reductase, **984**, **988**

NADPH-dependent flavoprotein reductase, 987

NADPH:quinone oxidoreductase, 934*t*

NaHCO₃, intestinal epithelial secretion, 1066, 1067*f*

Na⁺:K⁺ pump, **206**, 206-207, 207*f*, 211*t*

Nalidixic acid, **594**

- NANA. *See N-Acetylneuraminic acid*
- Native conformation, **42**
- NDP-sugar. *See Nucleoside diphosphate sugar*
- Near-equilibrium reaction, **284**
- Negative allosteric effectors, 152
- Negative cooperativity, **872**
- Negative feedback
 - in glycogen synthesis, 326
 - in hormonal cascade, **842**, 843*f*
- Negative superhelical DNA, **587**
- Neomycin, effects on protein synthesis, 734, 734*t*
- Neonatal isoimmune hemolysis, 1020cc
- Neonate(s)
 - cerebral lipid synthesis in, 389
 - nutritional considerations in, 1117cc
 - protein absorption, 1073
- Nephron(s), 1043, 1043*f*
- Nernst equation, **248**
- Nerve deafness, 387cc
- Nerve tissue, hydroxy fatty acid formation in, 373-374
- Nervonic acid, 364, 364*f*
- Nervous tissue, **920-932**
- Nested PCR, 760
- Neural tube defects, **1125**
- Neuraminic acid, **426**
- Neurocan, 356
- Neurological impairment, 237cc
- Neuromuscular junction, **954**, 955*f*
- Neuron-neuron interaction, **923**
- Neurons, 921
 - aminergic, **842**
 - motor, 921*f*
 - presynaptic, 924
 - transmembrane electrical potential in, 921-923
- Neuropeptides, 931-932, 932*t*
- Neurophysin, 842, 849
 - type I, synthesis, 851*f*, 851-852
 - type II, synthesis, 851
- Neurotensin, 848*t*, 932*t*
- Neurotoxins, 203
- Neurotransmitters, **554**, 853, 923, 923*t*
 - actions, 924
 - catecholamine, **929**, 930*f*
 - excitatory, **923**, 924
 - inhibitory, **923**, 924
 - peptide, synthesis, **931**
 - release, 924-927
 - storage, 924-927
 - synthesis, 924-927
 - transport, in mammalian cells, 211*t*
 - tryptophan metabolism and, 476
- Neutral amino aciduria, 1072cc
- Neutron beam radiation, **77**
- Neutrophil(s), function, regulation, 439
- N-glycosidic linkage, **61**, 61*f*, 737
- NHE (Na⁺/H⁺ exchanger). *See Sodium/hydrogen exchanger*
- Niacin, 142, **1121**
 - coenzymes, 142-143, 168*f*
 - deficiency, 476, **1121**
 - in alcoholism, **1121**
 - requirements, 1121
 - synthesis, 1121
- Niacin equivalents, 1121
- Nick translation, 773, 773*f*
- Nicotinamide adenine dinucleotide, 129, 129*f*, **142-143**, 143*f*, 514-515
 - and electron transport, in mitochondrion, 249*f*, 249-250
 - in glycolysis, 278-279
 - optical properties, 168-170
 - and pyruvate dehydrogenase reaction, 228*t*
 - synthesis, 475-476, 513*f*, 517
- Nicotinamide adenine dinucleotide phosphate, **143**, **234**
 - optical properties, 168-170
- Nicotinic-acetylcholine channel, **202**
 - inhibitors, 203
 - in muscle contraction, 203
 - regulation, 202-203
 - subunits, 203
- Nicotinic-acetylcholine receptor, **201**, **928**
 - antibodies, in myasthenia gravis, 929cc
- NIDDM. *See Diabetes mellitus, noninsulin-dependent*
- Niemann-Pick disease, 429*t*, 430, 938cc
- Nigericin, **212**, 212*t*, 213*f*
- Night blindness, in vitamin A deficiency, **1111**
- Nitrate(s), for angina pectoris, 292cc
- Nitric oxide, 457, 534*f*, 535, 995, 996cc
- Nitric oxide synthase(s), **982**, 995-997
 - endothelial (NOS-III), 996, **996**, 996cc
 - gene products, 995-996
 - induced (NOS-II), 996
 - neuronal (NOS-I), 996, **996**, 997*f*
 - reaction catalyzed by, 995
 - structure, 996-997
- Nitrogen
 - entry into human diet, 446, 446*f*
 - excretion. *See Urea cycle*
 - incorporation into amino acids, 447-452
 - interorgan transport, 452-453, 453*f*
 - partial pressure, 1027*t*
- Nitrogen balance, **447**, 447-448, 1089, **1090**.
 - See also Protein-energy malnutrition*
 - factors affecting, 1090, 1090*f*, 1092, 1093cc
 - negative, **447**, 447-448
 - positive, **448**
- Nitroglycerin, for angina pectoris, 292cc
- N-linked glycosylation, **61**, 61*f*, 737
- NMR. *See Nuclear magnetic resonance*
- NO. *See Nitric oxide*
- Nodule DNA, **599**, 599*f*
- Nonactin, 212*t*
- Noncompetitive inhibitors, **148**, 148*f*, 148-149
- Noncovalent bonds, bond strength, 65*t*
- Nonequilibrium reaction, **284**
- Nonheme proteins, 146, 1003
- Non-histone proteins, **605**
- Nonketotic hyperglycemia, 461cc
- Nonpolar molecules, **362**
- Nonsense codons, **719**
- Nonsense mutations, 721
- Nonsteroidal antiinflammatory drugs, **435**
 - non-aspirin, 435
- Nontranscribed spacer regions, **697**
- Norepinephrine, 853, **929-930**
 - actions, 883*t*
 - synthesis, 466-467, **1122**
 - transport, in mammalian cells, 211*t*
 - urinary excretion products, 468*f*
- NOS. *See Nitric oxide synthase(s)*
- Novobiocin, **594**
- NSAIDs. *See Nonsteroidal antiinflammatory drugs*
- Nuclear envelope, **16**
- Nuclear magnetic resonance, two-dimensional (2-D), 81*f*, 81-82
- Nuclear membrane pores, **203**, **204**
- Nuclease(s), **501**, **568**
 - and hydrolyzation of phosphodiester bonds, 568
 - and RNA turnover, 708-709
 - specificities, 568*f*
 - types, 569*t*
- Nucleic acid-hydrolyzing enzymes, 17*t*
- Nucleic acids, 1147
 - detection, 773-775
 - identification, 773-775
 - monomeric units, 490
 - as probes for specific DNA or RNA sequences, 773*f*, 773-774
- Nucleofilament(s), **666**
 - structure, 607*f*, 608, 608*f*
- Nucleoids, **609**
- Nucleolar organizer, **697**
- Nucleolus, **16**
- Nucleophilic substitution, at acyl carbon, 1138
- Nucleoproteins, 601-609
- Nucleoside(s), **1147**
 - deoxyribopyrimidine, 509
 - nomenclature for, 1147
 - purine, degradation, in immunodeficiency, 503cc
 - pyrimidine, 493*f*
 - tRNA, 701
- Nucleoside 5'-diphosphate reductase, **507**
- Nucleoside deaminase, **509**
- Nucleoside diphosphate kinase, 219*f*, **220**, **301**, **319**, 497
- Nucleoside diphosphate sugar, 342, 343
- Nucleoside kinases, 511
- Nucleoside monophosphate kinase reactions, 219*f*, **220**
- Nucleosome core, **605**
- Nucleosomes, **605**, 605*f*, 605-606, 697
- Nucleotidase(s), specificity, 501
- Nucleotide(s), **1147**
 - absorption of UV light, 493
 - adenine, 492*f*
 - balance of adenine and guanine, 500
 - chemistry, 492-493
 - coenzymes, synthesis, 514-516
 - conformational variations, 575*f*
 - deoxyribopyrimidine, 509
 - deoxythymidine, synthesis, 508
 - distribution, 491
 - four-letter alphabet of, 718, 718*t*
 - intervening nucleotide sequences (IVSs), **613**, 613*f*
 - metabolic functions, 490-492
 - metabolism, 517-518, 520
 - nomenclature for, 1147
 - overproduction, 498cc
 - properties, 493
 - purine. *See Purine(s)*
 - pyrimidine. *See Pyrimidine(s)*
 - reformation, 506-507
 - regulation, 490
 - in RNA, 679-680

Nucleotide(s)

*(continued)*sequence, of contiguous and overlapping genes, 612*f*

sequencing, 671-672, 672cc

sources, 490

synthesis, 516-517

uracil, 494*f*

5'-Nucleotide derivatives, 491

Nucleotide diphosphokinase, **505**Nucleotide excision repair, **635**, 635-636

defects, 638cc

in *E. coli*, 636*f*of human DNA, 637*f*

Nucleotide kinase(s), 511

Nucleotide-linked sugars

formation, 341-346, 342*f*

functions, 336

in sugar transformations, 342-343

Nucleotide-metabolizing enzymes, 511-513

Nucleus, **16**

Nutrient(s), 1056.

See also Macronutrients; Micronutrientsabsorption, 1057, 1058*f*

intestinal transport, 1067-1069

Nutrition. *See also* Fasting state; Macronutrients, Malnutrition, Starvation

in alcoholism, 1120cc

in cystic fibrosis, 1112cc

definition, 1088

dietary goals for United States and, 1101-1102, 1102*f*

neonatal, 1117cc

optimal, **1088**

prudent diet and, 1102

recommended balanced diet and, 1101-1103

in renal disease, 1092cc

vegetarian diets and, 1133, 1134cc

well-fed state, 528*f*, 547-548Nutritional status, **1133**

assessment, 1133-1135

factors affecting, 1133, 1133*f***O**OB gene. *See* Obesity gene

OB protein, as anti-obesity drug, 526cc

Obesity, 362, 378cc, 526cc, **527**, 547-548, **1094**

dietary considerations, 1094

genetic considerations, 526cc, 1094

health implications, 1094-1095

leptin and, 378cc

metabolic effects, 1094-1095

and noninsulin-dependent diabetes mellitus, 549cc

weight-reduction regimens and, 1095

Obesity gene, 1094

Obstructive jaundice, and vitamin K deficiency, **1117**

Occipital horn syndrome, 749cc-750cc

Oculocutaneous tyrosinemia, 467cc

O-glycosidic linkage, **61**, 61*f*, 738O-glycosylation, **61**, 61*f*, 738

Oils, 1144

Okazaki fragments, **647**

Oleic acid, 1143

Oligo-1,6-glucosidase. *See* IsomaltaseOligomeric enzymes, 152, **152**

Oligomeric protein, interaction between ligand sites, 154

Oligomycin, **260**Oligonucleotides, **567**, 567*f*, **824**Oligosaccharidase(s), **1059**Oligosaccharides, **187**, **1139**, 1142-1143

ceramide, 1145

globosides, 425

N-glycosylation, 737*N*-linkedbiosynthesis, 737, 738*f*complex type, 737, 739*f*, 740*f*high-mannose type, 737, 739*f*, 740*f*structure, 737, 739*f*, 740*f**O*-linked, structure, 740*f*lipid-linked, **350**biosynthesis, 351*f*

modification, 737

processing, 737

Omeprazole, **1069**, 1069*f*OMP decarboxylase, **506**, 506*f*Oncogenes, **888**, 889*t*One-carbon carrier, **460**Open complex, **695**Open system, 1039-1040, **1040**

Operator, 803

Operator-constitutive mutations, 805

Operons, **800-801**, 800-802.*See also* Lactose operon; Tryptophan operon

bacterial, 813-815

biosynthetic, of *E. coli*leader peptide sequences, 813, 813*f*

transcription attenuation, 813

E. coli, ribosomal protein, 813-814, 814*f**his*, 813self-regulation, 814, 815*f*Ophthalmoplegia, **1120**in thiamine deficiency, **1120**Opioid peptides, 847*t*, 883*t*Opsia, **937**Optical rotation, **80**

Optical rotatory dispersion, 80-81

Optimal nutrition, **1088**

Oral contraceptives

drug-nutrient interactions, 1133*t*

effects on vitamin C serum levels, 1127

folate requirements with, 1125

mechanism of action, 907cc

vitamin B₆, requirements with, 1124ccORC. *See* Origin of replication complex

Organelles

functional role, 15-20

protein targeting to, 739-743

Organic anions, transport, in mammalian cells, 211*t*

Organic chemistry, review, 1137-1147

OriC, **612**, **649**Origin of replication complex, **656**Ornithine, **454**decarboxylation, 459*f*

elevated levels, 481cc

synthesis, 458, 458*f*Ornithine transcarbamoylase, **454**, 455*f*

deficiency, 457cc

Orotate, formation, **505**

Orotic aciduria, 169cc

Osmoreceptor, **881**Osteocalcin, **1117**

Osteogenesis imperfecta, 749cc

type 1, 748*t*type 2, 748*t*

Osteomalacia, 1114

Osteoporosis, **1117**, 1127, 1128, 1128-1129

calcium and, 1128-1129

diet and, 1129cc

Ouabain, 207, 207, 207*f*Ovarian cycle, 866, 867, 869*f*

absence of fertilization and, 868-870

fertilization and, 870*f*; 870-871

programmed cell death in, 916cc

regulation by GnRH, 867*f*, 867-870Overnutrition, **1088**Oxalate, **460**

Oxaloacetate, 232-233, 237

Oxalosuccinate, 234

Oxidase(s), 129, 129*f*mixed function, **372**Oxidation, **381**, 1010-1011, 1012*f*, **1138**, 1143 β -Oxidation

and palmitate biosynthesis, comparison, 383

pathway, 383*f*stages, 382-383, 383*f* β -Oxidation sequence, **226**, 226-227Oxidation states, of iron, **1002**Oxidation-reduction potential, **247**, 247*t*, 257*f*Oxidation-reduction reactions, **129**

Oxidative metabolism, 217-266

Oxidative phosphorylation, **238**, 261*f*, 261-263

Oxidoreductase(s), 129-131

5-Oxoproline, **485**

Oxy-eicosatetraenoic acid, 436-440

Oxygen

partial pressure, 1026, 1027*t*

transport, 1026-1029

Oxygen binding, 115-124, 199*f*, 1031, 1031*f*.*See also* Bohr effect

Oxygen carrier, 1026-1029

Oxygen dissociation curve(s), 1029, 1029*f*Oxygen saturation curve(s), 1028cc, 1028*f*, 1028-1029Oxygenase(s), **129**, 129*f*, **984**Oxyhemoglobin, 115*f*, 122*f*Oxytocin, 842, 848*f*, 851*f*, 851-852, 858, 858*t*, 906Oxytocin transhydrogenase, 858*f***P**

P site, 727

*P*₅₀, 1028PABA. *See* *p*-Aminobenzoic acidPAF. *See* Platelet-activating factorPAI. *See* Plasminogen activator-inhibitor

Pain, 435

Palindromes, 609-611, **610**

Palmitate

biosynthesis, 367*t*acetyl CoA transport, 369-371, 371*f*comparison of schemes for, 385*t*regulation, 367*t*, 369metabolism, free-energy changes associated with, 222*t*

modification processes, 371-374

synthesis, 366

Palmitic acid, 191*f*, **192**, **366**, 1143release, from fatty acid synthesis, 369*f*

synthesis, reaction sequence, 368-369

- Palmitoleic acid, **1143**
- Palmitoyl CoA, in 3-ketodihydroxyphosphingosine synthesis, **420f**
- sn*-1 Palmitoyl-lysolecithin, in
dipalmitoyllecithin synthesis, **408f**
- Pancreas, **1057, 1059**
β cells, **529**
production, **550cc**
exocrine secretion in, cellular regulation of, **1060, 1061f**
functions, **1057, 1058f, 1059**
insulin production by, **550**
- Pancreatic amylase, **1073**
- Pancreatic enzyme(s), **1059**
activation, **1071-1072, 1072f**
deficiency, **1112cc**
essential serine residue, **1071**
secretion, **1071-1072, 1072f**
- Pancreatic lipase, **1078, 1078f**
deficiency, **1112cc**
- Pancreozymin, **1062**.
See also Cholecystokinin
- Pantothenic acid, **226, 1122**
- Papain, myosin cleavage by, **949f, 950**
- Papovavirus, in expression vector, **785**
- PAPS. *See* 3-Phosphoadenosine 5-phosphosulfate
- Paracellular epithelial transport, **1063, 1063f**
- Paracrine hormone(s), **841**
- Paramyotonia congenita, **956cc-957cc**
- Parathyroid hormone, **1112, 1112-1114**
actions, **849t**
in renal osteodystrophy, **1113cc**
source, **849t**
- Parkinson's disease, **467cc**
- Paroxetine hydrochloride (Paxil), **930**
- Partial proteolysis, **76, 743**
- Partially compensated acid-base state, **1046**
- Parvalbumin, **209**
- Parvovirus(es), and primer synthesis, **645**
- Pasteur effect, **269, 288**
- Patch recombinant heteroduplexes, **665, 665f**
- Patch recombinants, **667**
- PCNA. *See* Proliferating cell nuclear antigen
- PCR. *See* Polymerase chain reaction
- Pectin(s), **1056, 1097, 1098t**
- Pellagra, **476, 1121**
- PEM. *See* Protein-energy malnutrition
- Pentose phosphate(s), **336-340, 337f, 339f**
- Pentose phosphate pathway, **336, 336-341, 340f, 1119**
distribution, **341**
phases, **336**
reversible link with glycolysis, **338**
- Pentoses, **1139-1140**
- Pentosuria
essential, **344**
idiopathic, **345cc**
- Pepsin(s), **1056, 1070**
- Pepsin A, **1070, 1071t**
- Pepsinogen, **1070, 1071, 1071t**
autoactivation, **1070, 1071**
autocatalysis, **1070, 1071**
- Peptic ulcers, **436**
- Peptidase(s), **132**
gastric, **1070, 1071t**
intestinal, **1072**
pancreatic, **1071t**
in protein digestion, **1070**
- Peptide(s), **24**
biologically active, **30t**
digestion, **1072**
epithelial transport, **1072**
transport, in mammalian cells, **211t**
- Peptide bond(s), **28, 28-29, 1138**
cis configuration, **29, 29f**
cleavage, **132**
electronic isomer structures, **28f**
formation, **28f, 727-730, 1138**
trans configuration, **29, 29f**
- Peptide hormone(s), **840**.
See also Polypeptide hormones
intestinal, **1062, 1062t**
- Peptide neurotransmitters, synthesis, **931**
- Peptidyl site, **727**
- Peptidyltransferase, **727**
- Periodicity, of polynucleotides, **568**
- Peripheral neuropathy, **387cc**
in vitamin deficiency, **1118**
- Peripheral (extrinsic) proteins, in membranes, **186, 191**
attachment, **191-192**
binding to integral protein, **191f, 192**
electrostatic binding, **191f, 192**
hydrophobic amino acid sequence as anchor, **191f, 192**
- Peripherin, structure, **940f**
- Periportal hepatocytes, **451, 558**
- Perivenous hepatocytes, **451, 558**
- Permease, **198**
- Pernicious anemia, **1125**
- Peroxidase(s), **130**
- Peroxisomes, **19, 390f, 390-391**
in Zellweger syndrome, **20cc**
- Petechiae, **1127**
- PG hydroperoxidase reaction, **433f**
- pH, **7, 10f, 11f, 12cc**
and acid p*K*_a, **32t, 32-33**
of biological fluids, **7t**
blood, hepatic regulation of, **558**
buffering (buffers), **10-12, 11f**
in blood, **12cc**
calculation, **7**
versus conjugate acid and bases, **9-10**
and enzyme catalytic activity, **165-166**
intracellular, **1036**
in 6-phosphofructo-1-kinase regulation, **290f, 290-292**
and ionic form of amino acid, **32**
and ionic form of protein, **32**
isoelectric, **32-33**
optimum, **166**
phosphatase reactions and, **167f**
and p*f*, **35f**
plasma, **1036, 1046**
regulation, **7-12, 1036**
relationship to [H⁺], [OH⁻], and pOH, **7t**
- Phage. *See* Bacteriophage(s)
- Phagocytosis, **18, 18f**
- Phase angles, **77**
- Phase transition temperature (*T*_m), **194**
- pH-bicarbonate diagram, **1040, 1040f-1042f, 1049**
- Phenformin, and lactic acidosis, **291cc**
- Phenobarbital
cytochrome P450 induction by, **986**
and vitamin requirements, **1118cc**
- Phenylacetylglutamine, **456, 456f**
- Phenylalanine, **25, 463**
degradation, **463-469**
high levels, **465cc**
products, **465f**
side chains, hydrophobic interaction
between, **65f**
- Phenylalanine hydroxylase, **464, 464f, 544**
- Phenylethanolamine *N*-methyltransferase, **853, 855f**
- Phenylketonuria, **74cc, 465cc, 544**
- phi (ϕ) bond, **43, 43f**
- Phlorizin, **1077f, 1077t**
- Phorbol esters, **325**
- Phosphacan, **356**
- Phosphatase(s), **17t, 167f, 403f**
- Phosphate
and energy transfer between compounds, **225, 225f**
resonance forms, **224, 224f**
steady-state level, **138**
- Phosphate esters, **492, 492-493**
- Phosphatidic acid, **181, 376, 376f, 1144**
biosynthesis, from glycerol 3-phosphate, **403f**
major alcohols esterified to, in formation of glycerophospholipid, **181, 181f**
synthesis, **377f**
in triacylglycerol synthesis, **377f**
- Phosphatidic acid phosphatase, **403, 403f**
- Phosphatidylcholine, **181, 182f, 397, 1144**
charge on, **184t**
fatty acids in, **182**
in sphingomyelin synthesis, **422, 424f**
synthesis, **404, 404f, 405f, 407, 407f**
- Phosphatidylethanolamine, **181, 182f, 397, 1144**
charge on, **184t**
fatty acids in, **182**
in phosphatidylcholine synthesis, **405f**
in phosphatidylserine synthesis, **406f**
synthesis, **405f**
- Phosphatidylethanolamine-*N*-methyltransferase, transfer of methyl groups by, **405**
- Phosphatidylglycerol, **184t, 397, 398f**
- Phosphatidylglycerol phosphoglyceride, **181, 182f**.
See also Diphosphatidylglycerol
- Phosphatidylinositol, **182, 182f, 397, 398f, 1144**
in anchoring proteins to membranes, **192, 192f**
charge on, **184t**
function, **401-402**
synthesis, **406f**
- Phosphatidylinositol 4,5-bisphosphate, **399, 399f, 862**
- Phosphatidylinositol (GPI) anchor, structure, **402f**
- Phosphatidylinositol cycle, **901, 902**
- Phosphatidylinositol pathway, **883-885, 884t**
- Phosphatidylinositol synthase, **406**
- Phosphatidylserine, **397, 1144**
charge on, **184, 184t**
in phosphatidylethanolamine synthesis, **405f**
synthesis, **406f**
- Phosphoacylglycerols, **1143, 1144**
- 3-Phosphoadenosine 5-phosphosulfate, **356, 356f, 425f, 474, 474f**

- Phosphoanhydride bonds, **218**
- Phosphocholine cytidylyltransferase, **404**
- Phosphocreatine, **551**
- Phosphodiester bonds, **566**, 567*f*, 568, 622-627
- Phosphodiester bridge, 397-398
- Phosphodiesterase(s), **568**, **942**, 944*t*
- Phosphoenolpyruvate, 224*f*, 303*f*
- Phosphoenolpyruvate (PEP) carboxykinase, **301**, 301-303, 302*f*, 311*f*, **312**, **545**
- Phosphoenolpyruvate-dependent phosphotransferase system (PTS), 210
- Phosphoethanolamine cytidylyltransferase, **405**
- 6-Phosphofructo-1-kinase, 274-275, **286**
- in glycolysis, 286-287
 - hormonal control, 292-294
 - regulation, 287-292
 - regulatory features, 283, 283*f*
- 6-Phosphofructo-2-kinase, **293**
- bifunctional nature, 295-296
 - cardiac isoenzyme, 298*f*
 - covalent modification, 295*f*
 - hepatic isoenzyme, 296*f*
- Phosphoglucokinase, **316**
- Phosphoglucomutase, **314**, 342
- 6-Phosphogluconate dehydrogenase, **338**
- 6-Phosphogluconate pathway. *See* Pentose phosphate pathway
- 6-Phosphoglucono- γ -lactone, formation, **336**, 337*f*
- Phosphoglucose isomerase, 274, **303**
- Phosphoglycerate(s), interconversion, 133*f*
- Phosphoglycerate kinase, **225**, 225*f*, 276-277
- Phosphoglycerate mutase, 133, 277
- Phosphoglycerides. *See* Glycerophospholipids
- Phosphoguanidines, as energy rich compounds, 223*t*
- 4-Phosphoinositol glycerophospholipids, 182
- Phospholipase(s), 1078
- A₁, **406**, 407*f*
 - A₂, **406**, 407*f*, **434**, **1078**, 1079*f*
 - C, 862-865, 865*f*, **1060**
- Phospholipids, **180**, 397-409
- asymmetrical distribution of fatty acids in, 406-408
 - detergent properties, **399**, 409
 - fatty acyl groups in, conformation, 182-183, 183*f*
 - glycerol ether, **183**, 183*f*
 - in human tissues, 397
 - hydrolysis, 1078
 - interactions in aqueous medium, 187, 188*f*
 - metabolism, in liver, 409
 - role of, 398-402
 - structure, 396*f*, 397*f*, 397-398
 - synthesis, 402-409, 403*f*, 404-406
- Phosphomannose isomerase, **342**
- Phosphopentose epimerase, **338**
- Phosphoprotein phosphatase, 229, **229**, **295**, **322**, **325**, 325*f*, 325-326, **542**
- 5-Phosphoribosylamine, **494**
- Phosphoribosylpyrophosphate, 138cc, **497**, 516*f*, 516-517
- Phosphoribosylpyrophosphate synthetase, 138cc, 152cc
- Phosphoric acid anhydrides, as energy rich compounds, 223*t*
- Phosphoric-carboxylic acid anhydrides, as energy rich compounds, 223*t*
- Phosphorolysis, **314**, 314-317, **1138**
- Phosphorylase α , in liver, 326-327
- Phosphorylase kinase, **322**
- Phosphorylation, 282*f*, 342, 543*f*
- autophosphorylation, **879**
 - enzyme, **294**, 294*f*, 543*f*
 - oxidative, **238**, 261-263
 - protein, 878-880, 880*f*
 - substrate-level, **262**, **276-278**
- Photochemical dimerization, **629**, 632*f*
- Photolyase, **640**
- Photophobia, 467cc
- Photoreceptors, 936, 937*f*, 937-943
- Phototherapy, for neonatal hyperbilirubinemia, 1020cc
- Phrenosin, **184**
- pH-velocity profile, 166
- Physiological mediators, 490
- Phytanic acid, **306**, 387cc
- Phylomenaquinone. *See* Vitamin(s), K₁
- pI, **33**, 33-37, 34*t*, 35*f*
- Picolinate carboxylase, 475*f*, **476**
- Picolinic acid, **474**
- Pigmentation, skin, 467cc
- Pigmented epithelial layer, of eye, 936, 937*f*
- Pigs, stress syndrome in, 291cc
- Ping-pong mechanism, **140**, 140-142, 141*f*
- Pinocytosis, **18**, **750**, **1073**
- Pipecolate, **481**, 481*f*
- Pituitary gland
- anterior
 - hormone formation in, 849-851, 851*f*
 - hormones, 842, 843*f*, 847*t*
 - polypeptide hormones of, 844-846, 845*f*
 - responsiveness, testing, 844cc
 - tropic hormones, **842**, 843*f*
 - disorders, 846cc
 - hormones, in ovarian cycle, 867*f*, 867-870
 - posterior, hormones, 842, 843*f*, 858, 858*f*
- pK_a, **7**, 8*t*
- PKU. *See* Phenylketonuria
- Placenta, **552**
- Placental lactogen, **552**, 848*t*
- Planned cell death. *See* Apoptosis
- Plasma
- bicarbonate in, 1033*t*, 1035-1036
 - buffering (buffers) of, 1036-1038
 - chemical constituents, 14*t*
 - composition, 1036-1037, 1037*f*
 - immunoglobulins in, 92cc
 - lipoproteins. *See* Lipoproteins, plasma
 - pH, compensatory mechanisms and, 1046
- Plasma membrane(s), **2**, 16, 180, 180*f*
- anchoring of glycoproteins to, 401-402
 - characteristics, 396
 - erythrocyte
 - asymmetric distribution of lipids in, 192-193, 194*f*
 - fluidity, cholesterol and, 195cc
 - structure, 192, 193*f*
 - fluidity, cholesterol and, 195cc
 - functions, 180
 - gap junctions, **203**, 203*f*
 - glucose transport across, sodium-dependent, 209*f*, 209-210
 - glycoproteins, 187
 - lipids in, 186
 - Na⁺, K⁺-exchanging ATPase. *See* ATPase
 - proteins in, distribution, 192
 - of small intestinal epithelial cells
 - contraluminal, 1063-1064, 1064*t*
 - luminal, 1063-1064, 1064*t*
 - structure and function, 2-4, 16
 - transport systems, **197**
- Plasma proteins, electrophoretic analysis, 36*f*, 37*f*, 37cc
- Plasmalogen(s), **183**, 183*f*, **398**, 1144
- structure, 398*f*
 - synthesis, 408-409
- Plasmid(s), 766, 816
- crown gall, **794**
 - insertional inactivation of, 770, 771*f*
 - pBR322, **766**, 767*f*, 770
 - pSC101, **766**
 - relaxed-control, **766**
 - stringent control, **766**
- Plasmin, 166, **975**
- and blood clots, **172**
 - production, 975*f*, 975-976
- Plasminogen, **975**, 975-976
- Plasminogen activator-inhibitor
- type 1, **976**
 - type 2, **976**
- Platelet aggregation, 398, 436, **960**, 966, **967**
- Platelet plug formation, 967-968, 968*f*
- Platelet-activating factor, **398**, 398*f*
- Platelets, in blood coagulation, 966, 967, 968*f*
- PMN cell chemotaxis, 398
- PNP. *See* Purine nucleoside phosphorylase
- Point mutations, **721**
- Polarity, of DNA strands, **574**, 576*f*
- Polyacrylamide gel electrophoresis, 72
- Polyadenylation signal sequence, **704**, 705*f*
- Polyamine(s), 458, 473*f*, **609**
- Polycloning, **766**
- Polycyclic aromatic hydrocarbons, **985**
- Polycythemia, 722cc
- Polylinker, **766**
- Polymer(s), in food, **1057**
- Polymerase(s)
- RNA. *See* RNA polymerase(s)
 - Polymerase(s), DNA. *See* DNA polymerase(s)
- Polymerase chain reaction, 583cc, **759**, 759*f*, 759-760.
- See also* Reverse transcriptase PCR
 - clinical applications, 760
 - versus cloning, 768-770
 - inverse PCR mutagenesis, **790**, 791*f*
 - multiplex strategy, **769**, 769*f*
 - analysis of HGPRtase gene defects in Lesch-Nyhan syndrome, 770cc
 - nested, 760
 - and screening for HIV, 760cc
- Polymeric allosteric enzyme, 153*f*
- Polynucleosomes, 604*f*, **605**, 605-608
- Polynucleotide phosphorylase, **720**
- Polynucleotides, **1147**
- conformation, forces determining, 569
 - formation, 566-568
 - helical, single-stranded, conformation, 569*f*
 - nomenclature, 567
 - ribose-phosphate backbone, 572*f*
 - stabilization, 569
 - stacked conformation, 569*f*

- structure, in DNA, 567*f*
- unstacked conformation, 569*f*
- Polyol (aldose) dehydrogenase, **935**
- Polyol pathway, 551cc
- Polypeptide(s), **28**
 - domain structures, 47-48
- Polypeptide bond, 43*f*
- Polypeptide chains, 43*f*
 - antiparallel β -structure, 45*f*
 - noncovalent association, 48
 - β -pleated structure, 45*f*
 - β -structure, 45*f*
- Polypeptide hormone(s). *See also specific hormone*
 - actions, 846-849, 847*t*-849*t*
 - of anterior pituitary, 844*t*, 844-846, 845*f*
 - containing cystine disulfide bridge, 858, 858*t*
 - degradation, 857-858
 - formation, 849-853
 - genes, 849-853
 - inactivation, 857-858
 - intracellular action, 878-888
 - receptor interactions. *See* Hormone-receptor interactions
 - receptors
 - internalization, **859**, 876-878
 - structure, 875*f*, 875-876, 876*f*
 - secretion, cell regulation and, 859-866
 - signal transduction, G-proteins in, 859-860, 860*t*
- Polyphosphate(s), synthesis, 400-401
- Polyprenyl side chain, **927**
- Polyproline type II helix, **52**
- Polysaccharide-hydrolyzing enzymes, 17*t*
- Polysaccharides, **1139**, 1142
 - branched, 1142
 - hydrolysis, 1073-1076
 - nonreducing end, 1142
 - reducing end, 1142
 - synthesis, 346
- Polysomes, **716-717**
- Polytene chromosomes, **607**
- Polyunsaturated acids, **365**
- POMC. *See* Proopiomelanocortin
- Pompe's disease, 317cc
- Poor metabolizers, **986**
- Porcine stress syndrome, 291cc
- Pores
 - membrane, **197**, 197*t*, 197-198, 201-204
 - nuclear, **204**
- Porins, 201, **204**
- Porphobilinogen, 1012, **1013**, 1015*f*
- Porphobilinogen deaminase, 1013-1014
- Porphobilinogen synthase. *See* Aminolevulinic acid dehydratase
- Porphyria(s), **1011**, 1012*t*, 1014
- Porphyria cutanea tarda, 1012*t*, **1014**, 1014-1015
- Porphyrin, **236**, **1010**, 1012*t*
- Porphyrinogen(s), **1009**, 1009-1010
 - oxidation, 1010-1011, 1012*f*
- Positive allosteric effectors, 152, 153*f*
- Positive cooperation, **119**
- Positive modulators, 153
- Postreplication repair, 641, 641*f*
 - of rare lesions, **634**
- Postreplication SOS repair, **634**, 642, 642*f*
- Posttranscriptional cleavage, 823
- Potassium, transport
 - across plasma membrane, erythrocyte ghost studies, 207-208, 208*f*
 - active, 206
- Power stroke, in actin-myosin interaction, 959
- Precursor function, 491
- Precursor RNA molecule, 699
- Pregnancy, **552**
 - blood glucose regulation during, 552
 - folic acid requirements in, 1125
 - hormonal changes during, 552
 - nitrogen balance in, 448
 - starve-feed cycle during, 552
 - steroid hormone production during, 993cc
 - ⁵-Pregnenolone, in steroid synthesis, **896**, 898, 899*f*
- Preinitiation complex, **725**
- Prekallikrein, 961*t*, 961-963
 - deficiency, 963cc
- Preproinsulin, 743, 832
- Presbyopia, **934**
- Presynaptic neurons, **924**
- Pribnow box, 692, 695
- Primary transcript, **699**
- Primase(s), **644**, **655**
- Primer(s), **623**
 - for DNA replication, 644-645
 - RNA, 645*t*
 - synthesis, 644*f*
- Primosome, **650**, 651*f*
- Probes, 582, 583, 773-774
- Processivity, **623**
- Prochiral substrates, **158**
- Procollagen, formation, 746-747
- Product inhibition, **140**
- Proenzyme(s), **101**, 1059-1060, **1060**
- Progestational hormones, 894, **894**, 896
- Progesterone, 894, **896**
 - actions, **868**
 - excretion pathway, 902*t*
 - functions, 895*t*
 - metabolism, 991
 - secretion, 895*t*, 903*t*, 905*f*
 - structure, 895*t*
 - synthesis, **898**, 903*t*, 905*f*
- Programmed cell death. *See* Apoptosis
- Progress curve. *See* Reaction(s), velocity
- Progression-linked cell changes, **513**
- Prohormones, **858**
- Proinsulin, 39, 40*f*, 743, 744*f*
- Prokaryotes
 - definition, **2**, 3*f*
 - DNA, 611-613
 - genome size, 614
 - nucleoproteins, 609
 - organization, 3*f*
 - transcription in, 692-696, 693*f*
- Prokaryotic cells. *See* Prokaryotes
- Prokaryotic replication, 658*f*, 659, 659*f*
- Prolactin, 824, 846, 847*t*
- Prolactin release-inhibiting factor, 844*t*, 847*t*
- Prolactin-releasing factor, 844*t*, 847*t*
- Proliferating cell nuclear antigen (PCNA), **626**, **654**
- Proline, **27**, 458, 458*f*
- Promoter(s), 690, 690*f*, 697-698, 803
 - internal, **690**
 - for mRNA synthesis, 699
 - transcription factor interaction with, 698, 698*f*
- Pronucleus, 835
- Proofreading, **624**, **723**
- Proopiomelanocortin, 849, 850*f*, 850*t*, 851*f*
 - gene, **911**
- Propeller twist, **573**, 573*t*
- Propionate, **306**, 306-307, 307*f*, **559**
 - metabolism, diseases, 480cc
- Propionyl CoA, **384**, 384*f*, **479**
 - interconversion, 479*f*
 - metabolism, 479
 - production, 384
- Propionyl-CoA carboxylase, **479**, 1122
 - defect in, 480cc
- Proportionality constant (k), 134
- Prostacyclin, 883*t*, **968**
- Prostaglandin(s), 431-436, 1143
 - classes, 433
 - dietary precursors, 433
 - metabolism, inhibition, 435
 - PgG₂ conversion to PgH₂, 433*f*, 434
 - PgH₂
 - formation, 433*f*, 434
 - in thromboxane B₂ synthesis, 435, 435*f*
 - PgI₂, 1099cc.
 - See also* Prostacyclin
 - PgI₂, 1099cc
 - physiological effects, 435-436
 - principal, in humans, 433-444
 - structure, 431*f*, 1143
 - synthesis, 432*f*, 433-435, 435*f*, 435-436, **1097**
 - vasodilators, 436
- Prostaglandin synthase, **434**
- Prostaglandin synthase (PGS) complex, **434**
- Prostanoic acid, 432*f*, 433
- Prosthetic group, **115**, **128**
- Protanopia, **945**
- Protease(s), 1070
 - aspartate, **98**
 - cysteine, **98**
 - metallo, **98**
 - serine. *See* Serine protease(s)
- Proteasomes, **751**, 752*f*
- Protein(s), **24**
 - absorption, 1070*f*, 1070-1073
 - fetal, 1073
 - neonatal, 1073
 - acid-base balance and, 32-33
 - acidic, 30-31, **31**, 31*t*
 - amino acid sequence, 25*f*, 25-30
 - cleaving reagents, 75*f*, 75-76
 - determination, 74*f*, 74cc, 74-78, 76*f*
 - basic, 30-31, **31**, 31*t*
 - carbohydrate linkages, 61, 61*f*, 62cc
 - cellular concentrations, 68, 68*f*
 - chaperone, **63**
 - charge, separation by, 69-71
 - chemical properties, 30-39
 - common acid groups, p*K*_a, 31*t*
 - composition, 23-85
 - deficiency, 527cc
 - degradation, 452-453, 750-752
 - premature, in cystic fibrosis, 752cc
 - ubiquitin-dependent, 751*f*, 751-752
 - denaturation, **1070**
 - denatured, 67-68

Protein(s)

(continued)

digestion, 1070*f*, 1070-1073

dissociation constant (K'), **30**, 30-31, 31*t*

families, **88**

fibrous, 50-55

folding (noncovalent interactions), 62-67, 64*f*

function, 24-25

globular, **50**, 79*f*

glycation, 538*cc*

glycosidic linkages to amino acids in, 61*f*

with glycosyl phosphatidylinositol anchors, 192, 192*t*

glycosylation, 736-739

α -helical structure, 43-44

heme-containing, 1003-1005

heterotetrameric, **942**

higher-level organization, 42-49

HMG (high mobility group), **608**

H-NS, **609**

HU, **609**

import to mitochondria, 742

ionic form, 32

ionizable groups, and biological function, 30-39

iron-containing, 1003-1005

mass or size, separation by, 71-72

maturation, 735-739

membrane, 189

- diffusion, 193-196
- distribution, 192
- integral (intrinsic), **187**, 190-191, 191*f*
- mobility, 196, 196*f*
- peripheral (extrinsic), **186**, **191**
- transmembrane segment, 190, 191*f*

multidomain, **46**, 46-48, 47*f*

multifunctional, **494**

native conformation, **42**

non-histone, 601-608, **605**

oligomeric, interaction between ligand sites, 154

phosphorylation-dephosphorylation, 878-880, 880*f*

pI values, 34*t*, 35-36

pinocytosis, **1073**

plasma, Svedberg coefficients, 72*t*

posttranslational modification

- absence of, 746*cc*
- amino acid modification in, 744-746, 745*t*
- incorrect, in cystic fibrosis, 752*cc*

posttranslational modifications, **735**, 743-748

primary structure, **28**, 39-42

quaternary structure, **42**, 48-49

scaffold Sc1 and Sc2, **608**

secondary structure, **42**, 43*f*, 43-44

secretory pathway, 735-736, 736*f*

sequestration, by Golgi apparatus, 17

serine protease inhibitors, 103, 103*t*

sorting, in secretory pathway, 739-742

stability, 62-68

steady-state concentration, 68*f*

β -structure, 44, 45*f*

structure, 23-69

- bond strength, 65*t*
- characterization, 69-82
- conformation, **62**
- dynamic flexibility, **76**
- fluctuation, 65*t*
- purification, 69-74
- spectroscopic determination, 79-82
- stability, 63-67
- study, 69-82

structure-function relationships, 87-126

superfamily, **97**, 97*f*

supersecondary structures, 44, **44**

synaptic vesicle, 925, 925*f*, 925*t*, 926*f*

synthesis, 552-553, 683, 713-755.

See also Translation

- antibiotics and, 733-735
- elongation in, 727-730, 728*f*-729*f*
- in *Escherichia coli*, stringent control of, 815, 815*f*
- initiation, 725-727
- in mitochondria, 733
- termination, 732*f*, 733
- toxins and, 733-735

targeted to lysosomes, 739-742, 741*f*

targeting, signals for, 742-743

tertiary structure, **42**, 44-47, 46*f*

turnover, 447, 750-752, 1089

in visual cycle, 943, 944*t*

Protein, dietary, 1056-1057, **1089**

absorption, 1070*f*, 1070-1073

animal, 1091, 1101

contribution to daily nutrient supply, 1056, 1056*t*

digestion, 1070*f*, 1070-1073

energy content of (kcal), 1088

and energy production, 1089

intake, 1056*t*

- average American, 1094
- and calcium requirements, 1094
- excess, 1094-1095
- recommended, **1091-1092**, 1101

metabolism, 1089-1092

in renal disease, 1092*cc*

requirements, 1089

- and diet, 1091-1092
- growth-related, 1092
- in illness and recovery, 1092, 1093*cc*, 1094
- mixed animal and vegetable sources for, 1101

vegetable, 1091, 1101

in vegetarian diets, 1091, 1091*cc*

Protein C, 961*t*, 969, 970, **972**, 972-974, 974*f*

defects, thrombosis caused by, 971*cc*, 974

recombinant, primary structure, 973*f*

Protein data bank, **77**

Protein families, 87-126

Protein inhibitors, 103, 103*t*Protein kinase(s), **229**

catalytic domains, 879, 879*f*

and hormone action, 878-888

and inactivation of pyruvate dehydrogenase complex, 229

Protein kinase A, **294**, 295, **541-542**, 862, 862*f*Protein kinase A pathway, **862**, 862*f*-864*f*, **878**, 880-883, 883*t*Protein kinase C, **865**, **878**

activation, 865-866

stimulation, 904

subspecies, 885, 885*f*

Protein kinase C pathway, **878**, 883-885, 884*t*Protein kinase G pathway, **878**, 885-888Protein kinase M, **885**Protein malnutrition, 527*cc*Protein S, 970, **974**

deficiency, 974

Protein sparing, **1091**Protein-energy malnutrition, **1093**, 1093-1094Protein-hydrolyzing enzymes, 17*t*Proteoglycan(s), **351-352**, 351-357

clinical correlations, mucopolysaccharidoses, 352

functions, 353

structure, 352-353

synthesis, 355*f*, 356-357

Proteolipids, **187**

Proteolysis, and zymogen activation, 743-744

Proteolytic enzymes, 98-99, 132

Prothrombin, **964**, 964-965, 965*f*, 969

activation, 965, 966*f*, **1116**

carboxylation, **1116**, 1116-1117

Prothrombinase complex, 964-965

Protomers, **152**Proton acceptor, **7**Proton donor, **7**Protoporphyrin IX, **983**, **1003**, **1009**Protoporphyrinogen, conversion to porphyrin, 1010-1011, 1012*f*Protoporphyrinogen IX oxidase, action, 1012*f*

Protoporphyrinogen oxidase, 1016

Protransglutamidase, 967

Proximal histidine, **115**PRPP. *See* 5-Phosphoribosyl-1-pyrophosphatePrudent diet, **1102**

Pseudo-first-order reactions, 135

Pseudogenes, **615**, 826Pseudouridine, **701**, 1147Psi (Ψ) bond, **43**, 43*f*PTH. *See* Parathyroid hormonePUFAs. *See* Fatty acids, polyunsaturatedPUFA/SFA ratio, **1099**, 1099*cc*, 1100Pulmonary surfactant. *See* SurfactantPump(s), **198**

Na⁺, H⁺, 211*t*

Na⁺, K⁺, **206**, 206-207, 207*f*

proton, vacuolar, **927**

Purine(s), 489-523, **1146**

analogs, as anti-viral agents, 520

bases

- salvage, 516
- structure, 492*f*

degradation, 501-502, 502*f*

enzymes, 512-513

in gout, 490

interconversion, 500, 500*f*

in Lesch-Nyhan syndrome, 490

major derivatives, in cells, 492-493

metabolism, 489-503, 517-521

overproduction, 497-498

oxygenated, 1146-1147

in RNA, 679-680

structure, 219*f*, 1146

synthesis, 150, 494, 1123

- de novo*, **493**, 500, 519*f*
- regulation, 497*f*, 497-498

Purine nucleoside(s), degradation, in immunodeficiency, 503*cc*Purine nucleoside phosphorylase, **501**, 503*cc*

deficiency, and T-cell immunity defects, 502

- Purine ribonucleotides, *de novo* synthesis, 495*f*
- Purine ring, sources of carbon and nitrogen in, 496*f*
- Puromycin, effects on protein synthesis, 734, 734*r*, 735*f*
- Putrescine, synthesis, 459*f*
- Pyranose rings, 1140
- Pyridoxal, **1121**
- Pyridoxal phosphate, 142, **449**, 449*f*, **1121**
- in aldimine linkage to lysine residue, 449*f*
 - in amino acid metabolism, 460
 - in heme synthesis, **1012**
 - metabolic roles of, 1121-1122, 1122*f*
 - in transamination reaction, 449*f*
 - in tryptophan metabolism, 476
- Pyridoxal-dependent decarboxylase, 450*f*
- Pyridoxamine, **1121**
- Pyridoxine. *See* Vitamin(s), B₆
- Pyrimidine(s), **1146**
- analogs, as anti-viral agents, 520
 - bases, 493*f*
 - carbon and nitrogen atoms in, sources of, 506*f*
 - degradation, 509-511, 510*f*
 - in immunodeficiency, 490
 - interconversions, 509, 509*f*
 - metabolism, 489-507, 517-521
 - in orotic aciduria, 490
 - oxygenated, 1146-1147
 - in RNA, 679-680
 - salvage, 506-507, 517
 - structure, 219*f*, 1146
 - synthesis, 150, 504*f*, 504-506
 - de novo*, 516
 - in hereditary orotic aciduria, 505*cc*
 - regulation, 506, 506*f*, 512-513
 - during S phase, 512-513
- Pyrimidine nucleoside(s), 493*f*
- Pyrimidine phosphoribosyltransferase, **506**
- Pyrogens, 436
- Pyroglutamic acid, 857, 857*t*
- Pyrophosphatase, **319**, 722
- Pyrophosphate, 135, 224, **224**, 224*f*
- Pyruvate, 227, 227*f*
- Pyruvate carboxylase, 133, 133*f*, **302**, **309**, 1122
- Pyruvate dehydrogenase, **227**, 1119
- deficiency, 233*cc*
 - from *E. coli*, 228, 228*f*
 - reaction, 230*f*, 305, 369-370
 - coenzymes and, 228, 228*r*, 229*f*
 - prosthetic groups and, 228, 228*t* - regulation, 228-231, 230*f*
- Pyruvate dehydrogenase complex, 227-228, 230*f*, **928**
- Pyruvate kinase, **146**, **225**, 225*f*, **298**
- deficiency, 299*cc*
 - in glycolysis, 298-299
 - hepatic, inactivation, 299*f*
 - reaction catalyzed by, 147*f*, 273*f*, 278
 - regulatory features, 283, 283*f*
- Pyruvoyl prosthetic group, enzyme formation with, 461*f*
- 6-Pyruvoyl-tetrahydropterin synthase, **500**
- ## Q
- Quantal event, **925**
- Quaternary ammonium ion, 1138
- Quencher, **80**
- Queuosine, **701**
- Quinolinate, as neurotransmitter, 476
- Quinoproteins, synthesis, 469
- ## R
- R conformational state, **123**, 1029
- Rab3, **927**
- Racemase(s), **133**, 133*f*
- Raffinose, 1074*r*, **1076**
- Random coil, **569**
- Random primer labeling of DNA, 773
- Rate, 133, 134-135
- Rate constant k_{11} , 134, **134**
- Rate of diffusion, **196**, 196-197, 197*f*
- Rate of reaction, **128**, 134-135
- Rate-limiting enzymes, **174**
- Rates of reassociation, **614**
- RDAs. *See* Recommended dietary allowances
- RDS. *See* Respiratory distress syndrome
- Reaction(s)
- activation energy (E_a), 149
 - enzyme-catalyzed
 - initial velocity (v_i), **137**, 137*f*
 - mechanism, 159
 - progress curves, 133*f*
 - substrate saturation curve, 137 - nonequilibrium, **284**
 - nucleophilic substitution, 1138
 - order, substrate concentration as function of, 168*f*
 - oxidation-reduction, 1138-1139
 - potential energy barrier, overcoming, 149
 - rate, **128**
 - reversibility, 135
 - stereospecificity, **143**
 - types, 1138-1139
 - velocity, **128**, 133-135, 136*f*
 - zero-order, **135**
- Reaction half life ($t_{1/2}$), 134
- Read through mutations, 721, 722*t*, 723
- Reading frame(s), **720**
- RecA protein, **642**, **665**, 666*f*
- RecBCD enzyme, **665**, 666*f*
- Receptor(s). *See also* Hormone-receptor interactions
- cellular, **840**, 840*f*
 - structure, 875-876
- Receptor-mediated endocytosis, **416**, **750**
- Receptosomes, **877**
- RecJ, **639**
- Recognition, in membrane transport, **199**, 199*f*
- Recognition helix, **108**
- Recognition sites, specific, 396
- Recombinant DNA, **765**, **824**, 824-827
- in agriculture, 794-795
 - bacterial transformation with, 767
 - formation, 765*f*, 765-766
 - in gene library, 768
 - historical perspective on, 758-759
 - technologies, **765**, 790-795
 - vectors, 766
- Recombinase(s), **662**, **668-669**
- Recommended dietary allowances, **1109**
- Recommended protein intake, **1091-1092**
- Recovery, in membrane transport, **200**
- Red blood cell(s). *See* Erythrocyte(s)
- Red pigment, 937
- Redox couples, **247**
- Reducing equivalents, **222**
- Reducing sugar, **1142**
- Reductant, **1005**
- 5 α -Reductase, **898**, 901
- Reduction, **1138**, 1143
- Reductive biosynthesis, **338**
- Refed state, early, 533-534
- Refinement, 77
- Refsum's disease, 362, 387*cc*
- Regulator protein, recognition site, on lactose operon promoter sequence, 805*f*, 806-807
- Regulatory subunits, 155, **155**, 155*f*
- Relaxin, 848*t*
- Release, in membrane transport, **200**
- Release factor(s), **733**
- Releasing hormones, **842**, 843*f*, 844*t*, 857, 857*t*
- Remodeling reactions, 406-408
- Renal failure, and metabolic changes, 553
- Renal osteodystrophy, 1113*cc*
- Renal tubular acidosis, 1042
- Renaturation of DNA, 580-582
- Renin, **901**
- Renin-angiotensin system, **901**, 905*f*
- REP (repeated extragenic palindromic elements), **612**
- Rep protein(s), **648**, **651**
- Replication, mutation perpetuated by, 627*f*
- Replication complex, origin, **656**
- Replication factor A (RFA), **656**
- Replication factor C (RFC), **654**
- Replication origin, **649**
- Replication protein A (RPA), **656**
- Replicative transposition, **670**
- Replicons, **654**, **766**
- Replisome, **649**, 649*t*
- Reporter gene, 787
- Repressed genes, **608**
- Repression, **801**
- Repressor-constitutive mutations, 804
- Reproduction, human, 436
- Resolvase, **667**, **670**
- Resonance forms, **224**
- Resonance isomers, **28**
- Respiratory distress syndrome, 399, 400*cc*
- Respiratory quotient, 551
- Respiratory system, anatomy, 1027, 1027*f*
- Response elements, **985**
- Resting potential, of rod cell membrane, 941
- Restriction digest(s), **611**, **671**
- Restriction endonuclease(s), **568**, **609**, 609-611, 758, **760**, 760-762
- in restriction mapping, 760-761
 - sites of DNA cleavage by, 610*t*
 - type II, 610, 760
- Restriction enzyme(s), 824, 825*f*
- Restriction fragment length polymorphism, 775
- and clonal origin of tumors, 776*cc*
- Restriction maps, **671**, 671-672, 760-762, **761**, 761*f*
- and evolution, 762*cc*
- Restriction site bank, **766**
- Reticulocytes, **824**
- Retina, **932**, **935**
- ATP source for, 935-936

- Retina
- (*continued*)
- carbohydrate metabolism in, 270
 - structure, 937*f*
- Retinal, **1109**, 1110-1111
- isomerization, **936**
- 11-*cis*-Retinal, **937**, 937-938, 939*f*, 941*f*, 944
- all-*trans*-Retinal, 941, 944
- Retinitis pigmentosa, 387cc, 938cc
- peripherin gene mutation in, 940cc-941cc
- Retinoic acid, 894, 914, 914*f*, **1109**, 1110-1111
- Retinoic acid receptor(s), 912, **912**, 912*f*, 914
- Retinoid X receptor, 912, 912*f*
- Retinol, **1109**, 1109-1111
- 11-*cis*-Retinol, 941-942
- all-*trans*-Retinol, 942
- all-*trans*-Retinol dehydrogenase, 942
- Retinol equivalents, 1109
- Retinyl phosphate, **1110**, 1110-1111
- Retrovirus(es), **660**
- Reverse genetics, **792**
- Reverse phase high-performance liquid chromatography (HPLC), **73**, 73*f*
- Reverse transcriptase, **659-660**, **824**
- inhibitors, 661cc
- Reverse transcriptase PCR, 778, 779*f*
- Reverse transcription, 679
- Reversible link, **338**
- Reversible noncompetitive inhibition, 149, 149*f*
- Reye-like syndrome, 385cc
- Reye's syndrome, 533, 533cc
- RFLP. *See* Restriction fragment length polymorphism
- Rh antibody(ies), 1020cc
- Rhodanese, **474**
- Rho-dependent terminators, **696**
- Rhodopsin, **937**, 938*f*, 939*f*, 944*t*
- active, **941**
 - gene, 944-945
 - light activation of, 942
 - regeneration, 943
 - structure, 940*f*
- Rhodopsin kinase, 943, 944*t*
- Rho-independent terminators, **696**, 696*f*
- Riboflavin, 142, **1121**
- coenzyme forms, 143-144
 - deficiency, **1121**
 - in alcoholism, **1121**
- Ribonuclease. *See* RNase
- Ribonucleic acid. *See* RNA
- Ribonucleoprotein particles, 16, 686
- Ribonucleoside 5'-monophosphates, 679-680
- Ribonucleoside diphosphates, reduction, in deoxyribonucleotide synthesis, 507-511
- Ribonucleotide(s)
- in 2'-deoxyribonucleotide synthesis, 507*f*
 - concentrations in cells, 491
 - purine, *de novo* synthesis, 495*f*
- Ribonucleotide reductase, 507*f*, 508*f*
- Ribose, structure, 1140
- Ribose isomerase, **338**
- Ribosomal protein(s)
- operon, *E. coli*, 813-814, 814*f*
 - synthesis, 813-814, 815*f*
- Ribosomal RNA, 679
- cytoplasmic, 678*t*
 - DNA for, repetitive sequence in, 823, 823*f*
 - functions, 678*t*, 683
 - genes, transcription, 697-698
 - mitochondrial, 678*t*
 - mutation, and antibiotic-induced deafness, 734cc
 - processing, 702-703, 703*f*
 - self-cleaving, 686, 687*f*
 - structure, 678*t*, 683, 684*f*
 - synthesis, 678*t*, 683, 815
- Ribosomes, **16**, 683, 813
- classification, 715, 715*t*
 - composition, 715, 715*t*
 - free, 717
 - functional sites, 715, 716*f*
 - membrane-bound, 717
 - mitochondrial, 733
 - in protein synthesis, 715-717
 - self-assembly, 715
 - structure, 715, 716*f*
 - subunits, 715-717, 716*f*, 717*f*
- Ribozymes, **686**
- Ribulose, structure, 1140
- Ribulose 5-phosphate
- disposal mechanism for, **338**
 - interconversion, 339
 - isomerization, **338**
 - synthesis, 338
- Ricin, effects on protein synthesis, 735
- Ricketts, 212cc, **1114**
- Rifampicin, RNA polymerase and, 691, 692cc
- Rigor mortis, 957
- RNA, **16**, 678.
- See also* Transcription
 - antisense, **792**
 - base pairing in, 680, 681*f*
 - binding sites for other molecules, formation, 688-689
 - catalytic activity, 686-688
 - cellular, characteristics, 678*t*
 - classification, 678*t*, 679
 - hairpin structures, 680
 - helical structure, 680, 680*f*
 - heterogeneous nuclear (hnRNA). *See* Heterogeneous nuclear RNA
 - lariat structure, 706, 707*f*
 - messenger (mRNA). *See* Messenger RNA
 - precursor, introns in, 820
 - in ribonucleoprotein particles, 686
 - ribosomal (rRNA). *See* Ribosomal RNA
 - secondary structure, 680, 680*f*-682*f*
 - small cytoplasmic (scRNA). *See* Small cytoplasmic RNA
 - small nuclear (snRNA). *See* Small nuclear RNA
 - splicing, 705, **820**
 - alternate, and protein diversity, 706-708, 708*f*
 - signals, mutations, and disease, 705cc, 706, 707*f*
 - structure, 679-681, 680*f*
 - synthesis, 16, 678*t*, 679, 693*f*, 693-695, 694*f*
 - asymmetry in transcription and, 694, 694*f*
 - template, in DNA synthesis, 660
 - tertiary structure, 680-681
 - transfer (tRNA). *See* Transfer RNA
 - types, 681-689
 - U1, 705, 706*f*
 - U2, 705
 - viral, hammerhead structure, 686, 688*f*
- RNA polymerase(s), 689, 803
- antibiotics and, 691, 692cc
 - E. coli*, 691, 691*t*
 - I, 691, 691*t*
 - II, 691, 691*t*, 698, **698**, 698*f*
 - III, 691, 691*t*, 699, 700*f*
 - mitochondrial, 691, 691*t*
 - in primer synthesis, **644**, 645*t*
 - properties, 691, 691*t*
 - reaction catalyzed by, 690-691
 - recognition site, on lactose operon promoter sequence, 805*f*, 806-807
- RNA probes, 770, 773-774
- RNase, 160*f*, 161*f*, **709**
- RNase P, **686**
- RNPs. *See* Ribonucleoprotein particles
- Rods, **936**, 937*f*, 937-943
- membrane potential, changes after light pulse, 941, 942*f*
 - physicochemical properties, 945-946
 - steady-state potential, 942
- Rolling circle replication, **652**, 652-653, 653*f*
- Rotenone, **259**
- Rotor's syndrome, 1021cc
- Rough endoplasmic reticulum, 16, 735, 736*f*
- Rous sarcoma virus, in expression vector, 785
- rRNA. *See* Ribosomal RNA
- RuvA, **667**
- RuvAB protein, **665**
- RuvAC protein, **665**
- RuvB, **667**
- RuvC endonuclease, **667**
- S
- S1 nuclease, **824**
- Saccharidases, 1075, 1076*t*
- Saccharopine, **481**
- Salicylate poisoning, 1049cc
- Salivary glands, functions, 1057, 1058*f*
- Salmonella*, gene inversion in, 818-819, 819*f*
- Salt bridges, in deoxyhemoglobin, 122*f*
- Salt linkages. *See* Electrostatic interactions
- Salts, **4**, 1143
- SAM. *See* S-Adenosylmethionine
- Sandhoff-Jatzkewitz disease, 349cc, 429*t*
- Sanfilippo, 352cc
- Sanger procedure, of DNA sequencing, 763-765, 764*f*, 765*f*
- α -Sarcin, effects on protein synthesis, 735
- Sarcomeres, 946, 947*f*, 948
- Sarcoplasmic reticulum, **329**, **947**, 948*f*
- SARs (scaffold attachment regions), **608**
- Satellite DNA, **614**
- sequences, **616**
- Saturation kinetics, 197*f*, **199**
- Scaffold attachment regions. *See* SARs
- Scaffold proteins, **608**
- Scatchard analysis, **872**, 872*f*, 873*f*
- Schiff base, **449**, 449*f*, 449-450
- Scurvy, 749cc, **1127**
- Second messenger(s), 180, **208**, 328, **840**, 862-865
- Second order reactions, 134, **135**
- Secondary interactions, **101**
- Secondary structure, regular, **43**, 43*t*
- Secretagogues, **1060**, 1061*t*
- Secretin
- actions, 848*t*
 - as secretagogue, 1061*t*, 1063

- source, 848*t*
- structure, 1062*t*, 1063
- Sedoheptulose, formation, 339
- Selenium, **1132**
- Selenocysteine, **460**, 460*f*
- Semiconservative process, 64*f*, **643**, 643-644
- Senile cataracts, **935**
- Sense strand, 692
- Sepiapterin reductase, **500**
- Sequential induced-fit model, 154
- Sequential mechanism, **142**
- Serine, **27**, **350**, 351*f*, 459-460
 - in 3-ketodihydrospingosine synthesis, 420*f*
 - hydroxymethyltransferase, 461*f*
 - invariant sequences, 105*t*
 - in phosphatidylserine synthesis, 406*f*
 - in protein kinase pathways, 878
 - synthesis, 459, 459*f*, 1123
- Serine dehydratase, 450*f*, 459, **459**, 459*f*, 463
- Serine protease(s), **88**, 97-108, 98*f*
 - amino acid sequences, 103-105
 - binding characteristics, 100*t*, 101*f*, 101-103, 102*f*
 - covalent catalytic mechanism, 163
 - deficiency, 99*t*
 - exon-intron patterns, **104**, 104*f*
 - inhibitors, 103, 103*t*, 975
 - malfunction, 98cc, 99*t*
 - plasma, inhibitors, 975
 - role of, 99*f*
 - structure, 102*f*, 106, 106*t*
 - structure-function relationships, 103-105
 - in tumor cell metastasis, 99cc
 - zymogen, **101**, 101-103
- Serotonin, **476**, **554**.
 - See also* 5-Hydroxytryptamine
 - degradation pathway, 931, 931*f*
 - neurotransmitter function, 930-931
 - oxidative deamination, 931, 931*f*
 - as secretagogue, 1061*t*, 1061-1062
 - and sleepiness, 476
 - structure, 1062*f*
 - synthesis, 468, 476, 476*f*, 866, **1122**
 - urinary excretion products, 468*f*
- Serotonin-specific reuptake inhibitors, 930-931
- Serpin(s), **103**, **975**
- Sertraline hydrochloride (Zoloft), 930
- Serum albumin
 - in bilirubin transport, 1018-1019
 - in fatty acid transport, 379
 - steroid hormone binding to, 908-909
 - in triacylglycerol transport, 379
- Severe combined immunodeficiency
 - adenosine deaminase deficiency and, 502
 - gene therapy, 793cc
- Sex hormone-binding globulin, **908**
- Sex hormones, 894, **894**, 896
 - in ovarian cycle, 867*f*, 867-870
 - synthesis, 898, 900*f*
- SFAs. *See* Fatty acids, saturated
- SGLT. *See* Sodium glucose transporter
- SHBG. *See* Sex hormone-binding globulin
- Shine-Delgarno sequence, **727**
- Shock, 1026cc
- Shuttle vectors, **784**
- Sialic acid(s), **345**, 345-346, 426-427.
 - See also* *N*-Acetylneuraminic acid
- Sialidosis, 349cc
- Sickle cell anemia, 42cc, 827
 - prenatal diagnosis of, 828cc
 - single base pair change in, 828
- Side chain cleavage, of cholesterol, 896, **990**, 991*f*
- Sideroblastic anemia, **1122**
 - factors, 691, 695
 - subunit, 691
- Signal amplification, biochemical mechanisms, 920
- Signal peptidase, 736
- Signal peptide, **735**, 736*f*
- Signal recognition particle, **735**, 736*f*
- Signal recognition particle receptor, **735**
- Signal transduction, **840**
 - biochemical mechanisms, 920
 - inositides in, 399-401
 - in muscle contraction, 946
 - in vision, 936-937
- Silent mutations, **721**
- Simian virus 40, in expression vector, 785
- Single-copy DNA, 615
- Single-strand binding proteins (SSB), **647**, **648**
- Single-strand conformation polymorphism, **775**
- Site-directed mutagenesis, **786**, 786-790
 - of herpes simplex virus type I glycoprotein D, 789cc
 - of single nucleotide, 787-790
- Site-specific recombination, **662**, 662*t*, 668-669, 669*f*
- Skeletal muscle. *See also* Muscle
 - contractile proteins, molecular weights, 948*t*
 - contraction. *See* Muscle contraction
 - glycogen degradation in, regulation, 328-329, 329*f*
 - structure, 946, 947*f*
- Skin pigmentation, 467cc
- Sleep, tryptophan metabolism and, 476
- Sliding filament model, for muscle contraction, **946**
- Slipped, mispaired DNA (SMP-DNA), **601**, 602
- Slow-reacting substance of anaphylaxis (SRS-A), **439**
- Small cytoplasmic RNA, 678*t*
- Small intestine, **1057**
 - amino acid and peptide transport in, 1072cc, 1072-1073
 - functions, 1057, 1058*f*, 1059
 - pancreatic zymogen activation in, 1071-1072
 - saccharidases, 1075, 1076*t*
- Small nuclear ribonucleoproteins, **705**
- Small nuclear RNA, 678*t*
- Small nucleolar ribonucleoprotein complexes, **702**
- Smoking, effects on vitamin C serum levels, 1127
- Smooth endoplasmic reticulum, 16
- Smooth muscle, contraction, regulation, calcium in, 959, 959*f*
- snRNPs. *See* Small nucleolar ribonucleoprotein complexes
- snRNPs. *See* Small nuclear ribonucleoproteins
- Soaps, 1143
- Sodium
 - in acid-base imbalance, 1050-1052
 - active transport, 206
 - in enterocytes, concentrations and electrical potentials of, 1064-1065, 1065*f*
 - secretion, regulation, 436
 - transport across plasma membrane, erythrocyte ghost studies, 207-208, 208*f*
 - intestinal, 1064-1065
 - in mammalian cells, 211*t*
- Sodium, hydrogen (Na⁺, H⁺) pump, 211*t*
- Sodium, potassium (Na⁺, K⁺) pump, **206**, 206-207, 207*f*, 211*t*, **921**
- Sodium bicarbonate reabsorption, **1043**, 1044*f*
- Sodium channel myotonia, 956cc-957cc
- Sodium channels, **201**
 - intestinal epithelial, **1064**
 - ligand gated, 942
 - in nerve impulse transmission, 921, 922*f*
 - of photoreceptors, 942
 - regulation, 201-202
 - structure, 201-202, 202*f*
 - voltage gated, **921**
- Sodium chloride
 - absorption, 1064-1065
 - electrogenic, 1064-1065, 1065*f*
 - secretion, epithelial, 1066*f*, 1066-1067
 - transepithelial movement, **1064**
- Sodium dodecyl sulfate, **72**
- Sodium glucose transporter, 1067, 1068*f*, **1069**, 1076, 1077*t*
 - SGLT1, properties, 1076, 1077*t*
- Sodium lactate, reactions with water, 5*f*
- Sodium-bile acid cotransport system, **1084**
- Sodium-dependent transport systems, **1073**
- Sodium-glucose cotransport, 1067-1068, 1068cc
- Sodium/hydrogen (Na⁺/H⁺) exchange, 1065, **1065**, 1065*f*
- Soft clot, of fibrin, 966, 967*f*
- Solenoid arrangement, **607**
- Solute(s)
 - in cellular environment, 4-12
 - epithelial transport, **1063**, 1063*f*
- Somatocrinin. *See* Growth hormone-releasing hormone
- Somatomedins, **829**
- Somatostatin, 932*t*
 - actions, 847*t*
 - source, 847*t*
 - structure, 858, 858*t*
- Somatotropin, 829
- Sorbitol
 - and diabetes, 551cc
 - formation, 308*f*
 - synthesis, 935
- SOS postreplication repair, **634**, 642, 642*f*
- Southern blot technique, 774*f*, 774-775
- Southern hybridization, 828
- Specific activity, **74**
- Specific drug resistance, 521
- Specificity
 - of biological molecules, factors determining, 347
 - enzyme, 128-129
- Spermidine, synthesis, 458, 472-473
- Spermine, 458, 472-473, **499**
- Sphinganine, **421**, 421*f*
- D-4-Sphinganine. *See* Sphingosine

- Sphingolipid(s), **184**, 420-422, 1143, 1144-1145
- catabolism, pathway, 427-431, 428*f*
 - concentrations, 421
 - diseases related to, 427-431
 - in membranes, 184-185
 - storage, diseases, 429*t*
 - structure, 423*f*
- Sphingolipidoses, 396, 427-431, **429**, 429*t*
- Sphingomyelin, 421-422, 1144-1145
- charge on, 184*t*
 - in Niemann-Pick disease, 422
 - structure, 184, 185*f*, 423*f*
 - synthesis, 422, 424*f*
- Sphingomyelin synthase, **422**
- Sphingomyelinase, 430*f*
- deficiency, **430**
- Sphingosine, **184**
- biosynthesis, 420-421
 - derivatives, 421
 - structure, 184*f*, 420*f*
- Spina bifida, 463cc
- Spinocerebellar ataxia, 602cc
- Splice recombinant heteroduplexes, **665**, 665*f*
- Splice recombinants, **667**
- Spliceosome, 706
- Splicing, of DNA, **613**
- Spur cell anemia, 195cc
- Squalene, **413**, 1145
- in cholesterol synthesis, 413-415
 - formation, 413*f*
 - structure, 413*f*
- Squalene 2,3-epoxide, in lanosterol synthesis, 413*f*
- Squalene oxidocyclase, 414*f*
- Squalene synthase, **413**
- SRP. *See* Signal recognition particle
- SSCP. *See* Single-strand conformation polymorphism
- ssDNA, invasion, **666**
- Stable chair configuration, 161*f*
- Stacked conformation, **569**
- Stacking interactions, **576**
- StAR protein. *See* Steroidogenic acute regulatory protein
- Starch, **270**, **1073**, 1073-1074, 1075*f*
- Start signal, **719**
- Starvation, 527cc, **1089**
- cerebral glucose metabolism and, **920**
 - fuel supply during, 389
 - and ketosis, 389-390
 - and nitrogen balance, 447
 - physiological ketosis in, 390
 - substrate and hormone levels in blood during, 537*t*
- Starve-feed cycle, **526**, 526*f*, 528-538
- Steady state, **137**
- Stearic acid, 1143
- Stearoyl CoA desaturase, 372, **372**
- Steatorrhea, **1082**
- Stem-loop structures, 696*f*, 1006
- Stereo tracing, of HIV protease structure, 78*f*
- Stereochemistry, 1139
- Stereospecificity, **143**
- Steric hindrance, **67**, 120*f*
- Steroid hormone receptor(s), 909-914
- activation, 914-915
 - antigenic domains, **913**
 - autoregulation, **915**
 - DNA-binding domain, **913**, 913*f*
 - DNA-binding form, 909*f*, **910**
 - downregulation, 914-915
 - functional domains, **913**, 913*f*
 - genes, 894, 913, 914*f*
 - ligand-binding domains, **913**, 913*f*
 - model of, 913*f*
 - non-DNA-binding forms, **909**, 909*f*, 914, 915*f*
 - transcriptional effects, positive and negative, 911, 912*f*
 - upregulation, 914-915
- Steroid hormones, **840**, **1110**, 1143, **1145**.
- See also* Corticosteroid(s)
 - action, model for, 909, 909*f*
 - binding, to serum albumin, 908-909
 - binding proteins, 908-909
 - carbon number, 896
 - cardiotonic, **207**
 - classes, 896
 - excretion pathways, 901, 902*t*
 - functions, 895*t*
 - hormone response elements, **910**, 911*t*
 - inhibition of prostaglandin production, 435
 - metabolic inactivation of, 901, 902*t*
 - placental, 552
 - production, during pregnancy, 993cc
 - in programmed cell death, 915-916
 - receptor binding, 909-913
 - release, regulation, cell-cell communication and, 901-908
 - secretion, 895*t*
 - structure, 894-896, 895*t*, 897*f*
 - synthesis, 894, 896-901, 899*f*, 900*f*
 - in adrenal gland, 990, 991*f*
 - in corpus luteum, 896-898
 - cytochrome P450 in, 990-992
 - feedback regulation, 843*f*, 907
 - hormonal regulation, 896, 898*f*, 901-908, 903*t*
 - regulation, cell-cell communication and, 901-908
 - transport, in blood, 908-909
 - X-ray crystallography, 897*f*
- Steroid nucleus, 894*f*
- Steroid antiinflammatory drugs, 435
- Steroidogenic acute regulatory protein, **896**, 898*f*, 901
- Sterols, 231, 1145
- Stomach, functions, 1057, 1058*f*
- Stop codon, 733
- Stop signals, **719**
- Strand displacement, **663**
- Strand invasion, **663**, 666
- Streptokinase, and blood clots, **172**
- Streptomycin, effects on protein synthesis, 733-734, 734*t*
- Stress
- bacterial response to, 815
 - metabolic, nutritional considerations in, 1133
 - metabolic effects, 553, 554*f*
 - response to, 853
- Stress hormone, aldosterone as, 905
- Stringent control, **766**
- Stringent factor, **815**
- Stringent response, **815**
- Structural motifs, **44**
- β -Structure, 44, 45*f*, 79*f*
- Strychnine, 923, **923**, 923*f*
- Subacute cerebellar degeneration, in Lambert-Eaton myasthenic syndrome, 927cc
- Subacute necrotizing encephalomyelopathy, 258cc
- Subclinical nutritional deficiencies, **1108**
- Substance P, 848*t*, **932**, 932*t*
- Substrate(s), **128**
- binding site, **128-129**, 152cc, **155**
 - blood levels, 537*t*
 - complementarity with enzyme, 156-158
 - concentration, and reaction order, 168*f*
 - exogenous, **992**
 - and related enzymes, 17*f*
 - specificity, of enzymes, 156-158
 - strain, **156**, 156*f*, 156-158, 160-163, 161*f*
 - suicide, 150, **986**
- Substrate shuttle mechanisms, across inner mitochondrial membrane, **243**, 244*f*
- Substrate-bridged complexes, 146
- Substrate-level phosphorylation, **262**, **276-278**
- Succinate, **236**
- Succinate dehydrogenase, 148, **148**, **236**
- Succinyl CoA, **234**, 234-236, 236*f*, 479*f*, 1012
- Succinyl CoA synthetase, 235
- Succinylcholine, **203**
- Sucrase, 1076*t*
- Sucrase/isomaltase, 1059*t*
- Sucrose, 1074*t*, 1142
- Sucrose- α -glucosidase. *See* Sucrase
- Sudden infant death syndrome, 385cc
- Sugar(s). *See also* Carbohydrate(s)
- group translocation, in bacteria, 210
 - interconversions, 341-346, 342*f*
 - simple. *See* Monosaccharides
 - transport, in mammalian cells, 211*t*
- Sugar rearrangement system, **338**, 339*f*
- Suicide substrates, 150, **986**
- Sulfá antibiotics, and hemolytic anemia, 338
- Sulfá drugs, 149-150
- Sulfánilamide, 149-150, 150*f*
- Sulfatase(s), 17*t*, **356**
- Sulfate, 473*f*, **474**
- Sulfated tyrosine, **1062**
- Sulfátide(s), **185**, **425**, 1145
- in metachromatic leukodystrophy, 425
 - structure, 185, 185*f*
- Sulhemoglobin, 1030cc
- Sulfite, **474**
- Sulfogalactocerebroside. *See* Sulfatide
- Sulfur amino acids, diseases, 471cc
- Superhelical structure, **53**, 53*f*
- Superoxide dismutase, 1131
- Suppressor mutation, **723**
- Surfactant, **398**
- in atelectasis prevention, 399*f*
 - deficiency, in respiratory distress syndrome, 400cc
- Surgery, metabolic effects, 553
- SV-2, **927**
- Svedberg coefficient, **71**, 71*f*, 72*t*
- Symport, **200**, 200*f*, 209-210, 211*t*
- Synapses, **663**, 923-924
- chemical, **923**
 - electrical, **923**

Synapsin, **925**, 926*f*

Synaptic function, **924**, 927-931

Synaptic vesicles, **925**, 925*f*

- docking, **927**
- proteins, 925, 925*f*, 925*t*, 926*f*

Synaptobrevin/VAMP, **927**

Synaptophysin, **926**

Synaptotagmin, **926**

Syndecan, 356

Syntaxin, **927**

Synthesis, rate, 68*f*

Synthetase, **133**

T

T-conformational state, **123**, 1029

$t_{1/2}$ (reaction half life), 134

Tangier disease, 59cc

Target cell, **842**

Target site, **669**

TATA box, **699**

- locus, **651**

Taurine, 473*f*, **474**, **1078**

Taurocholic acid, 211*t*, **418**

Tauroconjugates, 1079, 1080*t*, **1084**

Tautomeric structures, 1146-1147

Tay-Sachs disease, 427, 429*t*, 430

TCA cycle. *See* Tricarboxylic acid cycle

TCDD. *See* 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin

Teenagers, nutritional considerations for, 1133

Telomerase(s), **659**, 659-660, 660*f*

- activity, in cancer, 658cc

Telomeres, 599, **603**, **659**, 660*f*

Telopeptides, **54**

Temperature, and enzyme catalytic activity, 165-166, 166*f*

- in hemolytic anemia, 166cc

Template, **623**

10-nm fiber, **607**

Ter locus, **651**

Terminal protein (TP), **659**

Terminal repeat sequences, 816

Termination codons, **719**

- disorders, 722cc

Termination sequence, 685

Terminator utilization substance, **651**

Terpenes, 1143, 1145

Testis, carbohydrate metabolism in, 270

Testosterone, 894, **896**

- excretion pathway, 902*t*
- functions, 895*t*
- secretion, 862, 864*f*, 895*t*
- structure, 895*t*
- synthesis, **898**, 903*t*, 906, **990**

Tetanus toxin, binding to vesicle-associated membrane protein, 927

Tetra-*N*-acetylchitotetrose-*d*-lactone, 160*f*

2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, **985**

Tetracyclines, effects on protein synthesis, 734, 734*t*

Tetrahedral intermediates, 164

Tetrahydrobiopterin, 501*f*, **996**

Tetrahydrobiopterin dependent enzyme, **464**, 465*f*

Tetrahydrofolate(s), **460**, 461*f*, **494**, **1123**

- active center, 462*f*
- in amino acid metabolism, 460-463, 462*f*
- and *de novo* purine and dTMP synthesis, 518-519, 519*f*
- formation, inhibition, 518*f*
- interconversion, 462*f*
- reduction reactions involving, 463*f*

Tetrahydrofolate reductase, site-directed inactivation, 151*f*

Tetrahydrofolic acid, 150*f*

Tetrahymena, rRNA precursor, self-splicing, 686, 687*f*

Tetraiodo-L-thyronine. *See* Thyroxine

Tetrose, formation, 338, 339*f*

TFIIH factor, **638**

α -Thal 1 or 2, 828-829

Thalassemia, 722cc, 827

- α , 828-829
- β -, 704, 705cc, 706, 707*f*, 828-829
- mutations in, 828-829
- prenatal diagnosis, 829cc

Theophylline, 688-689, 689*f*

Thermodynamics, **220**, 220-225

- first law of, **220**
- second law of, **220**

Thermolysin, **144**

THF. *See* Tetrahydrofolate(s)

Thiamine. *See* Vitamin(s), B₁

Thiamine pyrophosphate, 228*t*, **234**, 1119, **1119**, 1119*f*

Thiamine triphosphate, 1119

Thick filaments, myosin in, 949-951

Thin filaments, **948**

Thiocysteine, **474**, 474*f*

Thioesterase(s), **369**, **374**

6-Thioguanine, in leukemia treatment, **517**

Thiol esters, as energy rich compounds, 223*t*

Thiolysis, **381**

Thionyl peptides, actions, 439-440

Thioredoxin, **507**, **971**

Thioredoxin reductase, **507**

Thiosulfate, synthesis, 474*f*

Threonine, **27**, **350**, 351*f*, **463**, 464*f*, 878

Thrombin, 166, 965

- in blood coagulation, 966-967, 974*f*, 974-975
- in coagulation promotion and clot dissolution, dual role of, 972-974
- in fibrin formation, 964-966, 965*f*

α -Thrombin, active site cleft, 965-966, 966*f*

Thrombin receptor, 967

Thrombomodulin, 356, **973**

Thrombosis, and defects of protein C pathway, 971cc, 974

Thromboxane(s), 431-436, **434**, 1143, **1144**

- structure, 1144
- TXA₂, 968, 1099cc
- TXB₂, synthesis, 435, 435*f*

Thromboxane A synthase, **434**

Thudichum, J.L.W., 920

Thymidine kinase, gene, as selectable marker for transfected cells, 785

Thymidylate, synthesis, **463**

Thymidylate synthase, **508**

Thymine, degradation, 510*f*

Thymopoietin, 848*t*

α -Thymosin. *See* Thymopoietin

Thyroglobulin, in thyroid hormone synthesis, 854-856

Thyroid gland, iodine metabolism and, 1130

Thyroid hormone(s), 894

- actions, 847*t*
- iodine in, 1130-1131
- secretion, 862, 863*f*
- source, 847*t*
- structure, 856*f*
- synthesis, 469, 854-856, 856*f*

Thyroid hormone receptor(s), **912**, 914

Thyroid-stimulating hormone, 846

- actions, 847*t*, 862, 883*t*, 884*t*
- hormone-receptor interactions, 872-873, 874*f*
- source, 847*t*

Thyrotropin. *See* Thyroid-stimulating hormone

Thyrotropin-releasing hormone, 844*t*, 932*t*

- actions, 847*t*, 884*t*
- source, 847*t*
- structure, 857*t*

Thyroxine, **533**, 1130-1131

- and human growth hormone gene expression, 830
- release, 856, 857*f*
- structure, 856*f*
- synthesis, 854-856, 856*f*

Tiazofurin, structure, 520*f*

Tiazofurin adenine dimucleotide (TAD), **520**

Tight junctions, **1063**, 1066-1067

Tissue, rapidly growing, characteristics, 512-513

Tissue factor, **961**, 961*t*, 963*f*, 963-964, 964*f*

Tissue hypoxia, **1029**

Tissue plasminogen activator, 975*f*, 975-976

- and blood clots, **172**
- recombinant (rt-PA), 98cc

T_m . *See* Phase transition temperature

TNF. *See* Tumor necrosis factor

α -Tocopherol, **1116**

Topaquinone, **469**, 469*f*

Topoisomerase(s), **588**, 592-595

- in cancer treatment, 594cc
- type I, **592**, 592*f*, **649**
- type II, **592**, 593*f*, **648**, 648*f*

Total carbon dioxide, **1032**

Total parenteral nutrition, and zinc deficiency, 1131

Toxins

- effects on protein synthesis, 733-735
- RNA polymerase and, 691, 692cc

t-PA. *See* Tissue plasminogen activator

TPP. *See* Thiamine pyrophosphate

Trace minerals, 1130-1132

Transaldolase, **338**, 339-340

Transamidation, **344**

Transaminase(s), 141, 141*f*, **163**.

- See also* Aminotransferase(s); Transamination

Transamination, **226**, **448**, 448*f*.

- See also* Aminotransferase(s)

Transcellular epithelial transport, **1063**, 1063*f*

Transcortin, **908**

Transcription, **312**, **689**, 689-699

- in bacteria, 800-802
- elongation, **689**, **695-696**
- in eukaryotes, 696-699
- initiation, **689**, **695**
- in prokaryotes, 692-696, 693*f*
- of ribosomal RNA genes, 697-698
- by RNA polymerase II, 698, 698*f*
- by RNA polymerase III, 699, 700*f*
- termination, **689**, **696**, 696*f*

- Transcription factor(s), **696**, 911
 in carcinogenesis, 701cc
 for class III eukaryotic gene, 699, 700f
 interaction with promoters, 698, 698f
- Transcription factor binding element, **108**
- Transducin, **942**, 944f
- Transepithelial NaCl movements, **1064**
- Transfection, **784**, 784-785
- Transfer RNA, 679, **682**, 714
 aminoacylation, 721-724, 724f
 cloverleaf structure, 682f, 683
 cytoplasmic, 678f
 functions, 678f, 682-683, 717-718
 initiator, **725**
 mitochondrial, 678f
 precursors
 additions, 700-701, 702f
 cleavage, 700, 702f
 intron removal from, 700, 702f
 size, 678f, 683
 structure, 717-718
 synthesis, regulation, 815
- Transferase(s), **131-132**, 132f
- Transferrin, **1003**, 1020
- Transferrin receptor, **1003**, 1007f
- Transformation
 bacterial, with recombinant DNA, 767
 of cells, by DNA, **564**
- Transformation-linked cell changes, **513**
- Transforming agent, DNA as, **564**, 565
- Transformylase, 733
- Transgenic animals, **794**, 794f, 795cc, **835**, 836
- Transglutamidase, 966, 967, 967f, 968f
- Transition metal, 146
- Transition state (T_s), **159**, 163
- Transition state analogs, **160**, 160f
- Transitory spaces, **196**
- Transketolase, **338**, 338-340, 1119
- Translation, **714**
 colinearity with mRNA, 724-725
 directional, 724-725
 elongation factors. *See* Elongation factor(s)
 energy cost of, 733
 initiation, 725-727, 726f
 regulation, 748-750
- Translation initiation signal, **714**
- Translesion replication, **642**
- Translocase, **198**, 730
 F type, 206
 P type, 206
 V (vacuole) type, 206
- Translocation, in membrane transport, **199**, 199f
- Translocation mechanism, **198**
- Translocator, **198**
- Translocon, **735**
- Transmembrane domains, of receptors, **875**, 875f
- Transmembrane potential, 200, **201**
 in neurons, 921-923
- Transport. *See also* Membrane transport active, 198, **200**
 gastrointestinal, **1063**, 1063f
 passive, 199f, **200**
 mediated, 199f, **204**
- Transporter(s)
 acidic amino acid, **1073**
 active mediated, **206**
 Ca²⁺, **208**
 citrulline/ornithine exchange, **455**
 Cl⁻/HCO₃⁻, 211f
 dopamine, **929**
 E₁-E₂ type, **207**
 glucose, 204, **272**, **330**, 1068f, **1069**, 1076, 1077f
 H⁺, K⁺, 211f
 membrane, **198**.
See also Cotransporter(s); Membrane transport, systems
 monosaccharide, **1076**
 sodium-independent, **1076**
- facilitated-diffusion type, **1076**
 Na⁺, HPO₄²⁻, 211f
 primary active, **206**
 secondary active, **206**
 sodium glucose, 1067, 1068f, **1069**, 1076, 1077f
 SGLT1, properties, 1076, 1077f
 sodium-independent, **1073**
 tricarboxylate, **245**
- Types F, P and V, 206
- Transporter system, **198**
- Transposable elements. *See* Transposon(s)
- Transposase(s), **662**, **669**, 816
- Transposition, **662**, 662f, 669-670
- Transpositional site-specific recombination. *See* Transposition
- Transposon(s), **614**, **659**, **662**, **669**, **816**, 816-818, 818f
 and antibiotic resistance, 670cc
 composite, **670**
 direct repeats in, 670f
 genomic rearrangements promoted by, 671f
 structure, 816, 816f
 Tn3, 816-818, 817f
- Transsulfuration, **470**, 471cc
- Transverse tubules, **947**, 947-948, 948f
- Trehalase, 1059f, **1076**, 1076f
- Trehalose, 1074f, 1076
- Triacylglycerol(s), **362**, **364**, 364-365, 375-377, 397, **1077**, **1097**, 1144
 blood, hydrolysis, 380-381
 digestion, 1077, 1078f
 elevation, 380cc
 hydrolysis, 1078, 1078f
 metabolism, 362, 381f
 mobilization, 376-377
 serum level, carbohydrate intake and, 1100, 1100cc
 synthesis, 375f, 376, 376f, 377f, 403f, 552-553
 transport, 379
- Tricarboxylic acid cycle, **231**, 231f, 231-238, 453, **920**, 920-921
 acetyl CoA and, oxidation of acetyl group of, 231, 237-238
 ATP synthesis in, 238
 enzymatic reactions in, 232f, 232-237
 versus pentose phosphate pathway, 336
 regulation, 238, 239f
- Trichothiodystrophy (TTD), 638cc
- Trihydroxyphenylalanylquinone. *See* Topaquinone
- Triiodothyronine, **533**, 1130-1131
 release, 856, 857f
 structure, 856f, 914, 914f
 synthesis, 854-856, 856f
- Trimethyllysine, **535**
- Trinucleotide repeat expansions, in Huntington's disease, 823cc
- Triose, formation, 338, 339f
- Triose phosphate isomerase, 275
- Tripalmitin, metabolism, free-energy changes associated with, 222f
- Triple-stranded intermediate, **667**, 667f
- Trisaccharides, 1075
- tRNA. *See* Transfer RNA
- tRNA nucleotidyltransferase, 700-701
- tRNA^{Trp} synthetase, 811
- Tropomyosin, 55, 55f, 708, 708f, 948f, **952**
- Troponin, 948f, **952**
 C, **209**
 subunits, **953**, 953f
 as markers for myocardial infarction, 954cc
- Trypsin, **75**, 107f, **1071**, 1071f
- Trypsin inhibitor, 102f, **1071**
- Trypsinogen, 102f, **1071**
- Tryptophan, **25**, 474-476, 475f, **807**, 1121
- Tryptophan dioxygenase, **474**
- Tryptophan operon
 attenuation, model for, 811-812, 812f
 attenuator site, 810f, 810-813
 secondary structure, 811, 811f
 control by repressor protein, 808-810
 control elements, nucleotide sequence of, 809, 809f
 control sites, 808-813
E. coli, 807-813, 809f
- Tryptophan oxygenase. *See* Tryptophan dioxygenase
- Tryptophan pyrrolase. *See* Tryptophan dioxygenase
- TSH. *See* Thyroid-stimulating hormone
- Tuberculosis treatment, 450, 692cc
- d*-Tubocurarine, **203**
- Tubulin, **20**, **709**
- Tumor(s), clonal origins, determination using RFLP, 776cc
- Tumor cell(s)
 biochemical changes in, 513
 metastasis, 99cc
- Tumor necrosis factor, TNF- α , **548**, **553**, 553cc
- Tumor suppressor protein p53, 701cc
 DNA, structure, 113f
- Tumor-promoting agents, **325**
- Tunicamycin, 737
- Turnover number, **136**
- Tus protein, **651**
- Tyrosinase, **468**, 468f
- Tyrosine, **25**, **463**, 463-469
 degradation, 466f
 derivatives, 466-468
 metabolism, 463-464
 disorders, 467cc
 in protein kinase pathways, 878
 sulfated, **1062**
 therapy with, 467
- Tyrosine aminotransferase, **465**, 466f
 deficiency, 467cc
 Tyrosine hydroxylase, **466**
 Tyrosinemia(s), 467cc
 Tyrosine-specific kinases, **878**

U

U (units of enzyme activity), 136

UAA codon, **719**

UAG codon, **719**

Ubiquinone. *See* Coenzyme Q

Ubiquitin, **453, 751**, 751*f*, 751-752

UGA codon, **719**

Ultracentrifugation, 71

Ultraviolet light spectroscopy, 79, 79*f*

UMP. *See* Uridine 5'-monophosphate

Uncompetitive inhibitor, **149**

Uncouplers, **260**

Uncoupling protein, **205**

Undernutrition, **1088**

Unilamellar vesicles, 189

Uniport, **200**, 200*f*, 204, 212*r*

Unsaturated compounds, **1138**

Uracil, **493**, 510*f*, 679-680

Uracil DNA glycosylase, **635**, 635*f*

Urea, 211*t*, 453, 454*f*, 455, **540**.

See also Urea cycle

Urea cycle, **453-454**, 453-456, 455*f*

alternatives to, 456*f*

enzymes, 454, 455

deficiencies, 456, 457*cc*

metabolic disorders, 455-456

Ureagenesis, **245**

Urease-containing bacteria, **454**

Uric acid, **502**

elevation, in gout, 498*cc*.

See also Hyperuricemia

production, 501-503

Uridine 5'-monophosphate, **503**, 504-506, 505*f*

Uridine phosphorylase, **509**

Uridopropionase, **511**

Urine

acidity

titratable, **1045**

total, **1045**, 1045-1046

formation, 1043

volume, 1043

Urobilinogens, **1018**

Urobilins, **1018**

Uroporphyrinogen(s), **1011**, 1013-1014, 1016*f*

Uroporphyrinogen decarboxylase, 1014-1015

Uroporphyrinogen III cosynthase, **1014**

UTP

in CTP formation, 505*f*

formation from UMP, 505*f*

in glycogen synthesis, 219*f*, **220**

UV. *See* Ultraviolet

UvrA protein, **636**

UvrB protein, **636**

UvrC protein, **636**

UvrD protein, **636**

V

V class enzymes, **152**

V regions, **90**

Vacuolar proton pump, **927**

Valine, **25**, 26*f*, 448*f*, 453, 476-477, 478*f*.

See also Branched-chain amino acids

Valinomycin, 212, **212**, 212*f*, 212*t*, 213*f*

Valproic acid, **931**

van den Bergh reaction, **1018**

Van der Waals contact distance, **67**, 67*t*, 67*f*

Van der Waals dispersion forces, **66-67**, 67II+>*f*, 575-584, 1139

Variable (V) regions, **90**

Variable surface glycoprotein, **401**

Variagate porphyria, 1012*r*, **1016**

Vasoactive intestinal polypeptide, 932*r*, **1062**

actions, 848*t*

as secretagogue, 1061*r*, 1062

source, 848*t*

structure, 1062*t*

Vasoconstriction, in blood coagulation, 960

Vasopressin, 842, 844*r*

actions, 847*r*, 848*r*, 880-883, 882*f*, 883*r*, 884*r*

secretion, 881-882, 882*f*

source, 848*t*

structure, 858, 858*t*

synthesis, 851, 851*f*

Vectors, 780, 783

Vegetarian diet(s), **1091**

nutritional considerations with, 1133, 1134*cc*

and protein-energy requirements, 1091, 1091*cc*

serum cholesterol and, 1100

and vitamin B₁₂ (cobalamine) deficiency, 1126

Velocity profile of reaction. *See* Reaction(s), velocity

Versican, 356

Very low density lipoprotein(s), **58, 379**, 529.

See also Lipoproteins

in obesity, **1095**

Vesicle-associated membrane protein, 927

Vibrio cholerae, diarrhea caused by, 1068*cc*

Vibrio vulnificus, 1003*cc*

VIP. *See* Vasoactive intestinal polypeptide

Viruses, in expression vectors, 785

Vision, 932-946

genes for, chromosomal location, 944-945, 946*cc*

loss, 481*cc*

signal transduction in, 936-937

Visual cycle, 943, 943*f*, 944*r*

Visual pigments, 937, 944

absorption spectrum, 941*f*

amino acid sequences, 944, 945*f*

genes, 944-945

Visual proteins, **1110**

Vitamin(s)

A, **938**, 1109-1111

deficiency, **1111**

dietary sources, 1111

mechanism of action, 1111

metabolism, 1110, 1110*f*

structure, 1109, 1110*f*, 1145-1146

toxicity, **1111**

in vision, 1110-1111, 1111*f*

absorption, 1082

B₁ (thiamine), **1119**

deficiency, **1119-1120**

requirements, 1120-1121

structure, 1119, 1119*f*

therapy with, 479*cc*

B₆ (pyridoxine), 142, **1121**.

See also Pyridoxal phosphate

deficiency, 450, 476, **1122**

requirements, 1122

and anticonvulsant therapy, 1118*cc*

for oral contraceptive users, 1124*cc*

status, evaluation, 1122, 1124*cc*

structure, 1121, 1121*f*

B₁₂ (cobalamine), **1125**

deficiency, **1125, 1126**

dietary sources, 1126

metabolic role, in one-carbon metabolism, 1123*f*

metabolism, 1125-1126, 1126*f*

structure, 1125*f*, 1125-1126

C (ascorbic acid), 536, **1127**

and common cold, 1127-1128

deficiency, **1127**

functions, 1127-1128

megadoses, **1128**

precursors, 344

requirements, 1127

serum levels, factors affecting, 1127

transport, in mammalian cells, 211*t*

D

in calcium homeostasis, 1112-1114, 1115*f*

deficiency, **1114**

dietary sources, 1112, 1114

endocrine system, 906*f*, **907**

parathyroid hormone and, 1112-1114

requirements

and anticonvulsant therapy, 1118*cc*

in newborn, 1117*cc*

structure, 1113*f*

synthesis, 420, 1111-1114

toxicity, **1114**

D₁ (ergocalciferol), **420, 1112**

D₂ (cholecalciferol), **420**

actions, 907

metabolism, 894, **992**

photochemical conversion of 7-dehydrocholesterol to, 419*f*

structure, 1145

synthesis, 907-908, **1111**

deficiency, in alcoholism, 1120*cc*

E, **1114**

as antioxidant, **1116**

deficiency, 1114

requirements, 1116

structure, 1145-1146

supplementation, 1116

in newborn, 1117*cc*

tocopherols in, 1114-1116

toxicity, 1116

fat-soluble, 1109-1118

structure, 1145-1146

K (phytonadione), **1116**, 1116-1118

deficiency, **1117**, 1117*cc*, 1117-1118

epoxide, 971

function, 1116, 1116*f*

in protein glutamyl carboxylation reactions, 970*f*, 970-971

requirements

and anticonvulsant therapy, 1118*cc*

in newborn, 1117*cc*

synthesis, 1117

K₁ (phytylmenaquinone), **1116**

K₂ (multiprenylmenaquinone), **1116**, 1145-1146

requirements, anticonvulsants and, 1118*cc*, 1125

water-soluble, 1118-1119

coenzyme function, 1118

deficiencies, 1118

energy-releasing, 1118-1122

versus fat-soluble vitamins, 1118

hematopoietic, 1123-1126

Vitreous humor, **932**, 933

VLDL. *See* Very low density lipoprotein(s)

V_{max} , 137-138, 152

Voltage-gated channels, **201**, **921**, **922**, 923

disorders, 956cc-957cc

Von Gierke's disease, 317cc

von Willebrand factor, **967**

VSG. *See* Variable surface glycoprotein

vWF. *See* von Willebrand factor

W

Warfarin, **971**

Water, **4**, *4f*

in cellular environment, 4-12

diffusion, through membranes, 196

molecules, *4f*, 4-5

reactions with sodium lactate, *5f*

solvent properties, **5**, **5**

as weak electrolyte, 6

Waxes, 1143

Wear and tear pigment (lipofuscin), **19**

Werner's syndrome, 639cc

Wernicke-Korsakoff syndrome, **1120**, 1120cc

WIC (Women and Infant Children) program, 1128, 1130

Wilson's disease, **1132**

Wobble hypothesis, 719, *719t*

Wolman's disease, 19cc

Women, nutritional considerations for, 1133

X

Xanthine, 492

Xanthine oxidase, **502**

Xenobiotic regulatory elements, **986**

Xenobiotic-metabolizing enzyme(s), 993, *994t*

Xenobiotics, 992, **992**, *994t*

Xeroderma pigmentosum, **636**, 638cc

X-linked spinal and bulbar muscular atrophy, 602cc

X-ray crystallography, *106t*, *109f*, 116, *897f*

X-ray diffraction, **76**, *102f*

XREs. *See* Xenobiotic regulatory elements

Xylitol dehydrogenase deficiency, 345cc

Xylose, UDP-, 344

Xylose 5-phosphate, **338**, 338-340

Xylulose, structure, 1140

Y

YAC. *See* Yeast artificial chromosomes

Yeast(s), 613, 821

Yeast artificial chromosomes, 780-781

Z

Z line, **948**

Z-DNA, *571f*, *573t*, **574**

ZDV (zidovudine). *See* Azidothymidine

Zellweger syndrome, and peroxisome function, 20cc

Zero-order reactions, **135**

Zinc

absorption, **1131**

as cofactor, **1131**

deficiency, **1131**

as Lewis acid, 144, 145, *145f*

Zinc finger(s), **108**, *109f*, *110f*, 913, *913f*

Zinc metalloenzymes, *1071t*, **1072**, 1131

Zinc proteases, **144**

Zona fasciculata cells, in steroid synthesis, 898

Zona glomerulosa cells, in steroid synthesis, 898

Zona reticularis cells, in steroid synthesis, 898

Zonal centrifugation, **585**, 585-586

Zwitterion form, **33**, 33-34, **1146**

Zymogen granules, **1060**

Zymogens, **98**, 743-744, **1060**, 1071-1072

NORMAL CLINICAL VALUES: BLOOD*

INORGANIC SUBSTANCES

Ammonia	12–55 $\mu\text{mol/L}$
Bicarbonate	22–26 meq/L
Calcium	8.5–10.5 mg/dl
Carbon dioxide	24–30 meq/L
Chloride	100–106 meq/L
Copper	100–200 $\mu\text{g/dl}$
Iron	50–150 $\mu\text{g/dl}$
Lead	10 $\mu\text{g/dl}$ or less
Magnesium	1.5–2.0 meq/L
Pco ₂	35–45 mmHg
pH	4.7–6.0 kPa
Phosphorus	7.35–7.45
Po ₂	3.0–4.5 mg/dl
Potassium	75–100 mmHg
Sodium	10.0–13.3 kPa
	3.5–5.0 meq/L
	135–145 meq/L

ORGANIC MOLECULES

Acetoacetate	negative
Ascorbic acid	0.4–15 mg/dl
Bilirubin	
Direct	0–0.4 mg/dl
Indirect	0.6 mg/dl
Carotenoids	0.8–4.0 $\mu\text{g/ml}$
Creatinine	0.6–1.5 mg/dl
Glucose	70–110 mg/dl
Lactic acid	0.5–2.2 meq/L
Lipids	
Total	450–1000 mg/dl
Cholesterol	120–220 mg/dl
Phospholipids	9–16 mg/dl as lipid P
Total fatty acids	190–420 mg/dl
Triglycerides	40–150 mg/dl
Phenylalanine	0–2 mg/dl
Pyruvic acid	0–0.11 meq/L
Urea nitrogen (BUN)	8–25 mg/dl
Uric acid	3.0–7.0 mg/dl
Vitamin A	0.15–0.6 $\mu\text{g/ml}$

PROTEINS

Total	6.0–8.4 g/dl
Albumin	3.1–4.3 g/dl
Ceruloplasmin	23–43 mg/dl
Globulin	2.6–4.1 g/dl
Insulin	0–29 $\mu\text{U/ml}$

ENZYMES

Aldolase	0–7 U/ml
Amylase	4–25 U/ml
Cholinesterase	0.5 pH U or more/h
Creatine kinase (CK)	40–150 U/L
Lactic dehydrogenase	110–210 U/L
Lipase	2 U/ml or less
Nucleotidase	1–11 U/L
Phosphatase (acid)	0.1–0.63 Sigma U/ml
Phosphatase (alkaline)	13–39 U/L
Transaminase (SGOT)	9–40 U/ml

PHYSICAL PROPERTIES

Blood pressure	120/80 mmHg
Blood volume	8.5–9.0% of body weight in kg
Iron binding capacity	250–410 $\mu\text{g/dl}$
Osmolality	280–296 mOsm/kg H ₂ O
Hematocrit	37–52%

NORMAL CLINICAL VALUES: URINE*

Acetoacetate (acetone)	0
Amylase	24–76 U/ml
Calcium	0–300 mg/d
Copper	0–60 $\mu\text{g/d}$
Coproporphyrin	50–250 $\mu\text{g/d}$
Creatine	under 0.75 mmol/d
Creatinine	15–25 mg/kg body weight/d
5-Hydroxyindoleacetic acid	2–9 mg/d
Lead	120 $\mu\text{g/d}$ or less
Phosphorus (inorganic)	varies; average 1 g/d
Porphobilinogen	0
Protein (quantitative)	less than 165 mg/d
Sugar	0
Titrateable acidity	20–40 meq/d
Urobilinogen	up to 1.0 Ehrlich U
Uroporphyrin	0–30 $\mu\text{g/d}$

*Selected values are taken from normal reference laboratory values in use at the Massachusetts General Hospital and published in the *New England Journal of Medicine* 314:39, 1986 and 327:718, 1992. The reader is referred to the complete list of reference laboratory values in the literature citation for references to methods and units. dl, deciliters (100 ml); d, day.